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“Mi manderete a scuola?” chiese Peter Pan. 
“Sì” 
“E poi in ufficio?” 
“Credo di sì” 
“E presto sarò un uomo?” 
“Molto presto” 
“Ma io non voglio andare a scuola e imparare cose serie… 
non voglio diventare un uomo. 
Oh,… pensa se un giorno dovessi svegliarmi e accorgermi di avere la barba!” 
 
Peter Pan 
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Abstract 
 
The Lupus autoantigen La is an RNA-binding protein that stabilizes RNA polymerase III 
(Pol III) transcripts and supports correct RNA folding. In addition, La was shown to 
affect the biogenesis of mammalian microRNAs (miRNAs).  
In this study, we have analyzed the consequences of La depletion on the Argonaute 
(Ago)-bound small RNA (sRNA) population in human cells. We find that in the absence 
of La, distinct tRNA fragments are loaded into Ago proteins. Thus, La functions as 
gatekeeper ensuring correct tRNA maturation and thereby protects the cell from tRNA 
fragments, which might be potentially harmful by acting as unintended miRNAs.  
We further provide evidences, that viral non-coding RNAs (ncRNAs) perturb La’s 
gatekeeper function and induce the production of Ago-loaded tRNA fragments, 
mimicking the effects observed under La depletion. 
Interestingly, one specific isoleucine precursor tRNA (pre-tRNA) produces both, a tRNA 
and a functional miRNA, even when La is present. We demonstrate that this specific pre-
tRNA is able to partially escape from La binding due to its fully complementary 5’ leader 
and 3’ trailer sequences. The double-stranded RNA structure of this specific isoleucine 
pre-tRNA reduces the affinity to La and allows processing by components of the miRNA 
biogenesis machinery. 
In sum, our study unraveled a novel aspect of La biology, showing that it supports correct 
pathway selection and, by that, maturation of primary Pol III transcripts. Furthermore, we 
characterized in molecular detail the biogenesis of a non-canonical, pre-tRNA-derived 
miRNA. 
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Zusammenfassung 
 
Das Protein Lupus Autoantigen La bindet an das 3’ Ende von primären RNA Polymerase III 
(Pol III) Transkripten und schützt sie somit vor exonukleolytischem Abbau. Zudem 
fördert La die korrekte Faltung der gebundenen Transkripte. Des Weiteren wurde La als 
ein Faktor beschrieben, der die Biogenese einiger mikroRNAs (miRNAs) reguliert.  
In dieser Arbeit wurde der Einfluss von La auf die Population von kurzen RNAs 
untersucht, die mit Argonaut (Ago) Proteinen interagiert. Daraus ergab sich, dass La die 
Entstehung von einigen kurzen tRNA Fragmenten verhindert. In Abwesenheit von La 
akkumulieren diese tRNA Fragmente in Ago Protein-Komplexen und könnten daher 
fälschlicherweise als miRNAs wirken, was mögliche negativen Konsequenzen birgt.  
Zusätzlich liefert unsere Studie Hinweise dafür, dass diese Kontroll-Funktion von La 
durch virale, nicht-kodierende RNAs beeinträchtigt wird. Die Expression solch viraler 
RNAs führte zur Produktion von Ago-interagierenden tRNA Fragmenten. Somit ähnelte 
dieser Effekt den Auswirkungen einer La Depletion. 
Interessanterweise kann aus einer bestimmten Isoleucin Vorläufer-tRNA (pre-tRNA) 
sogar in Anwesenheit von La eine tRNA oder auch eine funktionelle miRNA entstehen. 
Wir konnten zeigen, dass die strukturellen Besonderheiten dieser pre-tRNA eine 
effiziente Bindung durch La verhindern. Dies beruht darauf, dass die 5’ und 3’ Überhänge 
der Isoleucin pre-tRNA stark komplementär zueinander sind. Die dadurch entstehende 
doppelsträngige Struktur verursacht zwar eine verminderte Affinität zu La, ermöglicht 
jedoch gleichzeitig die Prozessierung durch Komponenten der miRNA Biogenese 
Maschinerie.   
Zusammengefasst hat unsere Studie eine bis dahin unbekannte Funktion des Proteins La 
aufgeklärt. La besitzt eine wegweisende Rolle in der Reifung von primären Pol III 
Transkripten und verhindert dadurch, dass pre-tRNAs durch konkurrierende Prozesse 
fehlgeleitet werden, z.B. in den miRNA-Biogeneseweg. Zudem wurde der molekulare 
Mechanismus aufgeklärt, der dazu führt, dass eine nicht-kanonische miRNA aus einer 
pre-tRNA entstehen kann. 
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1. Introduction 
 
1.1. TRNA Biology: Ancient But Still Attractive  
 
The fundamental role of tRNAs in protein translation was unravelled very early in the 
history of molecular biology (Hoagland et al., 1958). By translating the code of nucleic 
acids into the code of proteins, tRNAs act as the Rosetta Stone of the cell, allowing 
genetic information to be expressed. In order to fulfil this central role, tRNA functionality 
needs to be guaranteed. Although the final mode of action of tRNAs within translation is 
conserved among all domains of life, it is striking how frequently convergent evolution 
resulted in different mechanisms to ensure that the requirement of functional tRNAs is 
satisfied. This aspect of tRNA biology, in particular, still leaves many open questions. 
Are some molecular mechanisms described in specific model organisms peculiar for them 
or are they shared as well by other species? 
Not only do the details in tRNAs’ life cycle remain partially elusive but also the plethora 
of RNA base modifications and the responsible enzymes are detected and characterized in 
only a few organisms (El Yacoubi et al., 2012). Furthermore, the extent of tRNA 
modification dynamics and the resulting regulatory potential have been addressed by a 
handful of studies, but still require broader investigations (Emilsson et al., 1992; Noon et 
al., 2003; Chan et al., 2010; Yi and Pan, 2011). 
In addition to their well-known function in translation, tRNAs fascinate also by their 
many non-translational activities (reviewed in Schimmel, 2017), starting from the 
chromatin insulator role of tRNA genes as shown for different eukaryotes (Kuhn et al., 
1991; Raab et al., 2012). Mature, aminoacylated tRNAs are involved as well in several 
pathways, for example, tRNA-Arg and the arginyl-tRNA-protein transferase act in a 
specific protein degradation pathway (Kaji, 1968; Balzi et al., 1990). Furthermore, 
aminoacylated tRNA-Glu has been shown to serve as a substrate for the biosynthesis of 
tetrapyrroles (i.e., chlorophyll and heme) in green plants, archaebacteria and many 
eubacteria (Huang et al., 1984; Schön et al., 1986; Jahn et al., 1992). Recently it has been 
reported that tRNA binding to cytochrome c leads to inhibition of caspase activation and 
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Figure 1.1: TRNA Maturation is a Multistep Process. Schematic representation of processing events and 
key enzymes required during the biogenesis of tRNAs. The La protein (blue) binds and protects the 3’ end 
of pre-tRNA transcripts supporting their correct folding. The order of the reactions, enzymes as well as 
cellular localization of the steps might vary under certain conditions and between different organisms. 
therefore blocks apoptosis (Mei et al., 2010). Intriguingly, mature tRNAs can be hijacked 
by retroviruses and long terminal repeat (LTR) retrotransposons during their replication 
cycles, and are thereby used as primers for reverse transcription (Rosenthal and 
Zamecnik, 1973; Mak and Kleiman, 1997).  
In the past decade a new aspect of tRNA biology has emerged, namely, the occurrence of 
tRNA-derived fragments. They seem to excerpt diverse biological roles and several 
modes of actions have been proposed. However, published data are not always satisfying 
and are often contradictory. In this regard, the elusive nature of tRNA-derived fragments 
is probably the most prominent challenge to tackle next within the tRNA field.  
 
1.1.1. Structure and Nucleotide Modifications Guarantee tRNA Functionality  
 
TRNAs are highly transcribed and represent one of the most abundant transcript class 
within a cell. It has been estimated that a single yeast cell contains three million tRNAs 
(Waldron and Lacroute, 1975). This tremendous amount of molecules is transcribed by 
RNA polymerase III (Pol III). The following sections aim to describe several processing 
steps tRNAs undergo before being loaded with the correct amino acid (Figure 1.1). 
 
The outcome of tRNA biogenesis are structurally highly conserved molecules which have 
co-evolved with the ribosome to match the requirements for protein synthesis (reviewed 
in Tamura, 2015; Zhang and Ferré-D’Amaré, 2016). Importantly, the folding of tRNAs is 
not only relevant for its fundamental role during translation, but its acquisition during the 
maturation of tRNAs also governs several subsequent reactions (e.g., removal of the 5’ 
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leader sequence from pre-tRNAs by RNase P) and structural determinants are 
continuously interrogated for quality control (e.g., by the tRNA nucleotidyltransferase).  
The typical secondary structure of tRNAs resembles a cloverleaf and according to 
distinguishing attributes the different stem-loops have been named D-arm, T-arm and 
anticodon arm (Figure 1.2A). The loop of the D-arm contains several dihydrouridine 
modified nucleosides, while the loop of the T-arm almost universally starts with a 
ribothymidine, which is uncommon in RNAs. It is followed by a pseudouridine (Ψ) and a 
cytidine, whereby the T-arm is alternatively also referred to as TΨC-arm. The anticodon 
itself, consisting of three nucleotides pairing with the codon triplet on the mRNA, is 
located at the center of the anticodon loop. Between the anticodon arm and the T-arm a 
segment of variable length can occur (variable arm).  
The first crystal structure of a tRNA was solved in the 70’s (Kim et al., 1973) and 
revealed the L-shape of this molecule. The acceptor stem and the T-arm form one 
segment, which is also called minihelix, while the D-arm together with the anticodon arm 
form the second part of the L-shape. These two branches are joined by the elbow which 
consists of the loops of the D- and T-arms (Figure 1.2B). Importantly, several Watson-
Crick interactions as well as extensive unconventional base pairings occur within this 
region and are essential for stabilizing the overall tertiary structure of the tRNA (reviewed 
in Zhang and Ferré-D’Amaré, 2016).  
  
Figure 1.2: Structural Characteristics of Mature tRNAs. (A) The secondary structure of tRNAs 
resembles a cloverleaf. D-arm, anticodon arm, variable arm, T-arm and the acceptor stem are depicted in 
different colors. The last four nucleotides at the 3’ end of the acceptor stem are indicated. They form a 
single-stranded overhang, whereby the terminal CCA is added post-transcriptionally. The preceding 
nucleotide (N) is termed discriminator base. (B) TRNAs adopt an L-shaped tertiary structure. The 
corresponding colors as in (A) are used. Figure adapted from Tamura (2015).    
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Figure 1.3: Frequent Modifications and Responsible Enzymes for Yeast Cytoplasmic tRNAs. 
Schematic representation of a tRNA with circles indicating nucleotides and lines indicating base pairings. 
Positions which are unmodified in all tRNAs are depicted with lighter circles, positions where 
modifications can occur are shown with darker circles. Figure adapted from El Yacoubi et al. (2012); 
abbreviations used as listed therein.  
A multitude of tRNA structures have been obtained meanwhile and some of them depict 
the tRNA bound by some processing and maturation enzymes or engaged at the ribosome 
during different translation steps (reviewed in Giegé et al., 2012). These data highlight the 
intrinsic flexibility of tRNAs, especially of the elbow, which accounts for the variability 
in the positioning of the two L-shaped segments relative to each other (Giegé, 2008; 
Giegé et al., 2012).  
Important for the correct folding (Helm et al., 1999) as well as for the structural 
stabilization of tRNAs (Anderson et al., 1998, see also sections 1.1.4.3 and 1.1.9) is their 
amazing repertoire of posttranscriptional modifications. Approximately 100 different 
nucleoside variants have been identified. Their generation requires the activities of an 
astonishing amount of highly specialized enzymes, which are very often responsible for 
position-specific modification of certain bases (Figure 1.3).  
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Due to the complex chemical properties of some of these nucleotide variants it is frequent 
that they are obtained in multi-step reactions through the action of several proteins 
(reviewed in El Yacoubi et al., 2012; Hori, 2014). Despite all the efforts life has dedicated 
to the evolution of these elaborated modifications, only few of them are strictly essential 
or are related to severe phenotypes. These are mostly located within the anticodon loop 
(Björk et al., 2001; Wolf et al., 2002; El Yacoubi et al., 2009) and the lack of specific 
modification has been implicated in different human diseases as well (Kirino et al., 2004; 
Wei et al., 2011; reviewed in Torres et al., 2014). TRNA modifications within the 
anticodon loop contribute in several ways to the accuracy of protein translation. First of 
all, modified nucleoside behave as identity determinants for the enzyme, specifically 
charging tRNAs with the correct amino (reviewed in El Yacoubi et al., 2012). Most 
importantly, tRNA modifications within the anticodon loop impact translation rates 
(Nedialkova and Leidel, 2015) and contribute to decoding accuracy by stabilizing codon-
anticodon interactions. In this context they are required either for allowing wobble 
interactions or for ensuring stringent discrimination of closely related codons. This is 
particularly relevant for so-called split codon boxes whereby different amino acids (or a 
stop codon) are decoded depending only on the last nucleotide of the codon (Björk et al., 
2007; Johansson et al., 2008). 
 
1.1.2. Organisation of tRNA Genes 
 
Currently, 610 tRNA genes are annotated at the genomic tRNA database (gtRNAdb) 2.0 
for the human genome (Chan and Lowe, 2015). According to the amino acid they carry, 
tRNA genes are grouped into different isotypes. Due to the degeneracy of the genetic 
code, one specific amino acid can be encoded by several codons, which are recognized by 
distinct tRNA isoacceptors. For the nomenclature of different tRNA isoacceptors, the 
sequence of the anticodon is used (e.g., tRNA-Ile-TAT and tRNA-Ile-AAT). A specific 
isoacceptor group consists of so-called isodecoders, i.e., tRNAs sharing a common 
anticodon. Although originating from different genomic loci, some mature tRNA 
isodecoders might have identical sequences. However, isodecoders can also slightly differ 
in their tRNA body sequence. The hierarchical grouping of tRNA genes is exemplarily 
shown in Figure 1.4 for the tRNA-Ile isotype. 
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Of note, not all possible tRNA isoacceptors are encoded in the genome (Figure 1.5). This 
is possible because wobble interactions (i.e., non-standard Watson-Crick pairings) can 
occur at the third base within a codon with the first base of a tRNA’s anticodon. Thus, a 
smaller set of tRNA isoacceptors allows decoding of all 64 possible codon sequences. 
Figure 1.5 also shows, that the number of certain tRNA isodecoder genes is over-
represented for certain isoacceptors, e.g., for tRNA-Cys-GCA (38), compared to others, 
e.g, to tRNA-Ser-GGA (1). The reasons for this fact remain elusive, since tRNA copy 
numbers do not always correlate with the codon usage rates. 
Regarding their distribution, tRNA genes are in general dispersed throughout the human 
genome, differing from the strictly clustered localization of rRNA repetitive units. Still, 
small clusters especially on chromosomes 1, 6 and 17 are present as well (Raab et al., 
2012). In the fission yeast Schizosaccharomyces pombe clustering is more pronounced 
and tRNA genes are found at centromeric DNA sequences (Kuhn et al., 1991). It has been 
shown that binding of Pol III-specific transcription factors to these tRNA genes is 
sufficient to hinder spreading of repressive chromatin marks to distal regions. 
Interestingly, the insulator function of tRNA genes is conserved in humans as well, 
although the small clusters are not present at centromeres (Raab et al., 2012).  
 
 
Figure 1.4: TRNAs Are Hierarchically Grouped into Isotypes (blue), Isoacceptors (violet) and 
Isodecoders (pink). Illustration of the different terms used to categorize tRNAs. See main text for details. 
Please note in the numbering of tRNA isodecoders that those sharing the same first number (e.g., tRNA-Ile-
TAT-2-1, tRNA-Ile-TAT-2-2 and tRNA-Ile-TAT-2-3) have identical mature tRNA sequences. 
Nevertheless, they can originate from distinct genomic loci which are unambiguously indicated by the 
second number. 
                                 INTRODUCTION         7 
 
Figure 1.5: Overview of Predicted Human tRNA Genes and Corresponding Codon Usage. The tRNA 
isotypes are grouped in different sets according to the number of anticodons used to decode the same amino 
acid. Potential suppressor tRNAs are shown in grey as no experimental evidence exists for their 
functionality in humans. Consider that the codons TGA, TAA and TAG are recognized as stop codons 
under normal conditions. Data obtained from the gtRNAdb 2.0 (Chan and Lowe, 2015).  
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The proximity of tRNA loci to each other is not only visible in regard to their position on 
the genomic DNA but is also evident from their spatial localization within the nucleus. 
The three-dimensional organization of tRNA genes has been studied in great detail in the 
budding yeast Saccharomyces cerevisiae and actively transcribed tRNA genes were 
detected in nucleoli (Thompson et al., 2003). TRNA genes were shown also in human 
cells to be enriched in nucleolus-associated chromatin domains (Németh et al., 2010), 
however, not many analyses have been performed in the human system. 
 
1.1.3. Transcription by Pol III  
1.1.3.1. Pol III Transcription Is Driven by Different Promoter Types  
 
Pol III is the largest of the three RNA polymerases and, yet, it is structurally the least 
characterized. Only recently, structures at ~4 Å resolution have been achieved by cryo-
electron microscopy (EM) (Hoffmann et al., 2015; Abascal-Palacios et al., 2018), 
although a first low resolution structure at 17 Å was published almost ten years before 
applying cryo-EM as well (Fernández-Tornero et al., 2007). The Pol III holoenzyme 
consists of 17 subunits, of which ten are unique to Pol III, while the other seven subunits 
are either shared by Pol I and Pol III or are present in all three RNA polymerases.  
Transcription by Pol III is directed by three distinct promoter types (I, II and III) which 
differ in regard to cis regulatory elements; consequently, the composition of transcription 
factors involved varies among the different promoters (Figure 1.6). Common to all 
promoters is the requirement of the general transcription factor TFIIIB. This complex 
consists of the TATA box-binding protein (TBP), the Pol III-specific transcription factors 
TFIIIB component B'' homolog (BDP), and TFIIB-related factor 1 (BRF1) or TFIIB-
related factor 2 (BRF2). While the binding of TBP to a TATA-box or TATA-like 
sequence is required for type III promoters, the presence of such sequence elements is not 
mandatory for the other two promoter types, but has been shown to increase transcription 
efficiency (Giuliodori et al., 2003). In addition, activity of type III promoters is facilitated 
by the binding of the small nuclear RNA-activating protein complex (SNAPc) to a 
proximal sequence element (PSE) and by the binding of OCT1 and STAF to the distal 
sequence element (DSE) (reviewed in Schramm and Hernandez, 2002). Of note, the 
promoter type III is found only in multicellular organisms. 
In contrast, the main characteristic of promoter type I and II is that the sequence elements 
driving transcription are located within the transcribed sequence. These so called A-box, 
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B-box, C-box and intermediate elements (IE) are therefore very often embedded in the 
mature transcripts (e.g., in tRNAs). In the case of type II promoters, which drive the 
expression of all tRNA genes with a minor exception, the A-box and B-box form together 
a specific binding site for positioning the multisubunit complex TFIIIC (Figure 1.6).  
 
1.1.3.2. Regulation of Pol III Transcript Levels  
 
As mentioned before, TFIIIB consists of three different proteins (TBP, BDP and BRF1 or 
BRF2), where the exact composition depends on the promoter type. BRF1 is required for 
transcription from internal promoters (type I and II), while it is replaced by the vertebrate-
specific BRF2 at type III gene-external promoters. This variance might account for the 
potential to regulate specifically gene expression of promoter type III genes 
Figure 1.6: Type I, II and III of Pol III Promoter Differ in Sequence Elements and Required 
Transcription Factors. See main text for details. IE, intermediate element; DSE, distal sequence element; 
PSE, proximal sequence element; TTTT transcription termination signal; TATA, TATA box or TATA-like 
sequence, parentheses indicate that not all type I and type II promoters contain a TATA element. Adapted 
from Dieci et al. (2007) and Oler et al. (2010).  
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independently from the other promoter types. In fact, recent X-ray crystallographic 
structures of BRF2-TBP complexes bound to different natural promoter sequences shed 
light on a fascinating feature of BRF2: the presence of a redox-sensing regulatory module 
wherein a conserved cysteine residue (C361) can cycle through reduced and oxidized 
states. In case C361 is oxidized, assembly of the complex on DNA is severely 
compromised (Gouge et al., 2015). Consequently, BRF2-dependent transcription of 
promoter type III genes is reduced during oxidative stress. Of note, the only tRNAs 
possessing such promoters are tRNA-SeC gene loci, while all the other tRNAs are 
transcribed from type II promoters (Oler et al., 2010). Selenocystein is especially required 
for the synthesis of several proteins directly involved in the oxidative stress response. 
However, the BRF2-dependent down regulation of tRNA-SeC levels during prolonged 
oxidative stress conditions and the resulting decrease of selenoproteins expression, lead to 
the induction of apoptosis (Gouge et al., 2015). This protective mechanism seems to be 
overcome in several types of cancers, where oncogenic BRF2 overexpression is observed 
(Cabarcas and Schramm, 2011). 
The regulation of tRNA-SeC expression by the BRF2 redox-sensor is probably the only 
known mechanism explaining how tRNA levels can be modulated at the transcriptional 
level. Indeed, several pieces of evidence emerged during the past years suggest that the 
protein synthesis machinery is not fuelled by a constant tRNA pool (reviewed in Kirchner 
and Ignatova, 2014; Orioli, 2017). First indications came from microarray-based analyses 
of different tissues, demonstrating remarked levels of tRNA heterogeneity among the 
tested samples (Dittmar et al., 2006). Furthermore, chromatin immunoprecipitation 
(ChIP) experiments revealed considerable variance in the tRNA loci occupied by Pol III. 
Also, the total amount of in silico predicted tRNA genes bound by Pol III varied between 
four different cell lines, ranging from ~30% to ~60% (Oler et al., 2010). Finally, a broad 
microarray-based study extensively demonstrated changes in the tRNA pool among 
proliferative, differentiating and senescent cells (Gingold et al., 2014). The tRNA content 
of several cancer types and cancer stages was also characterized recently, providing first 
evidences for the relevance of differing tRNA levels. These changes correlated with a 
shift in the codon-usage signature of genes involved in the driving processes of the 
analyzed conditions (Gingold et al., 2014; Goodarzi et al., 2016). A similar adaptive 
dynamic in tRNA supply and codon-usage demand has been proposed as well for cell 
cycle‐regulated genes (Frenkel-Morgenstern et al., 2012). All these findings depict the 
coordinated adaptation of the expressed tRNA subset and the codon-usage requested 
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under specific situations. According to such a system, the translation of the requested 
proteins will be favoured in contrast to unintended gene products (Gingold et al., 2014; 
Quax et al., 2015). Still, the chicken or the egg question remains, regarding the driving 
force for this co-evolution process: did the tRNA pool adapt to a varying demand or did 
the bias in codon-usage of important genes react to the altered tRNA composition? In 
both cases, the molecular mechanisms resulting in the differential tRNA expression 
remain largely elusive. The core elements of tRNA genes are very similar to each other 
and motif analyses of Pol III bound versus non-bound tRNA genes did not reveal any 
differences in A-box and B-box sequence composition (Oler et al., 2010) or only modest 
variances (Canella et al., 2010). However, when similar analyses were performed with 
tRNAs enriched during differentiation or proliferation, the sequence motif of the B-box 
differed between the two subsets and therefore might be a first indication of the 
underlying regulatory mechanism (Gingold et al., 2014). 
 
1.1.3.3. Transcription Termination by Pol III 
 
Similarly to the relatively unsophisticated organisation of Pol III promoters, transcription 
termination by Pol III is driven by a direct mechanism, simply requiring a short oligo(dT) 
tract on the non-template strand (Arimbasseri and Maraia, 2015). Neither post-
translational modification of the polymerase nor the activity of trans-acting factors is 
required for Pol III termination unlike for Pol II (Arimbasseri et al., 2013). Although the 
short oligo(dT) tract is the universal terminator for Pol III, the minimum length for 
efficient termination varies among different species. The yeast S. cerevisiae requires six 
or more Ts for efficient termination (Allison and Hall, 1985), while in vertebrates four Ts 
are generally sufficient (Bogenhagen and Brown, 1981; Cozzarelli et al., 1983). At the 
same time, sequence analyses of human tRNA loci revealed the presence of strong 
terminator sequences (i.e., having more than four Ts) more downstream than observed in 
S. cerevisiae (Orioli et al., 2011). The more proximal terminator sequences instead appear 
to be weaker in humans. This, together with other findings, suggests that transcription of 
tRNA genes in vertebrates is more prone to read-through events resulting in 3’ extended 
transcripts. The strong secondary terminators ensure thereby stringent termination 
(Arimbasseri et al., 2013).    
The context surrounding the stretch of four Ts influences the ability of Pol III to terminate 
transcription, at least in some situations (Gunnery et al., 1999). The ability of Pol III to 
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discriminate permissive oligo(dT) tracts is fundamental for the production of Lys-TTT 
tRNAs. Beside the required three Us in the anticodon, an invariant U immediately 
upstream of them is present, resulting in four consecutive Ts on the non-template strand 
(Mazabraud et al., 1987). On the other side, termination at non-canonical oligo(dT)-
stretches has been observed as well (Orioli et al., 2011). 
The underlying principle of transcription termination is based on two distinct processes, 
namely pausing of the polymerase and transcript release. The intrinsic nature of the 
oligo(dT) tract already accounts for slowing down Pol III, as the base pairing of the 
nascent oligo(rU) on the RNA with the oligo(dA) tract on the template DNA strand is the 
weakest possible interaction compared to other RNA:DNA hybrids (Arimbasseri et al., 
2013). This characteristic leads to the destabilization of the elongating polymerase 
complex. However, it is not sufficient to release the transcript and the requirement of the 
Pol III endonucleolytic cleavage activity (Huang et al., 2005; Arimbasseri and Maraia, 
2013) and the role of proximal RNA secondary structures (Nielsen et al., 2013; 
Arimbasseri et al., 2014; Nielsen and Zenkin, 2014; Gogakos et al., 2017) are still a 
matter of debate.  
As more and more details are being unravelled regarding the potent properties of Pol III 
transcript termination, it should still be considered that the 3’ ends of the transcripts are 
heterogeneous and differ in the number of Us incorporated before being released 
(Arimbasseri et al., 2013).   
 
1.1.4. Maturation of tRNA Ends 
1.1.4.1. 5’ End Processing of Pre-tRNAs by RNase P 
 
As described above, the primary Pol III transcripts all terminate on a stretch of Us, which 
is immediately bound by the Lupus autoantigen La protein at the transcription site 
(Fairley et al., 2005). This interaction is not only fundamental for protecting the 3’ end 
from exonucleolytic degradation but is also required for the efficient processing of Pol III 
transcript, in particular of tRNAs. RNA chaperone activities have been attributed to the 
La protein and it therefore facilitates correct folding of the bound pre-tRNAs (Pannone et 
al., 1998; Chakshusmathi et al., 2003; Belisova et al., 2005; Kucera et al., 2011; Naeeni et 
al., 2012). In addition, the interaction with La governs the hierarchy of the different tRNA 
processing events. Upon phosphorylation of La the 5’ end of the pre-tRNA becomes 
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accessible for the RNase P complex which removes the 5’ leader sequence by 
endonucleolytic cleavage (Fan et al., 1998; Intine et al., 2000).  
The human RNase P is a ribonucleoprotein (RNP) complex composed of ten protein 
subunits and the catalytic (Kikovska et al., 2007) RNA H1 (or RPPH1), which is 
transcribed as well by Pol III and localizes at least in part in the nucleoli and in the 
nucleoplasm (Jarrous et al., 1999). First studies performed with the RNA moiety of 
bacterial RNase P clearly demonstrated that the RNA is endonucleolytically active on its 
own, and was therefore the first true ribozyme being characterized (Guerrier-Takada et 
al., 1983). Of note, bacterial RNase P consists of the catalytic RNA and one single 
protein, while the number of protein components increased during evolution (Lai et al., 
2010). Studies performed in yeast demonstrated that the protein subunits of RNase P are 
required for cell viability, and that RNase P activity was decreased in vivo upon 
conditional depletion of single subunits (Lygerou et al., 1994; Chu et al., 1997; Dichtl and 
Tollervey, 1997; Stolc and Altman, 1997; Chamberlain et al., 1998). Still, the exact role 
of the protein components and the reason for the increased complexity of the eukaryotic 
complexes remain an open question, although the protein subunits might be involved in 
stabilization and folding of the RNA H1 (Esakova et al., 2008), and might increase the 
binding affinity of the RNase P for its substrates (Esakova and Krasilnikov, 2010). In 
addition, eukaryotic RNase P has acquired novel regulatory functions which might 
depend at least in part on the protein subunits (Reiner et al., 2006). Interestingly, the 5’ 
ends of mitochondrial tRNAs are cleaved by a protein only heterotrimeric complex which 
thus represents the only known exception to the ubiquitous RNA-catalysed RNase P 
enzymes (Holzmann et al., 2008). 
 
1.1.4.2. 3’ End Processing of Pre-tRNAs by RNase Z  
 
The canonical processing of the 3’ end of pre-tRNAs requires the endonucleolytic 
cleavage activity of a single protein termed RNase Z. However, the characterization of 
this endoribonuclease lags behind the deeper knowledge about the multisubunit RNase P 
complex. In particular, most studies regarding RNase Z activity and substrate specificity 
have been conducted in vitro and only in spare cases the in vivo requirement of RNase Z 
for the removal of the 3’ trailer from pre-tRNAs has been demonstrated (Pellegrini et al., 
2003; Dubrovsky et al., 2004; Brzezniak et al., 2011; Skowronek et al., 2014; Xie and 
Dubrovsky, 2015; Reinhard et al., 2017). 
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Two forms of RNAse Z exist, a short version composed of 280-360 amino acids (referred 
to as RNase ZS) and a long version composed of 750-930 amino acids (referred to as 
RNase ZL) (Späth et al., 2007). RNase ZS is found in representatives from all three 
domains of life, while RNase ZL is present only in eukaryotes. The latter very likely 
originated from gene duplication of RNase ZS, since sequence similarities to RNase ZS 
are found in the N- as well as in the C-terminal part of RNase ZL (Takaku et al., 2004). 
Remarkably, the genomes of eukaryotic organisms in general encode at least one RNase 
ZL protein (e.g., in S. cerevisiae and D. melanogaster), while distribution of the short 
RNase ZS form varies among eukaryotes. In humans, for example, both forms of RNase Z 
are present, whereby RNase ZS is encoded by the ELAC1 gene and RNase ZL by ELAC2.  
Localization studies showed that RNase ZS is found in the cytosol, while RNase ZL in the 
nucleus and in mitochondria. Interestingly, the dual localization of the latter protein is 
achieved by the alternative use of two translation initiation sites. This results in an RNase 
ZL variant containing a mitochondrial targeting sequence and a slightly shortened RNase 
ZL variant lacking 15 N-terminal amino acids and, therefore, most of the mitochondrial 
targeting sequence (Rossmanith, 2011). Since RNase ZL is the only RNase Z form found 
in some eukaryotes, it has been speculated that RNase ZL is sufficient for the biogenesis 
of nuclear- and mitochondrial-encoded tRNAs. However, it has been not clarified whether 
both RNase Z forms might have redundant functions at least under certain conditions, or 
if the RNase ZS encoded in some eukaryotic genomes has acquired a completely different 
specialization. Although these two proteins still remain largely uncharacterized in vivo, 
recent biochemical evidences confirmed the role of RNase ZL in the processing of 
mitochondrial tRNAs (Brzezniak et al., 2011; Reinhard et al., 2017). Furthermore, 
mutations in ELAC2 have been identified to occur in prostate cancer (Tavtigian et al., 
2001) and in other diseases (Haack et al., 2013; Akawi et al., 2016). 
An important aspect of 3’ processing of pre-tRNAs is the fact that eukaryotic tRNA genes 
do not encode the 3’ terminal CCA which is mandatory for aminoacylation of mature 
tRNAs. Hence, eukaryotic RNase Z enzymes are required to cleave pre-tRNAs 
immediately after the discriminator base, which is the unpaired nucleotide 3’ to the last 
base pair (bp) of the acceptor stem. The tRNA nucleotidyltransferase successively 
proceeds with the non-templated addition of the 3’ CCA end. The situation is different in 
archea and bacteria: some organisms encode only CCA-containing tRNA genes, others 
encode CCA-containing and CCA-less genes. Those organisms which do not encode any 
RNase Z only possess tRNAs with the CCA end already encoded in the genome. The 3’ 
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processing of such tRNAs relies on the action of 3’→5’ exoribonucleases. Although some 
other bacteria like, for example, Escherichia coli also encode the CCA end within all 
tRNAs genes, they still possess RNase Z proteins. They have been shown to be 
catalytically active in vitro and can cleave off the trailer of CCA-less pre-tRNA 
substrates. However, some evidence suggests that their physiological substrates are other 
RNA transcripts, unrelated to tRNAs (Perwez and Kushner, 2006). In those organisms 
encoding CCA-containing and CCA-less pre-tRNAs, the action of RNase Z is restricted, 
with some minor exceptions, to the CCA-less pre-tRNA subpopulation alone. In this way 
it has been demonstrated that the presence of the CCA motif downstream of the 
discriminator base inhibits RNase Z activity (Pellegrini et al., 2003; Dutta et al., 2013). A 
similar anti-determinant property of the terminal CCA sequence has been observed as 
well for several eukaryotic RNase Z enzymes and might therefore prevent mature tRNAs 
from being pinched at the acceptor stem (Nashimoto, 1997; Mohan et al., 1999).  
From the structural point of view, RNase Z enzymes are quite exotic endoribonucleases, 
as they are characterized by a metallo-hydrolase domain of the β-lactamase family. Such 
a domain is found in only one other RNA processing enzyme, namely, in the cleavage and 
polyadenylation specificity factor 73 (CPSF-73) protein which is the endoribonuclease 
cleaving the mRNA 3’ ends and allowing subsequent polyadenylation (Mandel et al., 
2006). These proteins exhibit zinc-dependent phosphodiesterase activity.  
A peculiarity of RNase Z is the so-called exosite, which is a flexible arm that protrudes 
from the main protein body as elucidated by the crystal structures of the RNase ZS from 
different organisms (de la Sierra-Gallay et al., 2005; Ishii et al., 2005; Kostelecky et al., 
2006). Although this element does not participate in the catalytic reaction, it was later 
shown to clamp the pre-tRNA by several hydrogen bond contacts (de la Sierra-Gallay et 
al., 2006).  
RNase ZS forms homodimers, whereby the one subunit might account for substrate 
recognition and the other for cleavage (de la Sierra-Gallay et al., 2005, 2006). Instead, the 
longer RNase ZL acts as a monomer but has sequence similarities to RNase ZS in its N- 
and C-terminal parts. This fact suggests that RNase ZL has lost the necessity to form 
homodimers by linking the two components within the same protein. It further seems that 
the two halves of RNase ZL have acquired specialization, as the N-terminal part has lost 
catalytic activity but still possesses the exosite, and, on the contrary, the C-terminal part is 
functionally active but does not contain the exosite (Takaku et al., 2003, 2004; Ma et al., 
2017).  
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1.1.4.3. Alternative Processing of Pre-tRNA Ends 
 
Most of the experimental evidence corroborates a model whereby pre-tRNA 5’ end 
processing precedes 3’ end processing (O’Connor and Peebles, 1991). In particular, the 
interaction of La with the newly synthesized pre-tRNAs buries their 3’ ends hindering 
removal of the trailer (Teplova et al., 2006), while it is conceivable with the recruitment 
of RNase P (Fan et al., 1998; Intine et al., 2003). In addition, a decrease of RNase Z 
processivity has been reported for substrates with 5’ extensions, suggesting that the 
removal of the leader sequence is preferred before cleavage of the trailer (Pellegrini et al., 
2003).  
Still, some exceptions to this 5’-before-3’ processing rule have been reported. In 
particular, studies conducted in S. cerevisiae wild type and mutant strains revealed that 
pre-tRNA-Trp transcripts undergo first maturation of the 3’ end, but still interact with the 
La homologous protein 1 (Lhp1), the budding yeast ortholog of the human La protein 
(Kufel and Tollervey, 2003).  
Not surprising instead is the more substantial effect manifested by yeast Lhp1 depletion 
strains concerning the general tRNA maturation process. Due to the loss of the Lhp1’s 
protective function, the 3’ ends of pre-tRNAs are readily trimmed by exonucleases, while 
the 5’ leader is removed only subsequently (Yoo and Wolin, 1997). Thus, reversal of the 
5’-before-3’ order in favor of the 3’-before-5’ processing can be observed in the absence 
of Lhp1 and acts as a backup mechanism to keep tRNA biogenesis running.  
However, 3’-before-5’ processing might not only intervene for rescuing the perturbed 
function of Lhp1. Some evidence indicates that a fraction of pre-tRNAs is processed on a 
Lhp1-independent manner even under normal growth conditions, but this alternative 
processing pathway is overshadowed by the canonical 5’-before-3’ order (reviewed in 
Maraia and Lamichhane, 2011). Such a situation could originate from the intrinsic 
property of Pol III transcription, namely the length heterogeneity of the terminal oligo(U) 
tail of pre-tRNAs. Analyses of pre-tRNAs from wild type S. pombe cells indicated in fact 
that these transcripts terminate on shorter U-stretches than noticed in yeast strain 
encoding a mutated Pol III subunit. The mutant strain exhibited reduced Pol III 3’ 
cleavage activity resulting in abnormal transcription termination characterized by longer 
terminal oligo(U) tracts. These particular pre-tRNAs showed strong association with the 
yeast La ortholog and their maturation obeyed the 5’-before-3’ hierarchy (Huang et al., 
2005). Contrarily, in the wild type condition a larger fraction of pre-tRNAs with few 3’ 
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terminal Us might exist and might escape binding by La proteins, whose availability 
appears to be a limiting factor (Huang et al., 2005; Maraia and Lamichhane, 2011). The 
maturation of such pre-tRNAs would consequently also be independent of RNase Z and 
rely on the action of diverse exoribonucleases as shown for pre-tRNAs with particularly 
short 3’ trailers (Skowronek et al., 2014). As suggested also by others, pre-tRNAs would 
thus be subject to a permanent competition between binding by La and exonucleolytic 
processing (Copela et al., 2008).  
The knowledge about the exoribunucleases involved in the 3’ trimming of pre-tRNAs is 
still relatively spare, and their identification required elaborated experimental strategies. 
All studies performed so far have been carried out in yeast due to the versatility of genetic 
tools available for monitoring tRNA 3’ end formation (Rijal et al., 2015). A major issue 
consists in the occurrence of several closely related exoribonucleases and which might 
therefore be able to adopt redundant functions. In this context, Rex1 was the first 3’→5’ 
exoribonuclease experimentally linked to the processing of selected pre-tRNAs (van Hoof 
et al., 2000; Copela et al., 2008; Ozanick et al., 2009; Skowronek et al., 2014), while the 
contribution of its homolog Rex2 seems to play a minor role (Skowronek et al., 2014).  
Of note, in Rex1 deletion strains the accumulation of polyadenylated pre-tRNA 
intermediates was observed (Copela et al., 2008; Ozanick et al., 2009; Skowronek et al., 
2014), similar to previous findings indicating that hypomodified initiator pre-tRNA-Met 
gets polyadenylated by Trf4, a subunit of the Trf4/Air2/Mtr4 polyadenylation (TRAMP) 
complex (Kadaba et al., 2004). In the latter case, it has been shown that the structural 
instability caused by the lacking modification activates the nuclear surveillance 
machinery, and that the polyadenylated initiator pre-tRNA-Met is degraded by the nuclear 
exosome (Kadaba et al., 2004). It has been therefore speculated that in Rex1 deletion 
strains, some pre-tRNA transcripts would accumulate unprocessed 3’ ends, and that this 
feature is recognized as well by the nuclear surveillance machinery (Ozanick et al., 2009). 
Alternatively, Trf4-mediated polyadenylation of some pre-tRNAs and subsequent 
trimming by Rex1 might be not related to degradation processes but might be the initial 
steps during the maturation of the 3’ end (Ozanick et al., 2009). In such a scenario 
polyadenylation might be a prerequisite for Rex1 exonucleolytic activity, but this aspect 
has not been well addressed so far.  
It is evident that a caveat for studying the role of exonucleases in tRNA maturation 
processes is to discern these activities from the effects directed to degrade tRNAs within 
quality control pathways (Copela et al., 2008; Ozanick et al., 2009; Hopper and Huang, 
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2015). In this regard, it is challenging to interpret the observation that yeast strains 
depleted for the nuclear exosome specific Rrp6 subunit accumulate different pre-tRNA 
precursors (Copela et al., 2008; Skowronek et al., 2014) as well as a structurally aberrant 
initiator pre-tRNA-Met (Kadaba et al., 2004). For more detail regarding the quality 
control pathway of tRNAs see section 1.1.9. 
 
1.1.5. CCA Addition by the tRNA Nucleotidyltransferase 
 
The eukaryotic end-processed tRNAs acquire their 3’ CCA end post-transcriptionally by 
the action of the tRNA nucleotidyltransferase (Hecht et al., 1958; Deutscher, 1972). This 
process has been shown to take place in the nucleus (Solari and Deutscher, 1982; Lund 
and Dahlberg, 1998). However, the enzyme resides as well in the cytoplasm where it is 
able to heal damaged tRNAs, similar to its bacterial counterpart (Mukerji and Deutscher, 
1972). Indeed, those prokaryotes which encode the terminal CCA within the tRNA genes 
also possess tRNA nucleotidyltransferase for repairing the tRNA 3’ ends (Zhu and 
Deutscher, 1987). Furthermore, a third isoform of the tRNA nucleotidyltransferase is 
imported into mitochondria accounting for CCA addition to the tRNAs encoded in the 
genome of these organelles (Mukerji and Deutscher, 1972; Chen et al., 1992). 
An intriguing characteristic of tRNA nucleotidyltransferases is their ability to specifically 
and exactly add the CCA overhang in a stepwise reaction without the requirement of any 
nucleic acid template. Interestingly, this property is shared by two distinct classes of 
tRNA nucleotidyltransferases which seem to have evolved independently from each other 
(Aravind and Koonin, 1999). Class I tRNA nucleotidyltransferases are found in archea 
and they share similarities to the eukaryotic poly(A) polymerases. Class II enzymes, 
instead, are found in bacteria and eukaryotes. The crystal structures of representatives 
from both classes have been solved (reviewed in Xiong and Steitz, 2006 and Betat and 
Mörl, 2015), unraveling extensive structural and mechanistic differences. Nevertheless, 
both enzyme types generate an environment which mimics Watson-Crick base pairing for 
selecting the correct nucleotide to incorporate; however, they exploit different strategies. 
The active site of class II enzymes forms a selectivity filter only via the side chains of its 
own amino acids. This mechanism is therefore referred to as “protein templating” (Li et 
al., 2002; Tomita et al., 2004). Contrarily, in class I enzymes the side chain of a specific 
amino acid as well as interactions with the phosphate backbone of the bound tRNA 
substrate contribute to the correct nucleotide selection (Xiong and Steitz, 2004).  
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During polymerization, tRNA nucleotidyltransferases undergo a specificity switch after 
the incorporation of the second C nucleotide and are prompted for the addition of the 
terminal A nucleotide. This exceptional feature distinguishes tRNA 
nucleotidyltransferases from the other template-independent polymerases, namely 
poly(A) polymerases, terminal RNA uridylyltransferases (TUTase) and the terminal 
deoxynucleotidyl transferase, as these enzymes simply add homopolymeric sequences to 
their targets. Mechanistically, this process has been unraveled thanks to the structural 
information acquired from class I tRNA nucleotidyltransferases. It has been described 
that the nucleotide binding pocket of the enzymes is subjected to changes in size and 
shape consequent to the progressive extension of the tRNA 3’ end in such a manner that 
only an ATP molecule can be accommodated in the active site for the final reaction. This 
conformational resetting is supported by the intrinsic flexibility of the so-called head 
domain which bears the catalytic center. Thus, during CCA addition the tRNA substrate is 
maintained in the same position (Shi et al., 1998a), while the head domain is repositioned 
progressively on the extending tRNA end (Xiong and Steitz, 2004). 
Of note, although the overall structure of class I and class II tRNA nucleotidyltransferases 
exhibits great differences, both enzymes are able to recognize their substrates on a similar 
way. TRNA nucleotidyltransferases are obligated to recognize their substrates 
independently of their sequences in order to attach the invariant CCA overhang to the 3’ 
ends of all tRNAs. Thus, it is not surprising that both enzyme classes almost exclusively 
interact with the sugar-phosphate backbone of the tRNAs and that their peculiar shape is 
the main determinant for substrate binding. TRNAs have an L shaped tertiary structure, 
whereby the acceptor stem together with the T-arm form the so-called minihelix, while 
the other edge is formed by the anticodon stem-loop and the D-arm. In this regard, tRNA 
nucleotidyltransferases have developed an extended cleft which is perfectly suited to 
accommodate the minihelix structure in such a manner, that the 3’ end of the tRNA is 
positioned within the active site of the head domain (Tomita et al., 2004; Xiong and 
Steitz, 2004). However, an interesting finding was done when in vitro CCA-addition 
assays were performed with an excess of the enzyme in respect to the RNA substrates. 
This condition ensured single-turnover kinetics and revealed that constructs consisting 
only of the minihelix portion were not suitable substrates for tRNA 
nucleotidyltransferases (Dupasquier et al., 2008), despite previous observations achieved 
under different experimental setups (Shi et al., 1998b). Even more intriguing is the fact 
that a full-length tRNA with a nick in the anticodon loop turned out as well to be an 
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unsuited substrate, although the anticodon loop is not contacted at all by the tRNA 
nucleotidyltransferases. Thus, it has been postulated that these enzymes possess the innate 
ability to sense structural stability of the tRNAs and are therefore involved in quality 
control mechanisms (Dupasquier et al., 2008).  
This hypothesis has been confirmed by the discovery of a tRNA nucleotidyltransferase-
dependent tRNA degradation pathway, whereby structurally unstable tRNAs and 
unfunctional tRNA-like sRNAs are marked by a second CCA-addition cycle. The 
resulting CCACCA 3’ end behaves like a degradation tag which might recruit several 
exonucleases (Wilusz et al., 2011). Recent and comprehensive crystallographic studies 
have revealed how tRNA nucleotidyltransferases are able to prevent damaged and 
therefore potentially harmful tRNAs from becoming available for protein synthesis. Once 
the first CCA has been added, the head domain of the tRNA nucleotidyltransferase adopts 
a conformation which is competent for a second CCA-addition cycle and a new 
nucleotide for the polymerization reaction is bound. By doing so, the head domain 
generates a clockwise screw motion leading to the overwinding and compression of the 
bound substrate. A stable tRNA is resistant to this tension and is released without further 
consequences. Instead, the torque force applied on defective tRNAs causes the on-enzyme 
refolding of the bound RNA, whereby a small bulge is ejected in proximity of the 3’ end. 
If the substrate adopts such a conformation the tRNA nucleotidyltransferase is 
consequently able to catalyze a second CCA-addition cycle. The enzyme therefore 
employs a strategy resembling the action of a vise for interrogating the structural property 
of the bound tRNA (Kuhn et al., 2015).  
 
1.1.6. Extravagant Splicing Mechanism for tRNA Introns 
1.1.6.1. A Specialized Splicing Machinery Removes tRNA Introns 
 
Of the 606 annotated human tRNAs, 34 contain an intron sequence (Chan and Lowe, 
2015). The proportion of intron-containing to intron-less tRNA genes varies substantially 
across different organisms. In S. cerevisiae for example, 21.5% of the tRNAs harbor 
introns, compared to 5.6% of the human genome (Chan and Lowe, 2015). Also the length 
of the embedded introns differs and usually ranges between 6 and 133 nucleotides, 
whereby extraordinary long introns of about 200 nucleotides have been predicted in some 
insects (Chan and Lowe, 2015; Lu et al., 2015). The position within the body of 
eukaryotic tRNAs instead is extremely conserved and introns mostly start at the second 
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nucleotide 3’ to the anticodon sequence. Some particular exceptions have been found 
instead in archea, whereby the most extreme case is represented by the so-called “split 
tRNA genes”. Here, mature tRNAs are produced by the ligation of two halves originating 
from completely independent transcripts (Randau et al., 2005a, 2005b). 
Apart from such exotic tRNA precursors, it has been shown by chemical and enzymatic 
probing of several yeast pre-tRNAs that the presence of the introns does not significantly 
affect their secondary and tertiary structure compared to their mature species. The intron 
sequence generates a double-stranded segment by base-pairing with elements of the 
anticodon loop and thereby forms a helix just extending the anticodon stem (Swerdlow 
and Guthrie, 1984; Lee and Knapp, 1985). While archeal pre-tRNA introns are 
characterized by a bulge-helix-bulge motifs present at both splice sites (Daniels et al., 
1985; Thompson and Daniels, 1990; Marck and Grosjean, 2003), the structural features of 
eukaryotic intron-containing pre-tRNAs are less sophisticated. In this regard, the presence 
of a so-called A-I (for anticodon-intron) interaction upstream of the 5’ splice sites is 
required, as well as the typical tRNA folding (Mattoccia et al., 1988; Reyes and Abelson, 
1988; Baldi et al., 1992). It is therefore not surprising that splicing of pre-tRNA introns in 
archea and in eukaryotes exhibits some mechanistic differences, for example in the 
positioning of the splicing enzymes on their substrates (reviewed in Belfort and Weiner, 
1997). The rest of this section will focus on the molecular aspects of tRNA splicing in 
eukaryotes. 
In these organisms, removal of pre-tRNA introns relies on the function of a dedicated 
tRNA splicing endonuclease (TSEN) complex, which is not related to the spliceosome 
required for pre-mRNA processing. First described in yeast (Rauhut et al., 1990; Trotta et 
al., 1997) and later in humans (Paushkin et al., 2004), the eukaryotic TSEN complex is a 
heterotetramer composed of Sen2, Sen34, Sen54 and Sen15 subunits, whereof Sen2 and 
Sen34 are catalytically active. Each of these two subunits catalyzes a phosphoester 
transfer reaction, resulting in the cleaved intron and in the 5’ and 3’ tRNA halfes. These 
bear respectively at the resected ends a 2’,3’-cyclic phosphate and a 5’-OH (Peebles et al., 
1983). Studies conducted in yeast mutant strains argued that Sen2 is responsible for the 
cleavage reaction at the 5’ site (Ho et al., 1990), while Sen34 is designated to cut at the 3’ 
site (Trotta et al., 1997). In addition, it has been proposed that Sen34 is involved in 
positioning the RNA within the active site of Sen2, therefore supporting cleavage at the 5’ 
site as well (Trotta et al., 2006). 
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The two structural subunits, Sen54 and Sen15, have been shown to interact, respectively, 
with Sen2 and Sen34 (Trotta et al., 1997; Li et al., 1998). Unfortunately, the structure of 
the eukaryotic TSEN complex has not been solved yet, and the only information available 
is a model based on the crystal structure of a dimeric archeal splicing endonuclease bound 
to an RNA substrate (Xue et al., 2006). These data corroborate the hypothesis formulated 
almost two decades in advance that the TSEN complex acts as a molecular ruler for the 
correct positioning of the enzyme on the intron-containing pre-tRNA (Reyes and 
Abelson, 1988). In particular, it has been proposed that the Sen54 subunits contact the 
characteristic structures present also in mature tRNAs which are required as well for 
correct splicing (Di Nicola Negri et al., 1997; Li et al., 1998; Xue et al., 2006). 
A major issue to be considered regarding splicing in eukaryotes is that although the 
molecular components of the TSEN complex are conserved across evolution, the 
localization of tRNA splicing is totally different between yeast and vertebrates. As 
mentioned previously, the first steps in tRNA maturation occur in the nucleus, where 
RNase P and RNase Z are localized (reviewed in Hopper et al., 2010). This also applies 
for the vertebrate’s TSEN complex (Melton et al., 1980; Paushkin et al., 2004) but not for 
the yeast’s complex which localizes in the cytoplasm and associates with the 
mitochondrial outer membrane. This finding implies that end-processed, intron-
containing pre-tRNA intermediates are exported from the nucleus, spliced at the 
mitochondrial surface and re-imported into the nucleus where the final steps of 
maturation take place. The reason for such a laborious process is not well understood. It 
has been found that the depletion of TSEN complex components results in impaired 
rRNA processing (Volta et al., 2005). This phenotype could not be complemented by 
exogenous, nuclear-targeted TSEN complex, while pre-tRNA splicing and further 
maturation occurred normally (Dhungel and Hopper, 2012). Thus, it is tempting to 
speculate that in yeast the localization of the TSEN complex at the mitochondrial 
membrane has acquired novel functions unrelated to tRNA splicing. The TSEN complex 
has been shown additionally to cleave the mRNA encoding the cytochrome b mRNA 
processing 1 (Cbp1) protein, which co-translationally localizes at the mitochondrial 
surface (Tsuboi et al., 2015). Of note, the nuclear localized human TSEN complex has 
been related to pre-mRNA processing (Paushkin et al., 2004). All together, the distinct 
localization of the tRNA splicing machinery in yeast and humans might result from the 
necessity to adapt the function of the endonucleases to novel requirements unrelated to 
tRNA biogenesis.  
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1.1.6.2. Diverse Strategies for Joining the tRNA-Splicing Intermediates 
 
Following the endonucleolytic cleavage of the pre-tRNA intron, the resulting two tRNA 
halves need to be ligated. In the past years several studies have contributed to shed light 
on this process, which has been, and to some extent still is, enigmatic. Two different 
strategies have been reported and the text-book knowledge is that fungi and plants rely on 
the so-called 5’-phosphate ligation pathway, while other organisms like vertebrates use 
the 3’-phosphate ligation pathway. However, since extracts from mammalian cell lines 
are able in vitro to catalyze the same reactions of the 5’-phosphate ligation pathway 
(reviewed in Yoshihisa, 2014) and some mutations in the corresponding genes have been 
implicated in tRNA splicing abnormalities and severe diseases (Hanada et al., 2013; 
Karaca et al., 2014; Schaffer et al., 2014), the 5’-phosphate ligation pathway might be 
active also in vertebrates, at least to a minor extent (see also section 1.1.10.1).  
The 5’-phosphate ligation pathway requires two enzymes, the multi-domain protein tRNA 
ligase 1 (Trl1) (Greer et al., 1983; Xu et al., 1990) and the tRNA 2’-phosphotransferase 1 
(Tpt1) (McCraith and Phizicky, 1990). The former enzyme catalyzes three distinct 
reactions which finally yield the ligated tRNA with a 2’-phosphate left at the splice site. 
To this end, the cyclic phosphodiesterase domain of Trl1 first opens the 2’,3’-cyclic 
phosphate at the 3’ terminus of the 5’ tRNA half generating a 2’-phosphate. Next, the 5’ 
end of the 3’ tRNA half is phosphorylated by the NTP-dependent polynucleotide kinase 
domain of Trl1. The actual ligation reaction is subsequently carried out by a third domain, 
whereby the phosphorylated 5’ end of the 3’ tRNA half is first activated by transfer of 
AMP from an adenylated Trl1 intermediate and then joined to the 5’ tRNA half (Greer et 
al., 1983). Finally, Tpt1 removes the 2’-phosphate still present at the splice junction 
(McCraith and Phizicky, 1990) by transferring it onto a nicotinamide adenine 
dinucleotide (NAD+) molecule generating ADP-ribose 1”-2” cyclic phosphate (McCraith 
and Phizicky, 1991; Culver et al., 1993). 
The characterization of the 3’-phosphate ligation pathway largely benefited from recent 
studies performed in the human system. It has been known for several years that the 
phosphate at the newly formed phosphodiester bond joining the two tRNA halves is 
derived from the 3’-phosphate resulting at the 5’ tRNA half after splicing (Filipowicz and 
Shatkin, 1983; Filipowicz et al., 1983; Laski et al., 1983). This differs from the situation 
in fungi and plants, where the phosphate at the splice junction originates from the de novo 
phosphorylation of the 5’ end of the 3’ tRNA half as mentioned above. Isolation of the 
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vertebrate’s enzyme which directly ligates the 2’,3’-cyclic phosphate and the 5’-OH 
termini had been achieved already in the past (Perkins et al., 1985). However, molecular 
characterization of this RNA ligase occurred almost three decades later (Popow et al., 
2011). The enzyme has been named RTCB (previously also known as HSPC117) and was 
shown to form a multimeric protein complex together with ASW, RTRAF, FAM98B and 
the DEAD-helicase DDX1. Further studies revealed that the ATPase activity of the latter 
protein is required for RTCB-mediated ligation reactions (Popow et al., 2014). Even more 
intriguing is the fact that an additional protein, ZBTB8O (also known as archease), 
drastically stimulates the multiple turnover activity of the ligase in a GTP-dependent 
manner. Thus, ZBTB8O supports the formation of a guanylated RTCB intermediate. It 
has been proposed that the GMP moiety would be then transferred to the 3’ end of the 5’ 
tRNA half (Popow et al., 2014). However, in vertebrates neither has the activation of the 
3’ end by this GMP transfer been experimentally proven, nor has the activity which opens 
the 2’,3’-cyclic phosphate at the 3’ end been identified. 
Interestingly, Trl1 in yeast and the RTCB ligase in metazoa, although differing in their 
molecular mode of action, share an additional function which is not related to tRNA 
splicing. It has been specifically shown that they participate in the unfolded protein 
response pathway which is triggered by the non-canonical splicing of the relevant 
HAC1/XBP1 mRNA. In this context, Trl1/RTCB join the resulting two exons allowing 
translation of the transcription factor encoded by the spliced mRNA (Sidrauski et al., 
1996; Jurkin et al., 2014; Kosmaczewski et al., 2014; Lu et al., 2014).  
 
1.1.7. Mechanisms of tRNA Export from the Nucleus  
 
As illustrated by the biogenesis of intron-containing tRNAs in yeast (see section 1.1.6.1), 
the movement of tRNAs between the nucleus and the cytoplasm is neither unidirectional 
nor dependent on a single mechanism. Kinetic measurements after nuclear 
microinjections provided the first piece of the complex mosaic depicting the subcellular 
trafficking of tRNAs. It was shown that export of tRNAs was not driven by diffusion 
despite their small molecular size, but was likely to be mediated by some carrier (Zasloff, 
1983). As more studies identified the factors required for the nuclear-cytoplasmic 
transport of proteins, their influence on tRNA localization was investigated. It was thus 
found that tRNA transport depends on the nuclear pool of RanGTP (Izaurralde et al., 
1997). Soon after the responsible export factor was identified in vertebrates, and on 
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account of its role in tRNA metabolism it was termed Exportin-t (Xpo-t) (Arts et al., 
1998a; Kutay et al., 1998). Sequence comparisons revealed that Xpo-t is a homolog of the 
yeast protein Los1 (Kutay et al., 1998), which was previously shown to affect processing 
of intron-containing tRNAs (Hopper et al., 1980; Hurt et al., 1987; Sharma et al., 1996; 
Simos et al., 1996). It is now clear that Xpo-t is a member of the karyopherin-β family 
which is regulated by the GTPase Ran. Xpo-t directly binds tRNAs in the nucleus by the 
cooperative interaction with RanGTP and it mediates the export through the nuclear pore 
complexes. In the cytoplasm, hydrolysis of RanGTP occurs by the action of the Ran 
GTPase-activating protein which leads to the release of the tRNA cargo.  
Chemical and enzymatic footprinting assays (Arts et al., 1998b) and later the crystal 
structure of a RanGTP-Xpo-t-tRNA complex (Cook et al., 2009) demonstrated that Xpo-t 
contacts the phosphate backbone of tRNAs mainly at the acceptor stem and the T-arm 
which together form the so-called minihelix portion. In addition, the 5’ end of the tRNA 
is buried in a binding pocket and its 3’ end lies within a groove on the protein’s surface. It 
is thus evident that Xpo-t binding per se subjects tRNAs to a quality control as it requires 
the structural elements of correctly processed and folded tRNAs. Because the anticodon 
stem is not contacted at all, the presence of a tRNA intron (which always occurs at this 
site) does not hinder binding of the export complex. This property is important since in 
yeast, end-matured, intron-containing tRNA intermediates need to be delivered to the 
tRNA splicing machinery which is localized in the cytoplasm. Until recently, only 
Los1/Xpo-t was experimentally shown to fulfil this task, however, the existence of at least 
one additional factor exporting intron-containing tRNAs was assumed (reviewed in 
Hopper, 2013). In this regard, a genome-wide screen of vast yeast mutant collections 
provided first evidence that Crm1, known in vertebrates as Exportin-1 (Xpo1) might have 
such an overlapping function (Wu et al., 2015). Crm1/Xpo1 is as well a member of the 
karyopherin-β family and is the major export factor of nuclear proteins and of several 
RNP complexes (Fornerod et al., 1997; Stade et al., 1997). In addition, the two 
components of the general mRNA export machinery, namely, Mex67 and Mtr2, known in 
vertebrates as NXF1 and NXT1, respectively, might also contribute to the export of 
intron-containing tRNAs (Wu et al., 2015). However, it is not yet clear to what extent and 
under which conditions this export pathway might be exploited.   
As it will be described in more detail within section 1.1.8.2, tRNAs can be aminoacylated 
already within the nucleus for quality control purpose. In addition, cytoplasmic tRNAs 
are imported into the nucleus not only in response to stress conditions but also 
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constitutively (Grosshans et al., 2000; Shaheen and Hopper, 2005; Takano et al., 2005). 
Importantly, the positioning of the terminal nucleotide of the tRNA within the crystal 
structure of the ternary RanGTP-Xpo-t-tRNA complex does not preclude the presence of 
an amino acid (Cook et al., 2009). In fact, a recent study demonstrated that Los1, the 
yeast homolog of Xpo-t, interacts with uncharged, as well as with aminoacylated, tRNAs 
(Huang and Hopper, 2015). Therefore, experimental evidence suggests that at least for 
certain tRNA Los1/Xpo-t is involved in the primary export of intron-containing tRNAs as 
well as in the export of mature tRNAs either in their aminoacylated or in the deacylated 
form.  
Although Xpo-t/Los1 has been extensively shown to play the major role in trafficking 
tRNAs to the cytoplasm, the fact that Los1 yeast deletion strains have a normal growth 
phenotype (Hurt et al., 1987) suggests that other overlapping export and re-export 
pathways of mature tRNAs exist. Indeed, even before being identified as the canonical 
export factor of precursor miRNAs (pre-miRNAs) (Lund et al., 2004), it was found that 
Exportin-5 (Xpo5) is involved in tRNA export processes in a RanGTP-dependent manner 
(Bohnsack et al., 2002; Calado et al., 2002). In contrast to the Los1 deletion strain, the 
primary export of intron-containing tRNA intermediates is not impaired in yeasts lacking 
Msn5, the ortholog of Xpo5. Instead, mature tRNAs originating from intron-containing as 
well as intron-less tRNA genes accumulate in their nuclei (Murthi et al., 2010). It has 
been therefore proposed that Xpo5/Msn5 might be dedicated to the general export and re-
export of charged tRNAs (Murthi et al., 2010; Huang and Hopper, 2015). Supporting this 
hypothesis is the fact that Xpo5 transfers the tRNA to the cytoplasm in a quaternary 
complex together with eEF1A, which is the eukaryotic elongation factor delivering 
aminoacylated tRNAs to the ribosome (Bohnsack et al., 2002; Calado et al., 2002; Huang 
and Hopper, 2015). It had been proven already in previous studies that the reduction of 
eEF1A levels leads to nuclear accumulation of mature tRNAs (Grosshans et al., 2000), 
but at the time of these investigations the dependency on Xpo5/Msn5 was unknown. Still 
nowadays some properties of the aminacyl-tRNA-eEF1A-Xpo5-RanGTP complex remain 
puzzling. For example, first in vitro analyses indicated that Xpo5/Msn5 binds directly to 
the tRNA and, consequently, it interacts with eEF1A on a tRNA-dependent manner 
(Bohnsack et al., 2002; Calado et al., 2002). A recent in vivo study however opened the 
possibility that Xpo5/Msn5 might dimerize with eEF1A in the absence of tRNAs whereby 
eEF1A would be required to stabilize the binding to the tRNA (Huang and Hopper, 
2015). This issue is very intriguing because structural studies of eEF1A (Andersen et al., 
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2000) and of its prokaryotic ortholog EF-Tu (Nissen et al., 1995) demonstrate that they 
contact the aminoacylated tRNA at its 3’ end. Also the 3’ end of pre-miRNAs participates 
in the interaction with Xpo5 and is placed into a tunnel formed by the protein (Okada et 
al., 2009). All together, Xpo5/Msn5 and eEF1A should both be able to bind to the 3’ end 
of tRNAs. It remains a matter of speculation how this interaction, which at a first glance 
would seem to be mutually exclusive, looks like in the quaternary aminoacyl-tRNA-
eEF1A-Xpo5-RanGTP complex. Interestingly, this export pathway not only ensures that 
mature tRNAs gain access to the cytoplasm and that eEF1A is constantly excluded from 
the nucleus (Bohnsack et al., 2002), but it seems also that specific transcription factors 
can be trapped on the aminoacyl-tRNA-eEF1A-Xpo5-RanGTP complex and are thereby 
transported out of the nucleus (Mingot et al., 2013).  
 
1.1.8. Final Processing by Aminoacyl-tRNA Synthetases 
1.1.8.1. Loading of the Cognate Amino Acid 
 
In contrast to all biogenesis steps described so far, which rely on generalized recognition 
mechanisms, the enzymes involved in loading a given tRNA with its cognate amino acid 
are highly specialized and thus extremely accurate in order to avoid the deleterious 
potential of mischarged tRNAs. As a consequence, eukaryotes possess the complete set of 
20 different ARS activities. Each of them is dedicated to the direct charging of a specific 
amino acid onto the same cytoplasmic tRNA isotypes, i.e., all those tRNA isoacceptors 
whose anticodon sequences decode the same amino acid. Of note, 18 ARSs are encoded 
by separate genes while a bifunctional ARS (EPRS) loads glutamic acid or proline on the 
cognate tRNAs using two distinct domains (Cerini et al., 1991). According to the standard 
nomenclature, all other cytoplasmic ARSs are named with the single-letter amino acid 
code followed by “ARS” (e.g., the alanyl-tRNA synthetase is reffered to as AARS). 
The general aminoacylation reaction catalyzed by ARSs can be divided into two steps. 
First, the amino acid is activated at its carboxyl group by ATP generating an aminoacyl-
adenylate intermediate. Successively, the amino acid is transferred to the 3’-terminal 
adenosine of the tRNA by which an ester bond is formed (reviewed in Ibba and Soll, 
2000). Surprisingly, two different types of ARSs seem to have evolved independently 
from each other in order to fulfill this fundamental task. ARSs can therefore be divided 
into class I and class II types depending on the presence of specific sequence motifs. The 
active site of class I ARSs is characterized by a Rossmann fold, while class II ARSs 
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possess an anti-parallel β-fold. These structural domains do not only determine a different 
mode for binding the ATP and the tRNA substrate, but even more strikingly they affect 
the chemistry of the catalyzed reaction. Indeed, class I ARSs attach the amino acid to the 
2’ hydroxyl group of the tRNA adenosine end, while class II ARSs to the 3’ hydroxyl 
group (reviewed in Sprinzl, 2006). In solution however, spontaneous transacylation 
occurs (Reese and Trentham, 1965; Griffin et al., 1966) resulting in a mixture of 2’ and 3’ 
aminoacylated tRNAs. Nevertheless, only tRNAs carrying the amino acid at the 3’ 
position are able to accomplish all steps occurring during translation. Of particular note, 
the 2’ hydroxyl group at the terminal adenosine has been shown to participate actively in 
the peptide bond formation (Weinger et al., 2004). It is therefore crucial that the tRNAs 
delivered to the ribosome are in the 3’ aminoacyl configuration. Studies determining the 
kinetics of the transacylation reaction suggested that an enzymatic factor exists, which 
enhances this reaction and stabilizes the useful 3’ aminoacylated tRNAs (Taiji et al., 
1983). This 2’-3’ isomerase activity has later been attributed to the elongation factor 
which binds aminoacylated tRNAs and delivers them to the A-site of the ribosomes (Taiji 
et al., 1985; Nissen et al., 1995; Safro and Klipcan, 2013).   
It is plausible to assume that the aminoacylation of tRNAs is one of the most ancestral 
processes to have emerged during evolution and, consequently, these reactions would be 
expected also to be highly conserved. Instead, this is not at all the case (reviewed in 
Woese et al., 2000). As already mentioned, the charging of different tRNA isotypes is 
accomplished by two structurally unrelated classes of ARSs, suggesting that novel 
enzymes have evolved and ultimately have replaced, at least for some amino acids, the 
original ARSs. Even more stunning is the fact that archea and some bacteria exploit an 
indirect aminoacylation pathway to generate tRNA-Gln and in some cases also tRNA-Asn 
(reviewed in Tumbula et al., 1999). With some exceptions, these organisms lack the genes 
encoding the ARSs for direct aminoacylation. Instead, tRNAs charged with Gln (or Asn) 
are generated by tRNAs-Gln (or tRNAs-Asn) which are first misacylated by a non-
discriminating glutamyl-ARS (or aspartyl-ARS) with Glu (or Asp). In a second reaction, 
the “precursor” amino acid is converted on the tRNA to Gln (or Asn) by an 
amidotransferase (Wilcox and Nirenberg, 1968). Importantly, this transamidase pathway 
is responsible for the generation of tRNA-Gln also in eukaryal organells, mitochondria 
and chloroplasts, which do not possess a Gln-ARS (Martin et al., 1977; Schön et al., 
1988; Nagao et al., 2009). In general, human mitochondria possess a complete set of 
tRNAs (mt-tRNAs) which are transcribed from the mitochondrial genome, while most of 
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the mitochondrial ARSs are encoded by specialized genes on the nuclear DNA (reviewed 
in Diodato et al., 2014). An exception are Gly- and Lys-ARS which originate from one 
nuclear gene respectively encoding the cytoplamic as well as the mitochondrial protein 
isoforms (Shiba et al., 1994; Tolkunova et al., 2000). 
It was realized quite early, that some cytoplasmic ARSs assemble together in a 
macromolecular multisynthetase complex (Bandyopadhyay and Deutscher, 1971), which 
encompasses at least nine ARS activities (Cirakoglu et al., 1985; Kerjan et al., 1994) 
together with three accessory proteins (Quevillon and Mirande, 1996; Quevillon et al., 
1997, 1999). The latter have been termed aminoacyl tRNA synthetase complex-
interacting multifunctional protein 1-3 (AIMP1-3), since they also exert diverse biological 
functions not related to the aminoacylation of tRNAs (Knies et al., 1998; Kim et al., 2003; 
Park et al., 2005).  
The fact that different ARSs assemble together suggests that concentrating these enzymes 
in something which could be interpreted as “aminoacylation factories” might have some 
beneficial consequences. Indeed, it has been shown that tRNAs aminoacylated by the 
multisynthetase complex contribute mainly to protein synthesis, rather than those 
aminocylated by an ARS variant not present in high molecular mass complexes (Kyriacou 
and Deutscher, 2008). In addition, several ARSs, including the multisynthetase complex, 
have been found associated to the ribosome (Irvin and Hardesty, 1972; Ussery et al., 
1977; Kaminska et al., 2009). These studies reinforced a hypothesis which was 
formulated in earlier times, namely, that for overcoming the great demand of 
aminoacylated tRNAs required during protein synthesis, tRNAs might be re-acylated 
immediately after supplying the amino acid for translation (Smith, 1975; Negrutskii and 
Deutscher, 1991, 1992; Stapulionis and Deutscher, 1995). In this regard, channeling 
tRNAs from the ribosome directly to ARSs and back might be an efficient strategy for 
maintaining adequate levels of charged tRNAs.  
 
1.1.8.2. ARSs Safeguard Correct tRNA Maturation at Several Steps 
 
The many sections of this introduction underline the great efforts spent by the cell in the 
production of functional tRNAs. It is thus fundamental to ensure that the final products 
are processed correctly whereby ARSs play an important proofreading role. Although 
their main function is exerted in the cytoplasm, ARSs are also present in the nucleus 
where they undertake the first aminoacylation reaction of the newly synthetized tRNAs. It 
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has been shown that those tRNAs which fail to be loaded with their cognate amino acids 
due to structural deficiencies are hindered from entering the cytoplasm and therefore do 
not join the translation cycle (Lund and Dahlberg, 1998; Sarkar et al., 1999).    
Furthermore, ARSs safeguard the correct aminoacylation of tRNAs at several steps 
resulting in a great accuracy. First of all, each ARS is specialized in order to recognize its 
cognate tRNA by extensive interactions not only with the anticodon, but also with the 
acceptor stem and in particular with the discriminator base. Also, features which are 
characteristic for certain tRNA isoacceptors are efficiently recognized by these enzymes. 
In this regard, specific nucleotide modifications have been shown to signal the identity of 
the tRNA (reviewed in Ibba and Soll, 2000). ARSs are required to face an even greater 
challenge when discriminating between cognate and similar non-cognate amino acids, as 
these can differ in as little as a single methyl group. It was noticed quite early, that ARSs 
are able to hydrolyse non-cognate aminoacyl-adenylate intermediates avoiding the likely 
event of misacylating an incorrect tRNA (Baldwin and Berg, 1966). Studies performed 
over several years revealed that ARSs can be equipped with two intrinsic editing 
activities. The first is in fact directed against the aminoacyl-adenylate intermediate itself, 
so that the wrong amino acid is prevented from loading. This mechanism is referred to as 
“pre-transfer proofreading”. The “post-transfer proofreading” mechanism intervenes if a 
tRNA has been misacylated avoiding its release from the enzyme. Instead, it is transferred 
to the editing site which removes the incorrect amino acid (reviewed in Jakubowski, 
2012). Only those aminoacyl-tRNAs passing all these checkpoints are finally used by the 
ribosomes to assemble the polypeptides which make up the proteomic landscape of the 
cell.  
 
1.1.9. Quality Control and Turnover of tRNAs 
 
Several enzymes involved in the biogenesis of tRNAs fulfill not only their actual task, 
they also monitor the quality of the tRNA intermediates with which they interact. As 
mentioned already, this is the case for the tRNA nucleotidyltransferase, Xpo-t and ARSs. 
The former protein adopts an ingenious strategy for actively interrogating the structure of 
its substrates. Instable tRNAs are thereby marked with a CCACCA end which finally 
leads to their degradation (see section 1.1.5 for more details).  
Instead, Xpo-t (Cook et al., 2009) and ARSs (Lund and Dahlberg, 1998; Sarkar et al., 
1999; and reviewed in Ibba and Soll, 2000) achieve a quality control function due merely 
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to their structural properties which allow stringent binding of correctly matured and 
folded tRNAs. The fate of those tRNAs that do not pass such checkpoints is still unclear. 
Do proteins exist that specifically recognize misprocessed tRNAs and channel them into 
degradation pathways? An alternative possibility might hold true, considering that newly 
synthesized transcripts are constantly threatened by degradation, for example through the 
nuclear surveillance pathway (reviewed in Wichtowska et al., 2013). In fact, it has been 
reported that ~50% of all newly transcribed tRNA precursors are degraded by the 
exosome (Gudipati et al., 2012; Schneider et al., 2012). From this perspective, aberrant 
tRNAs might be easy prey for exonucleases due to their inefficient protective interaction 
with processing enzymes (Copela et al., 2008). Indeed, experimental evidence revealed 
that pre-tRNAs are processed more slowly if they do not possess certain modifications 
resulting in degradation by the concerted action of the TRAMP and of the nuclear 
exosome complexes (see section 1.1.4.3 and Kadaba et al., 2004).  
Importantly, tRNAs quality is not only controlled during their production, but also at their 
mature state. Although tRNAs are extremely stable with half-lives ranging from hours to 
days (Weber, 1972; Kanerva and Mäenpää, 1981) a pathway has been identified over the 
last decade that is dedicated to the degradation of aberrant, mature tRNAs (Alexandrov et 
al., 2006). Most of the studies have been performed in yeast strains lacking enzymes 
responsible for certain tRNA modifications which showed remarked growth phenotypes 
when they were shifted to higher temperatures (Alexandrov et al., 2006; Chernyakov et 
al., 2008; Whipple et al., 2011; Turowski et al., 2012). It was understood that under these 
conditions the aminoacylation levels as well as the steady-state levels of hypomodified 
mature tRNAs decreased very rapidly (reduction by 50% within 30 min). For this reason 
the newly identified pathway acting on mature tRNAs was termed rapid tRNA decay 
(RTD) and was shown to by independent from the genes involved in the nuclear 
surveillance, i.e., the TRAMP and the exosome complexes. Also, the degradation of 
tRNAs seemed to be uncoupled from translation since it occurred even during 
cycloheximide treatment (Alexandrov et al., 2006). Later analyses unraveled the 
molecular components involved in RTD, namely, the two 5’-3’ exonucleases Xrn1 and 
Xrn2 (also known as Rat1 in yeast) which localize, respectively, in the cytoplasm and the 
nucleus (Chernyakov et al., 2008).  
An important topic for deciphering the mechanistic details of RTD concerns its substrate 
specificity. It was clear that the lack of modifications itself is not sufficient to trigger 
RTD, as only a subset of tRNAs known to possess the missing modifications were 
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targeted by Xrn1/2 (Alexandrov et al., 2006; Chernyakov et al., 2008). Careful analyses 
revealed that those tRNA species with less stable acceptor and T-stems were preferred 
RTD substrates. In other words, the structural stability of such tRNAs relies more on 
certain modifications, and if these are lacking, the tRNAs are easily degraded, most likely 
because their 5’ end is more accessible for the exonucleases (Whipple et al., 2011). These 
observations were later confirmed by a high-throughput mutation screening, which 
underscored the importance of the tRNA acceptor stem for conferring resistance to RTD. 
However, an unexpected result emerged, since mutations distributed all over the tRNA 
sequence, and not only within the acceptor and T-stem, affected the susceptibility to 
RTD-mediated degradation. The overall integrity of tRNAs seems therefore to be 
monitored. Still, it is not clear how this is detected in the case of mutations which 
apparently should not alter the tertiary structure of tRNAs (Guy et al., 2014). 
Another intriguing aspect is that RTD might selectively act on aminoacylated tRNAs as 
this pool was affected under the different experimental setups, while the levels of 
deacylated tRNAs remained constant (Alexandrov et al., 2006; Chernyakov et al., 2008). 
Several observations support this hypothesis. First of all, RTD competes with eEF1A for 
binding of aminoacylated tRNAs, whereby overexpression of eEF1A inhibits tRNA 
degradation (Dewe et al., 2012). In addition, end-extended tRNA species, which are not 
charged with an amino acid, are not targeted by Xrn1 (Kramer and Hopper, 2013).   
As mentioned previously, Xrn1 and Xrn2 are differentially localized within the cell. Xrn1 
is involved mainly in the degradation of cytoplasmic mRNAs, while Xrn2 contributes in 
the nucleus to the processing of several RNAs, the removal of aberrant transcripts as well 
as Pol II transcription termination (reviewed in Houseley and Tollervey, 2009; Wolin et 
al., 2012). Deletion of both exonucleases has an additive effect in the context of RTD, 
suggesting that both contribute to tRNA degradation (Chernyakov et al., 2008). The 
reason for the requirement of exonucleases localizing in both cell compartments remains, 
nonetheless, largely elusive. Obviously, Xrn1 might be the last instance catching and 
removing aberrant tRNAs which passed all the previous quality control checkpoints as 
well as mature tRNAs which acquired destabilizing damages over time (Chernyakov et 
al., 2008; Kramer and Hopper, 2013). The implications for Xrn2 and nuclear tRNA 
turnover, instead, are more sophisticated. Retrograde tRNA import has been well 
documented during the last years. Although tRNAs have been suggested to be 
constitutively re-imported, nuclear tRNA accumulation is acquired during cellular stress 
conditions (Shaheen and Hopper, 2005; Shaheen et al., 2007; Murthi et al., 2010; 
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Miyagawa et al., 2012). To date, only spare evidence indicates that Xrn2 might 
specifically degrade the mature initiator tRNA-Met following its accumulation in the 
nuclei of heat-stressed HeLa cells (Watanabe et al., 2013). Additionally, some tRNAs 
might reach the cytoplasm before all required nuclear processing events were fulfilled. 
Retrograde transport would thus act as a backup mechanism to return tRNAs which were 
precociously exported. Back in the nucleus, such tRNAs might get a second chance for 
maturation or, alternatively, they might be eliminated (Kramer and Hopper, 2013). 
However, a direct role for Xrn2 in such a context has not been proven yet.  
 
1.1.10. Many Faces of tRNA Fragments 
 
The recent advances in the field of next generation sequencing significantly boosted 
knowledge regarding the widespread occurrence of stable tRNA-derived fragments 
(tRFs). They can be grouped into different categories according to the region from which 
they originate within the longer tRNA transcripts (Figure 1.7). 
Figure 1.7: Different Types of Fragments Originate from Pre-tRNAs (upper panels) or Mature 
tRNAs (lower panels). Possible processing enzymes are indicated at the top of the panels. The regions of 
the tRNA from which the fragments derive is indicated in red. 3’ U-tRF are trailers of pre-tRNAs termi-
nating on a U-stretch. 5’ leader exon fragments and tRNA introns accumulate if splicing is impaired. Some 
tRFs derived from intron-containing pre-tRNAs or mature tRNAs interact with YBX1 (YBX1-tRF). TRNA-
derived stress-induced small RNAs (tiRNAs) are generated by cleavage within the anticodon loop. 5’-tRFs 
begin at the 5’ end of mature tRNAs, 3’ CCA-tRFs usually begin within the T-loop and all of them 
terminate with the CCA end. Internal tRF (i-tRF) can originate from several regions but per definition do 
not span the 5’ and 3’ CCA ends. This is represented by a pale red coloring. Figure adapted from Megel et 
al., (2015), nomenclature of most fragments according to Keam and Hutvagner (2015). 
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Several lines of evidence indicate that at least some tRFs are not just transient by-
products of tRNA turnover, but are a distinct class of sRNAs with regulatory potential. In 
general, the processing of tRNAs into smaller fragments seems to be conserved across 
species (Kumar et al., 2015) and the expression levels of tRFs does not always correlate 
with the abundance of the tRNAs from which they originate. Their production exhibits 
site-specific patterns, and the resulting fragments have characteristic lengths suggesting 
the involvement of specialized enzymes (Figure 1.7) (Cole et al., 2009; Li et al., 2012; 
Telonis et al., 2015). Finally, the functionality of certain tRFs has been proven (Ivanov et 
al., 2011; Goodarzi et al., 2015; Sharma et al., 2016).  
Nevertheless, the major challenge still consists in translating the vast amount of 
descriptive data into functional networks. 5’-tRFs and 3’ CCA-tRFs, for example, are 
easily defined by sequence analysis; however, according to the current literature their 
biogenesis as well as their function seem a potpourri of distinct processes (reviewed in 
Gebetsberger and Polacek, 2013; Keam and Hutvagner, 2015). A critical examination of 
the published studies is therefore required to clarify the reliability of the proposed models. 
In particular, at the beginning, research on tRFs was driven by the discovery of several 
non-canonical miRNAs, and some of these studies were probably biased by assigning 
them miRNA-like characteristics (Cole et al., 2009; Haussecker et al., 2010).  
 
1.1.10.1. Pre-tRNAs as an Early Source of tRFs 
 
Some tRFs can promptly be generated from newly transcribed pre-tRNAs and are, to 
some extent, a physiological consequence of tRNA maturation (Figure 1.7). This is the 
case for 3’ U-tRFs which have been detected in mammalian cell lines. They are the 3’ 
trailers resulting from RNase Z cleavage and Pol III transcription termination. Hence, 
they end on the typical U-stretch. So far, evidence for the functionality of 3’ U-tRFs has 
been achieved only for a fragment originating from a pre-tRNA-Ser, which was shown to 
positively affect cell proliferation rates (Lee et al., 2009). The molecular mechanisms 
underlying this effect are still unknown. Some indication exists that 3’ U-tRFs might 
associate with Argonaute (Ago) proteins, the key players of miRNA-mediated post-
transcriptional gene silencing. However, their relative preference for Ago3-4 compared to 
Ago1-2, as well as their inability to repress target constructs, clearly indicate that 3’ U-
tRFs act in a different way than miRNAs (Haussecker et al., 2010). Thus they might 
interact primarily with factors yet to be identified.  
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In addition, different types of fragments from intron-containing pre-tRNAs have been 
detected recently in cells with mutations in the CLP1 gene (Hanada et al., 2013; Karaca et 
al., 2014). Human patients bearing such mutations, as well as related animal models, 
show severe phenotypes ranging from neuromuscular disorders to progressive and 
widespread neurodegeneration. CLP1 has been described as the first mammalian RNA 
kinase (Weitzer and Martinez, 2007) and was found to interact with the TSEN complex 
which cuts off the introns of pre-tRNAs (Paushkin et al., 2004). Even more importantly, 
different CLP1 mutations turned out to affect the integrity of the TSEN complex and 
thereby resulted in impaired pre-tRNA cleavage. Although some debate exists concerning 
the effect of CLP1 mutations on the steady-state levels of mature tRNAs (Karaca et al., 
2014; Schaffer et al., 2014), it was proven that the accumulation of pre-tRNA fragments 
possesses cytotoxic potential. These harmful sequences were identified in a mouse model 
and consisted of the 5’ tRNA exon half of some pre-tRNAs still containing the 5’ leader 
(Hanada et al., 2013). Also, spliced introns were found to be enriched in fibroblasts 
derived from affected patients (Karaca et al., 2014).  
As illustrated in section 1.1.6.2, the text-book knowledge concerning removal of tRNA 
introns in vertebrates implies that rejoining of the two tRNA parts is achieved via the 3’-
phosphate ligation pathway (Filipowicz and Shatkin, 1983; Filipowicz et al., 1983; Laski 
et al., 1983). This strategy does not require the phosphorylation of the splicing 
intermediates, and thus it should not depend on the kinase activity of CLP1. Nevertheless, 
the mass of evidence provided in the studies mentioned above indicates that an alternative 
ligation strategy resembling the 5’-phosphate ligation pathway of fungi and plants might 
be present as well in vertebrates (Hanada et al., 2013; Karaca et al., 2014; Schaffer et al., 
2014). Further investigations are required to unravel the interplay between these different 
splicing mechanisms and to clarify whether toxic fragments might also occur in CLP1 
wild type conditions.  
 
1.1.10.2. Mature tRNA Halves 
 
The most distinct class of tRNA-derived fragments consists of those generated by 
cleavage within the anticodon loop, resulting in two similarly long halves (Figure 1.7). 
Interestingly, tRNA halves have been observed already in the 70’s appearing very rapidly 
in E. coli after infection by bacteriophage T4 (Yudelevich, 1971). Later works revealed 
that tRNA cleavage was mediated by a specific endoribonuclease and was part of an 
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antiviral response of the host leading to the suicide of infected cells (Levitz et al., 1990). 
It is not surprising that effective tRNA cleavage has a potent cytotoxic effect. This is 
exploited as well by some bacteria (Ogawa et al., 1999; Tomita et al., 2000) and yeast 
species (Lu et al., 2005; Klassen et al., 2008; Chakravarty et al., 2014) which secrete so-
called ribotoxins to kill surrounding competitor cells.  
TRNA halves have been identified in eukaryotes also under physiological conditions. 
This is the case for example for the recently described Sex HOrmone-dependent TRNA-
derived RNAs (SHOTRNAs), which are expressed at high levels in sex hormone-
dependent breast and prostate cancer cells (Honda et al., 2015). However, most of the 
studies performed so far focussed on tRNA halves induced in response to cellular stress, 
and the resulting fragments have been therefore termed tRNA-derived stress-induced 
small RNAs (tiRNAs) (Lee and Collins, 2005; Jöchl et al., 2008; Thompson et al., 2008).  
The endonuclease Rny1, which is responsible for the production of tiRNAs in yeast, is a 
member of the RNase T2 family (Thompson and Parker, 2009). In humans, instead, 
tRNAs are sliced into halves by angiogenin (ANG), which is unrelated to Rny1 and is a 
member of the RNase A family (Saxena et al., 1992; Fu et al., 2009; Yamasaki et al., 
2009). ANG has been long known as a secreted growth factor with potent angiogenic 
properties, and was first isolated from the supernatant of an adenocarcinoma cell line 
(Fett et al., 1985). In the following years, the broad spectrum of ANG functions started to 
be unravelled and its ribonucleolytic activity was discovered. However, ANG is 
considerably less active compared to other RNases of the same family (reviewed in Sheng 
and Xu, 2016) and in fact only a small proportion of the general tRNA pool, less than 5%, 
are targeted during stress responses (Thompson et al., 2008; Pang et al., 2014). Due to 
this rather moderate effect on tRNA levels, ANG-mediated cleavage does not exert the 
same harmful potential as ribotoxins. On the contrary, the production of tiRNAs turned 
out to be beneficial for the cell while coping with several kinds of stress. Interestingly, 
tiRNAs are involved in distinct mechanisms, which might reflect a specialization of the 
fragments originating from different tRNA isoacceptors.  
One of these cytoprotective pathways was discovered following hyperosmotic stress of 
mouse embryonic fibroblasts or following excitotoxic stress of human motorneurons. 
Apoptosis is induced under these conditions and an early event triggered by the resulting 
signaling cascade is the release of cytochrome c from the mitochondria (Bevilacqua et al., 
2010; Ivanov et al., 2014). Biochemical in vivo studies revealed that certain tiRNAs 
produced by ANG bind to cytochrome c in the cytoplasm, and on this account they halt 
                                 INTRODUCTION         37 
the further progression of apoptosis. Thus, tiRFs can function as anti-apoptotic molecules 
(Saikia et al., 2014).  
Even more profound is the effect mediated by tRNA halves in the regulation of 
translation following induction of oxidative stress, heat shock, or ultraviolet irradiation. 
Indeed, certain 5’-tiRNAs, but not their 3’ counterpart, were proven to promote phospho-
eIF2-independent arrest of translation and assembly of stress granules (Yamasaki et al., 
2009; Emara et al., 2010). Subsequent studies revealed that these 5’-tiRNAs are able to 
displace eIF4G, a component of the eIF4F translation initiation complex, from the 5’ cap 
of mRNAs. It turned out that the inhibitory property of these 5’-tiRNAs, mainly derived 
from tRNA-Ala and tRNA-Cys, depends on the presence of the D-loop and on a common 
5’-terminal oligoguanine motif (Ivanov et al., 2011). The latter has been shown to adopt a 
so-called G-quadruplex structure which is essential for the activity of 5’-tiRNAs (Ivanov 
et al., 2014). Also, the G- stretch was shown to allow specific interaction with YBX1, a 
well-known RNA-binding protein (RBP) (Ivanov et al., 2011, 2014). Recent findings 
suggest that the binding of 5’-tiRNAs to YBX1 is not required for displacement of eIF4F 
and therefore for translational repression. Instead, depletion of YBX1 results in the 
inability of cells to assemble 5’-tiRNAs-dependent stress granules (Lyons et al., 2016).  
Interestingly, an independent study identified another class of tiRNAs interacting with 
YBX1 in breast cancer cells. These YBX1-interacting tRFs (YBX1-tRFs) were longer 
than conventional tRNA halves and were generated from an intron-containing pre-tRNA-
Tyr as well as from the 3’ part of several mature tRNAs (Figure 1.7). YBX1-tRFs were 
induced under hypoxic conditions in breast cancer cells, however not in highly metastatic 
subpopulations of the parental cell line. Although it has not been addressed whether their 
production depends on ANG-mediated cleavage, the consequences of their accumulation 
have been characterized. It appears that these rather unconventional tRNA-derivates 
compete, via a novel sequence motif, with the 3’ UTRs of several mRNAs for binding to 
YBX1. The upregulation of YBX1-tRFs leads to the displacement of the RBP from its 
target transcripts which finally results in their destabilization. This regulation has been 
proposed to modulate oncogenesis in breast cancer and seems to be avoided by highly 
metastatic cells which do not boost YBX1-tRFs production (Goodarzi et al., 2015). 
In summary, the ANG-tiRNA-axis might have evolved as a protective system to adapt 
and to fine-tune the cellular response to stress. As it is often the case, viruses are able to 
turn molecular pathways of the host to their own advantage and this was proven to occur 
also during infections by the respiratory syncytial virus (RSV) with ANG-dependent 
38      INTRODUCTION    
 
             
tiRNAs. Initially, an increased production, in particular, of 5’-tiRNAs was described 
following RSV infection of a lung epithelial cell line (Wang et al., 2013). Later analyses 
demonstrated that a specific, RSV-induced 5’-tiRNA interacts by sequence 
complementarities with the mRNA of apolipoprotein E receptor 2 (APOER2). This 
finally results in the post-transcriptional repression of APOER2 which in turn promotes 
RSV replication (Deng et al., 2015). Although the underlying molecular mechanism is 
still unknown, it should be noted that several characteristics of 5’-tiRNA evidence that 
this regulation occurs in a different way than miRNA-mediated repression (Wang et al., 
2013; Deng et al., 2015).     
All the aforementioned examples of tRFs production rely on cleavage within the 
anticodon loop which thus seems to be favoured for endonucleolytic cutting. 
Interestingly, the tRNAs derived from cells lacking either NSun2 or TRDMT1 (also 
known as DNMT2), two tRNA methyltransferases, turned out to be more susceptible to 
ANG-mediated cleavage (Schaefer et al., 2010; Blanco et al., 2014). Methylation of 
specific nucleotides therefore has a protective effect which was said to depend on the 
influence of these modifications on the accessibility of the anticodon loop (Schaefer et al., 
2010). In addition, substrate specificity of ANG does not depend on the tRNA structure 
per se, but is restricted to single-stranded RNA. Cutting occurs preferentially after 
pyrimidine bases which are followed by adenine. The highest ribonucleolytic activity is 
thereby directed toward a CA substrate sequence (Russo et al., 1996). These 
characteristics pointed attention towards the universal, single-stranded, 3’ CCA end of 
tRNAs. It was shown in fact that it is cut by ANG very rapidly after induction of 
oxidative stress resulting in general translational repression (Czech et al., 2013). Finally, 
ANG might also be involved in the generation of other tRFs beside tiRNAs, since in vitro 
assays performed with the recombinant protein revealed its ability to cleave as well within 
the loop of the T-arm (Li et al., 2012). 
  
1.1.10.3. Puzzling Diversity of tRFs 
 
The majority of tRFs expressed under normal conditions probably arose from what 
previously was engaged as functional tRNAs. Supporting this hypothesis is the fact that 
the 5’ and 3’ ends, respectively, of 5’-tRFs and 3’ CCA-tRFs, are identical to those of 
mature tRNAs. In addition, a study performed in the ciliate Tetrahymena thermophila 
demonstrated, by two-dimensional thin-layer chromatography, that a particular fraction of 
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3’ CCA-tRFs possesses base modifications which are also present in the corresponding 
region of the full-length tRNAs (Couvillion et al., 2012). Finally, in human breast cancer 
cells the 3’ half of the aforementioned SHOTRNAs carry an amino acid at their 3’ end 
(Honda et al., 2015). Still, the trait which triggers the production of the different tRFs 
from, to all appearances, functional tRNAs is unknown, while the majority of these 
molecules remains intact. One possibility could be that, under certain conditions, a 
subpopulation of tRNAs acquires damages which cause severe conformational changes. 
These would consequently provoke ribonucleolytic processing but through a pathway 
unrelated to the total degradation achieved by the RTD (Mishima et al., 2014).  
This point leads to another matter of debate, namely, the identification of the enzymes 
involved in the biogenesis of 5’-tRFs, 3’ CCA-tRFs and the recently described internal 
tRFs (i-tRFs) (Telonis et al., 2015). As already mentioned in section 1.1.10.2, various 
recombinant RNases including ANG, were able to fragment a tRNA substrate in vitro, 
and they gave rise to a processing pattern resembling the endogenous tRF content of a cell 
(Li et al., 2012). Unfortunately, the physiological role of these ribonucleases in the 
generation of 5’-tRFs, 3’ CCA-tRFs or i-tRFs requires further confirmation.  
Early studies dedicated to the global profiling of sRNAs have pointed attention towards 
another protein which might be involved in the biogenesis of tRFs, i.e., the RNase III 
enzyme Dicer, the same endonuclease that finalizes the maturation of miRNAs (Cole et 
al., 2009; Haussecker et al., 2010; Maute et al., 2013). However, an aspect which has not 
been well addressed in these reports is that tRNAs fold in the typical cloverleaf structure 
which does not correspond to a canonical double-stranded Dicer substrate (Zhang et al., 
2002). Although it is conceivable that pre-tRNAs might adopt alternative secondary 
structures (Babiarz et al., 2008), it is not clear how tRNAs, which have undergone all 
maturation events, should refold into double-stranded hairpins to enable cleavage by 
Dicer. Indeed, other reports clearly indicate that at least some tRFs are not generated by 
the endonucleases involved in miRNA biogenesis since they can be detected in Drosha 
and/or Dicer knockout cell lines (Li et al., 2012; Kumar et al., 2014).  
Despite their mysterious production, tRFs were reported by several groups to associate 
with members of the AGO clade (Cole et al., 2009; Haussecker et al., 2010; Burroughs et 
al., 2011; Li et al., 2012; Maute et al., 2013; Keam et al., 2014; and reviewed in 
Shigematsu and Kirino, 2015). To some extent, their potential to behave like miRNAs 
was demonstrated by different artificial assays (Haussecker et al., 2010; Li et al., 2012) 
but, also in this regard, contradictory results were obtained (Thomson et al., 2014). 
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Nevertheless, the 3’ CCA-tRFs termed CU1276, which is derived from a tRNA-Gly, is 
expressed in human B cells and some lines of evidence indicate that CU1276 is a bona 
fide miRNA. It associates with Ago proteins and is able to repress an endogenous target 
mRNA thereby modulating proliferation and DNA damage responses. Interestingly, when 
comparing the enrichment of CU1276 with overexpressed Ago1-4 proteins, interaction 
with Ago2 seemed to be less favored compared to Ago1, Ago3 and Ago4 (Maute et al., 
2013). Similar observations were done by different groups analyzing other tRFs 
(Haussecker et al., 2010; Kumar et al., 2014). Also, it emerged that Ago proteins tend to 
enrich tRFs which are shorter than canonical miRNAs, i.e., ≤ 21 nucleotides long 
(Haussecker et al., 2010; Telonis et al., 2015). Of note, interaction of Ago2 with certain 
full-length tRNAs or nascent tRNA transcripts was reported as well (Maniataki and 
Mourelatos, 2005; Woolnough et al., 2015).  
Altogether, it is indisputable that some tRFs are loaded into Ago proteins, though this 
interaction displays many differences compared to miRNAs. Further investigations are 
required to clarify to what extent Ago-tRF associations are dedicated to the sequence-
specific regulation of gene expression or, alternatively, might participate to pathways 
unrelated to miRNA-like functions. 
In fact, several findings emerged during the last years which corroborate the idea that 
tRFs also act independently of the miRNA machinery. One of these examples resembles 
the inhibitory effect on translation achieved by 5’-tiRNAs during stress responses (see 
section 1.1.10.2). In this case, translational repression is mediated by 5’-tRFs via a 
distinct mechanism that does not require any complementarity to the regulated mRNAs 
(Sobala and Hutvagner, 2013) and probably depends on the association of such 5’-tRFs 
with the multisynthetase complex (Keam et al., 2017). In contrast, a specific 3’ CCA-tRF 
originating from tRNA-Leu-CAG was recently shown to positively affect the translation 
of two ribosomal proteins, i.e., RPS15 and RPS28. Although the exact mechanisms 
leading to the enhanced translation are still elusive, the 3’ CCA-tRF excerpts its function 
in virtue of the sequence complementarity to the mRNAs encoding for the two ribosomal 
proteins (Kim et al., 2017). 
TRFs are also able to influence gene expression at the transcriptional level. Following the 
identification of several 5’-tRFs in mammalian sperm, their functional role was analyzed 
in embryonic stem cells and in zygotes. It turned out that inhibition of a specific tRF 
derived from tRNA-Gly resulted in the direct upregulation of certain genes (Sharma et al., 
2016). Thus, the tRF content of sperms might be markedly involved in the regulation of 
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early developmental processes (Chen et al., 2016; Sharma et al., 2016). The expression of 
these derepressed transcripts was previously shown in pre-implantation embryos to be 
driven by activation of endogenous MuERV-L retroelements (Macfarlan et al., 2012). No 
mechanistic information is available at the moment that might explain the effect of the 
tRNA-Gly-derived tRF, but an intriguing finding was reported some years ago. It was 
noticed that 3’ CCA-tRFs are often complementary to endogenous retroviral LTR 
elements (Li et al., 2012), and recent findings confirmed that 3’ CCA-tRFs inhibit the 
replication of endogenous retroviral sequences (Schorn et al., 2017). 
Another important insight revealed in the study by Sharma et al. (2016) is the fact that the 
tRFs present in the mature sperm are probably derived from an external source only at a 
late stage of spermatogenesis. Indeed, it is long known that, while travelling through the 
epididymis, sperms fuse with extracellular vesicles called epididymosomes (reviewed in 
Sullivan, 2015). These are likely to deliver their high tRF-content to the sperm cells 
(Sharma et al., 2016). Secretion of tRFs is certainly not restricted to the reproductive 
tract, as they were already detected in different kind of vesicles (Guzman et al., 2015; Li 
et al., 2015), as well as circulating in serum (Dhahbi et al., 2013) and in urine (Speer et 
al., 1979; Zhao et al., 1999). In addition, the vast amount of RNA profiling data sets 
indicates that, compared to healthful samples, tRFs are differentially expressed in several 
cancer types as well as during viral infections (Speer et al., 1979; Maute et al., 2013; 
Wang et al., 2013; Goodarzi et al., 2015; Guo et al., 2015; Guzman et al., 2015; Selitsky 
et al., 2015; Telonis et al., 2015; Pekarsky et al., 2016). Owing to this information and to 
the recent progress in unraveling their molecular functions, tRFs are becoming more and 
more the focus of clinical research. These fascinating molecules could soon be used as 
biomarkers or possibly as drug targets for cancer therapy. Also in this regard, our 
knowledge will benefit from getting a deeper view into this new and puzzling field of 
tRNA biology. 
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1.2. The miRNA Pathway 
 
MiRNAs are sRNAs that guide post-transcriptional regulation of gene expression by 
targeting miRNA-induced silencing complexes (miRISCs) to specific mRNAs. This is 
achieved by sequence complementarity between the miRNA and, in most cases, the 3’ 
UTR of the target mRNA. Subsequently, miRISC mediates translational repression as 
well as destabilization of the bound transcripts. By doing so, miRNAs are important 
regulators of developmental processes and cellular homeostasis. Their function is 
frequently perturbed in cancer and in several human pathologies contributing to the 
progression of these diseases.  
 
1.2.1. The Nuclear Part of MiRNA Biogenesis  
  
Canonical miRNAs are transcribed by Pol II (Lee et al., 2004) and they can originate 
from independent gene units but very often they are embedded within intronic regions of 
protein-coding mRNAs as well as ncRNAs. Also, in latter cases transcription can be 
either coupled to host gene expression or can be driven by independent promoters 
(reviewed in Finnegan and Pasquinelli, 2013). Different miRNAs tend to cluster together 
within the genome and, consequently, some primary-miRNAs (pri-miRNAs) are 
expressed as polycistronic transcripts. In any case, miRNAs are embedded within hairpin 
structures of the pri-miRNA. A multi-step processing pathway consisting of two 
endonucleolytic cleavage events is therefore required to liberate the ~22 nt long mature 
miRNAs (Bartel, 2004; Kim, 2005; Kim et al., 2009) (Figure 1.8). 
 
  
Figure 1.8: The Biogenesis of Canonical MiRNAs Occurs via Several Processing Steps. Schematic 
representation of the events and of the proteins which are required for the maturation of miRNAs. The key 
characteristics of the secondary structure of the different miRNA processing intermediates are indicated as 
well. 
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The first reaction occurs in the nucleus and is catalyzed by the Microprocessor complex. 
It is composed of the RNase III enzyme Drosha and a cofactor called Dgcr8 in 
vertebrates, and Pasha in other organisms (Denli et al., 2004; Gregory et al., 2004). The 
hairpin structures recognized by the Microprocessor complex typically have a 35 bp long 
stem which is closed by a loop and is flanked by single-stranded segments at both sides. It 
is long known that Dgcr8 is a RBP and that Drosha endonucleolytically cleaves the 
hairpin ~22 bp away from the apical loop / 11 bp away from the basal junction. However, 
over the last decade a debate was ongoing concerning the features which determine the 
site of Drosha cleavage (Zeng et al., 2005; Han et al., 2006; Ma et al., 2013). A detailed 
mechanistic insight was achieved only recently after succeeding to express and purify the 
recombinant Microprocessor complex (Nguyen et al., 2015). These findings were further 
implemented by the subsequent description of Drosha’s crystal structure (Kwon et al., 
2016). Taken together, it is now clear that Drosha forms a heterotrimeric complex 
together with two Dgcr8 proteins. Drosha itself acts as a ruler by binding to the basal 
junction and positioning its two catalytic domains in such a manner that after cutting a 
typical pre-miRNA with a two nt overhang at the 3’ end is released. A preference for a 
UG motif spanning the junction between the basal single-stranded region and the double-
stranded regions of the hairpin was also observed. Accordingly, the Dgcr8 dimer binds to 
the apical part and has a strong affinity for a UGU sequence just at the beginning of the 
loop.    
Following processing by Drosha, the resulting pre-miRNA is exported to the cytoplasm 
by Xpo5, a member of the karyopherin-β family of nucleocytoplasmic transport factors. 
As already mentioned in section 1.1.7, the ability of Xpo5 to export RNAs from the 
nucleus was first described independently from its role in the biogenesis of miRNAs 
(Bohnsack et al., 2002; Brownawell and Macara, 2002; Calado et al., 2002). Only later 
studies demonstrated that Xpo5 is mainly dedicated to the RanGTP-dependent transfer of 
pre-miRNAs to the cytoplasm (Yi et al., 2003; Bohnsack et al., 2004; Lund et al., 2004). 
Structural studies revealed that the Xpo5-RanGTP complex surrounds the stem of pre-
miRNAs, whereby both termini of the pre-miRNA, in particular the 3’ end, are 
completely shielded in a tunnel-like structure (Okada et al., 2009). Thus, Xpo5 might not 
only account for the export of pre-miRNAs but also for their protection from 
exonucleolytic degradation or trimming (Yi et al., 2003). Indeed, evidences provided in a 
recent publication confirmed this hypothesis. However, the same study also demonstrated 
that Xpo5 is not essential for the biogenesis of miRNAs, since they were generated in 
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Xpo5 knockout cells, even though at lower levels compared to wild type cells (Kim et al., 
2016). So far, it is not clear inasmuch alternative maturation pathways might co-exist with 
the Xpo5-dependent miRNA production or if they serve as a backup mechanism 
exclusively when the canonical pre-miRNA export machinery is missing.  
 
1.2.2. The Cytoplasmic Part of MiRNA Biogenesis  
 
Following export, pre-miRNAs are subjected to a second endonucleolytic maturation 
step, which removes the apical loop. This processing event is performed by Dicer 
(Hutvágner et al., 2001), a multidomain protein, which is also a member of the RNase III 
family (Lau et al., 2009; Wang et al., 2009). The human genome encodes for a single 
Dicer protein, which is specialized for production of miRNAs. Also in this case, the 
enzyme itself acts as a molecular ruler that determines the site of the endonucleolytic 
cleavage, occurring ~22 nt apart from the open end of double-stranded stem. It has been 
shown that this exact processing is achieved by positioning the phosphorylated 5’ end of 
the pre-miRNA into a binding pocket located in a RNA-binding domain called PAZ (Park 
et al., 2011; Tian et al., 2014). The PAZ domain forms one end of the L-shaped Dicer 
protein (Lau et al., 2012) and it is located in a fixed distance relative to the catalytic 
center, which consists of two neighboring RNase III domains (Zhang et al., 2004). This 
structural organization ultimately determines the position where the double-stranded stem 
is going to be cleaved. Importantly, the PAZ domain also recognizes the 3’ end of pre-
miRNAs, which have a typical two nt overhang generated by the preceding Drosha 
processing (Tian et al., 2014). Thus, substrates with a phosphorylated 5’ end and with a 
two nt 3’ overhang are most efficiently processed by human Dicer (Park et al., 2011). 
Some intriguing aspects concern the N-terminal ATPase/RNA helicase domain, which 
forms, at the opposite side of the L-shaped Dicer structure, a clamp-like end holding the 
bound pre-miRNA by interactions with the loop (Lau et al., 2012). Of note, depending on 
the organism, some specialized Dicer proteins exist that prefer to process long double-
stranded RNAs with blunt ends rather than pre-miRNAs. Indeed, the helicase domain was 
shown to account for this selectivity (Soifer et al., 2008; Welker et al., 2011; Flemr et al., 
2013; Taylor et al., 2013; Sinha et al., 2015). Recent cryo-EM structures of the 
Drosophila melanogaster Dicer-2 enzyme shed light onto this aspect and revealed a 
“threading” mechanism that enables the helicase domain to feed double-stranded RNAs to 
the catalytic center (Sinha et al., 2018). Nevertheless, it should be mentioned, that the N-
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terminus of Dicer also serves as an interface for the interaction with some RBPs, i.e., 
TRBP or PACT in mammals and Loquacious or R2D2 in flies (Lee et al., 2006; Ye et al., 
2007; Daniels et al., 2009; Hartig and Förstemann, 2011). These factors, in turn, were 
shown to influence the substrate selectivity of Dicer and, among other functions, they also 
enhance the activity and accuracy of the cleavage reaction (Daniels et al., 2009; Fukunaga 
et al., 2012; Taylor et al., 2013; Sinha et al., 2015; Wilson et al., 2015; Jakob et al., 2016).  
Finally, Dicer processing results in a sRNA duplex, which possesses a two nt long 
overhang at both 3’ ends and which is a short-lived intermediate. Only one of the two 
strands, termed the guide strand, is preferentially assembled into an Ago protein, the 
direct binding partners of mature miRNAs. The opposite strand, instead, is usually 
degraded and it is referred to as passenger strand or miRNA*. Depending on the location 
of the selected strand within the original pre-miRNA sequence, the suffixes -5p or -3p are 
sometimes used to indicate whether the mature miRNA is derived respectively from the 
5’ or from the 3’ arm of the hairpin.  
The selection of the correct strand for Ago-loading follows the so-called asymmetry rule, 
i.e., the strand with the less stably paired 5’ end will become the guide strand (Khvorova 
et al., 2003; Schwarz et al., 2003). This discrimination process is achieved by the so-
called RISC-loading complex, whereby some evidences indicate that Dicer itself might 
sense the thermodynamic stability of the ends of the sRNA duplex, but, to do so, it 
requires the interaction to TRBP or PACT (Noland et al., 2011). Importantly, it has been 
shown for different organisms that the transfer of the sRNA duplex to the Ago proteins is 
facilitated by the action of the heat shock protein 90 (Hsp90), and of some co-chaperones 
(Iwasaki et al., 2010, 2015; Johnston et al., 2010). The chaperone machinery might 
therefore stabilize unloaded Ago molecules in an open conformation, which is prone to 
accept the sRNA duplex (Iwasaki et al., 2010; Johnston et al., 2010). Nonetheless, the 
exact molecular mechanism that enables the dissociation of the two strands has not yet 
been fully understood. In contrast to the aforementioned report by Noland et al. (2011), 
Ago proteins themselves have been proposed to act as the asymmetry sensor for the 
sRNA duplex (Suzuki et al., 2015) and the N-terminus of Ago proteins might also directly 
displace the passenger strand (Kwak and Tomari, 2012).  
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1.2.3. Ago Proteins, the Key Players of the MiRNA Pathway 
 
The biogenesis steps recapitulated in the previous sections finally give rise to a mature 
miRNA, which is a single-stranded ribo-oligonucleotide with a characteristic size of     
~22 nt, a phosphate at its 5’ terminus and an OH group at its 3’ end. The binding partners 
of miRNAs are the members of the Ago clade, which, in mammals, comprises four 
proteins (Ago1-4). They are evolutionarily related to the PIWI protein clade, whereby 
both clades together form the Argonaute protein family. Although PIWIs bind to a 
distinct class of sRNAs, termed PIWI-interacting RNAs (piRNAs), they do not have 
many similarities with the miRNA pathway. The occurrence of the piRNA system, in 
fact, is restricted mainly to the germline of animals where it protects the genome from the 
deleterious potential of mobile elements (reviewed in Czech and Hannon, 2016; Huang et 
al., 2017). 
Nevertheless, the members of the Ago protein family share a common structural 
organization, which is composed of N-terminal, PAZ, MID and PIWI domains. Their 
respective function has been analyzed in great detail over the past two decades, and 
several crystal structures of human Ago complexes have nicely contributed to the 
molecular understanding of miRNA-Ago interactions (Elkayam et al., 2012; Schirle and 
MacRae, 2012; Schirle et al., 2014). These studies revealed that human Ago2 consists of 
two lobes comprising the N–PAZ and the MID–PIWI domains, while the central cleft 
enables positioning of the miRNA along its target mRNA. The 5’ end of the miRNA is 
tightly anchored in a binding pocket mainly formed by the MID domain, while the 3’ end 
of the miRNA bends into a dedicated pocket within the PAZ domain. Interestingly, the 
loading of a miRNA was proposed to confer structural stability to the Ago protein 
(Elkayam et al., 2012). 
Some Ago proteins also possess endonucleolytic cleavage activity, referred to as slicer 
activity, which is explicitly directed toward the target RNA. In vertebrates, only Ago2 has 
retained this particular characteristic that is based on the structural similarity between the 
PIWI domain and the RNase H endonuclease (Liu et al., 2004; Meister et al., 2004; Song 
et al., 2004). Importantly, a tetrad composed of DEDX, where X is D or H, confers the 
catalytic activity (Nakanishi et al., 2012), but the mere presence of these essential 
residues is not sufficient to ensure slicing. Additional elements, located in the N-terminal 
as well as in the PIWI domains, affect the cleavage ability of human Ago2 (Faehnle et al., 
2013; Hauptmann et al., 2013; Nakanishi et al., 2013; Schirle et al., 2014). A central 
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question within the miRNA field concerns the necessity of maintaining a catalytic 
competent Ago protein within the genome of vertebrates. Indeed, perfectly 
complementary target sites, which are a prerequisite for cleavage, are rarely found in 
mammalian mRNAs (Yekta et al., 2004; Karginov et al., 2010; Shin et al., 2010). Instead, 
the slicer activity of Ago2 is exploited when full-complementary exogenous small 
interfering RNAs (siRNAs) are introduced into cells to knock down the expression of a 
specific gene. In a physiological context, the catalytic activity of Ago2 was proven to be 
of vital importance for the embryonic development in mouse (Liu et al., 2004). However, 
this requirement is not related to the slicing of target mRNAs, but rather to the processing 
of non-canonical miRNAs like, e.g., miR-451 (Liu et al., 2004; Jee et al., 2018; see also 
section 1.2.5).  
In sum, miRNA-mediated gene silencing in mammals is not achieved by Ago2-dependent 
slicing of the target mRNAs, but the activity of miRISC complexes is executed via a 
different mechanism (see next section) and all four Ago proteins contribute to an equal 
extent to this process. 
 
1.2.4. An Interplay of Processes Leads to the Repression of Targeted Transcripts 
 
MiRNAs simply guide Ago proteins to target sites, which are mainly located within the    
3’ UTRs of protein-coding transcripts. The region of the miRNA between nt 2-7 is critical 
for the specific interaction with the target mRNAs and is referred to as the seed sequence 
(reviewed in Bartel, 2009). MiRNAs, which share a common seed sequence, but differ at 
the remaining positions, are grouped into miRNA families and are likely to regulate a 
similar set of transcripts.  
Still, the binding of Ago per se does not influence the translational output of the targeted 
mRNA and miRISC complexes need to recruit additional factors for repression (reviewed 
in Jonas and Izaurralde, 2015). The key players bridging the interaction to such 
downstream factors are GW182 proteins, named after its representative in D. 
melanogaster (Behm-Ansmant et al., 2006). They are known in vertebrates as 
trinucleotide repeat-containing 6 (TNRC6) proteins and comprise three paralogs, i.e., 
TNRC6A-C. Although TNRC6 proteins are largely unstructured, two distinct functional 
domains were identified: the N-terminal Ago-binding and the C-terminal silencing 
domains (Till et al., 2007; Eulalio et al., 2009; Lazzaretti et al., 2009). Both regions 
mediate the contacts to the interaction partners by glycine and tryptophan (GW)-
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containing repeats, thus the name GW182 in D. melanogaster. The W residues in the 
Ago-binding domain of TNRC6 can hook into two dedicated pockets on the surface of 
Ago’s PIWI domain (Schirle and MacRae, 2012; Pfaff et al., 2013). Similarly, W residues 
in the silencing domain of TNRC6 proteins were shown to account for the interaction to 
other factors (Christie et al., 2013; Chen et al., 2014; Mathys et al., 2014). Resembling a 
Swiss army knife, miRISCs are equipped with a set of powerful tools, which are grouped 
together by TNRC6 proteins serving as a scaffold. Among these downstream factors, the 
most important are two deadenylation complexes: CCR4-NOT and PAN2-PAN3. 
Deadenylation is also tightly coupled to the decapping of the mRNA 5’ end by a complex 
containing the decapping protein 2 (DCP2). Altogether, these processes finally allow the 
cytoplasmic 5’→3’ exonuclease XRN1 to degrade the targeted transcripts. According to 
the currently favored model, the miRNA-mediated regulation of gene expression is thus 
mainly accomplished by the destabilization of the mRNAs (Guo et al., 2010; Eichhorn et 
al., 2014). In addition, translational repression mechanisms contribute, albeit to a minor 
extent, to the combination of processes, which ultimately culminate in the inhibition of 
gene expression (reviewed in Jonas and Izaurralde, 2015). 
 
1.2.5. Many Roads Lead to Ago: Generation of Non-canonical MiRNAs 
  
The biogenesis of miRNAs obeys simple rules and has evolved as a robust system to 
ensure the production of functional, Ago-loaded sRNAs. Nevertheless, it has been 
observed recurrently that certain miRNAs are generated by exotic strategies, which do not 
depend at least on one of the Drosha or Dicer processing steps (reviewed in Daugaard and 
Hansen, 2017). This is the case, for example, for miRNAs arising from other ncRNA 
transcripts, as it was demonstrated for a snoRNA-derived miRNA (Ender et al., 2008; 
Taft et al., 2009) and, apparently, for certain tRNA fragments (see sections 1.1.10.1 and 
1.1.10.3). The advent of deep sequencing technologies revealed that the total sRNA 
population of a cell is characterized by the presence of a multitude of such fragments. 
Unfortunately, it was tempting to classify as a miRNA any of these processing products 
just in virtue of their miRNA-like size, while sometimes it was omitted to verify whether 
they associate with endogenous Ago proteins. 
Most commonly, non-canonical miRNAs do not require Drosha processing. Some 
miRNAs, for instance, are generated from so-called mirtrons. These are short introns with 
hairpin potential which, after splicing from primary transcripts, are debranched and 
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exported from the nucleus. The hairpins within such mirton sequences might possess 5’ or 
3’ tails which are trimmed by exonucleases before running through the remaining miRNA 
biogenesis steps (Berezikov et al., 2007; Okamura et al., 2007; Ruby et al., 2007; 
Ladewig et al., 2012).  
Endogenous siRNAs (endo-siRNAs) are another class of non-canonical miRNAs, which 
does not require the activity of the Microprocessor complex. In mammals, the expression 
of endo-siRNAs is mainly restricted to oocytes and to early pre-implantation embryos 
(Babiarz et al., 2008; Tam et al., 2008; Watanabe et al., 2008). These long, highly-
complementary double-stranded RNAs can result, e.g., from bidirectional transcription of 
a genomic locus or from gene-pseudogene transcript pairs (reviewed in Okamura and Lai, 
2008). As already mentioned, endo-siRNAs are not recognized by the Microprocessor 
complex and also the human Dicer protein cannot easily cope with their unconventional 
structure. This is mainly due to the strong selectivity conferred by the N-terminal helicase 
domain (see section 1.2.2.). Interestingly, it has been shown that an oocyte-specific Dicer 
isoform lacks the helicase domain and can thereby efficiently cleave endo-siRNAs. 
However, this smart strategy seems to be restricted to rodents and it is not clear how such 
miRNAs are processed in other mammals (Flemr et al., 2013). In addition, a long debate 
is ongoing regarding the occurrence in vertebrates of virus-derived siRNAs, which, 
instead, are widely produced in plants and in many invertebrates as an antiviral immune 
response (reviewed in Ding and Voinnet, 2007; Cullen et al., 2013).  
In contrast to the long, highly complementary endo-siRNAs, endogenous short-hairpin 
RNAs (shRNA), which were identified in different tissues, are optimal Dicer substrates 
(Babiarz et al., 2008, 2011). A recent study revealed that this particular pre-miRNA 
category is more frequent then initially thought. Endogenous shRNAs are transcribed by 
Pol II and their 5’ ends possess a 7-methylguanosine (m7G) cap, while their 3’ ends result 
from transcriptional termination. Of note, the nuclear export of such shRNAs does not 
depend on Xpo5. Instead, it utilizes Xpo1 together with the phosphorylated adaptor for 
RNA export (PHAX), the system which usually shuttles snRNAs to the cytoplasm for 
their maturation (Xie et al., 2013; Kim et al., 2016).  
Interestingly, also some viruses express miRNAs which are processed by the host via 
non-canonical mechanisms. In the case of the bovine leukemia virus (BLV) miRNA-
containing shRNAs are produced by Pol III as individual transcripts which do not require 
Drosha processing (Kincaid et al., 2012; Rosewick et al., 2013). Follow-up studies further 
demonstrated that the BLV shRNAs have a triphosphorylated 5’ end, which needs to be 
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converted into a monophosphate to allow for the accumulation of some of these viral 
miRNAs (Burke et al., 2014, 2016). 
Also other viruses have developed strategies to generate Drosha-independent miRNAs. 
For instance, some viruses encode chimeric transcripts and usurp different cellular 
endonucleases to liberate the pre-miRNA hairpins. This applies, e.g., to the murine 
gammaherpesvirus 68 (MHV68), whereby tRNA-like sequence direct RNase Z to release 
the pre-miRNAs (Bogerd et al., 2010). Similarly, the herpesvirus saimiri (HVS) uses the 
Integrator complex to separate its pre-miRNAs from other ncRNAs contained in a longer 
precursor transcript (Cazalla et al., 2011).  
As already mentioned in section 1.2.3, the catalytic activity of Ago2 is essential for the 
development of vertebrates and this is mainly due to the atypical biogenesis mechanism 
of miR-451 (Cheloufi et al., 2010; Cifuentes et al., 2010). Indeed, the highly 
complementary stem of pre-miR-451 is too short to be accommodated into Dicer. This, 
and other conserved characteristics (Yang et al., 2010; Dueck et al., 2012), enable Ago2 
to bind and to cleave pre-miR-451 within its 3’ hairpin arm. The resulting intermediate is 
then trimmed by the PARN exonuclease to generate the mature miRNA (Yoda et al., 
2013). Interestingly, a recent publication demonstrated that miR-486-5p, although being 
processed by the canonical biogenesis pathway, strictly requires Ago2 to slice and remove 
its passenger strand (miR-486-3p) from the miRNA duplex generated by Dicer. If this is 
impaired, miR-486-3p accumulates and inhibits the function of the complementary miR-
486-5p (Jee et al., 2018).  
Of note, the strict dependency on Dicer for the biogenesis of miRNAs was questioned by 
the finding that miRNAs derived from the 5’ arm of pre-miRNAs can be generated also in 
the absence of Dicer, at least to a certain extent. It has been hypothesized that pre-
miRNAs are directly loaded into Ago proteins, which thereby protect their 5’ ends. At the 
same time, 3’→5’ exonucleases remove part of the hairpin producing miRNAs with a 
short 3’ extension compared to their counterparts matured under physiological conditions 
(Kim et al., 2016). Finally, a class of Ago-bound fragments that neither depend on 
Drosha, nor on Dicer was recently described. These so-called agotrons are derived from 
short intron sequences and are not further processed after debranching. Consequently, 
agotrons are longer than normal miRNAs (Hansen et al., 2016). They were shown to 
excerpt miRNA-like functions, however they have been also proposed to modulate the 
function of Ago proteins, possibly by stabilizing unloaded Ago proteins (Stagsted et al., 
2017). 
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In sum, nature came up with exceptions to any step of the miRNA biogenesis. It is 
attractive to speculate that these alternative pathways emerged to allow expression of 
distinct miRNAs independently from regulatory mechanisms, which generally affect the 
production of classical miRNAs. 
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2. Aims of the Study 
 
In this PhD project, we aimed to identify and characterize so far unknown non-canonical 
miRNA biogenesis pathways. To this end, we started studying the effects of the RBP La 
on cellular miRNAs. In the rest of our analyses, we mainly focussed on the crosstalk 
between the miRNA pathway and processing of Pol III transcripts, which are the main 
targets of La. 
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3. Results 
 
3.1. Generation of a La-specific Antibody 
 
The Lupus antigen La protein plays a central role in the biogenesis of several highly 
structured RNAs and recent evidences expanded its relevance to sRNA pathways (Liu et 
al., 2011; Liang et al., 2013). Within this context, we decided to study the function of La 
in more detail.  
In order to investigate La in molecular detail, we aimed to generate a La-specific 
polyclonal antibody. We expressed and purified full-length recombinant La protein which 
was used for the immunization of a rabbit (Figure 3.1). 
  
Figure 3.1: Expression of Recombinant La Protein for Antibody Production. Left panel: Schematic 
overview of the purification strategy. Right panel: Aliquots of the indicated steps (lanes 1-7) were taken 
during the protein purification and were resolved by SDS-PAGE for Coomassie-staining. The molecular 
size marker is depicted on the left. Substantial amounts of the cleaved GST-tag were still present in the 
flow-through of the second GSTrap column. Nevertheless, this fraction was used for the antibody 
production.  
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Figure 3.3: Experimental Procedure to Investigate the 
Relevance of La on sRNA Pathways. HEK293 cells were 
transfected with either a siRNA against La or a control 
siRNA. For both conditions, Ago1-4 complexes were isolated 
by Ago-APP and the co-precipitated RNAs were used to 
generate sRNA libraries. The sRNAs were also profiled from 
total RNA which was extracted from the corresponding input 
samples. 
Antibodies were subsequently affinity purified from the animal’s serum using 
recombinant La protein as affinity matrix. Western blot analyses revealed that the purified 
polyclonal antibody recognized overexpressed FLAG/HA (FH)-tagged, as well as the 
endogenous La protein (Figure 3.2). The signal appearing at ~50 kDa was proven to be 
specific as it disappeared upon siRNA-mediated La knockdown. Importantly, Figure 3.2 
also indicates that the adopted experimental knockdown conditions ensured an efficient 
depletion of La. 
 
 
 
 
 
 
 
 
 
 
3.2. La Affects the Cellular sRNA Population 
 
We next investigated the global impact of La depletion on the sRNA population of the cell. 
In particular, we hypothesized that the abundance of sRNAs loaded into Ago proteins might 
be affected by the knockdown of La, since this has been already reported for some miRNAs 
(Liu et al., 2011). Thus, we decided to profile by deep sequencing the impact of La 
depletion on total RNA and on the Ago-associated fraction of sRNAs (Figure 3.3).  
 
 
 
  
Figure 3.2: The Antibody Specifically Detects La in Total 
Cell Lysates. FH-La (lane 1), endogenous La (lanes  2-4) 
from HEK293 or from La knockdown (kd) samples (lane 3) 
were analyzed by Western blotting. Detection of tubulin 
served as loading control. Molecular size marker weights are 
depicted on the left. 
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In order to not restrict our view on only one of the four human Ago proteins, we opted for 
a novel peptide-based method termed ‘‘Ago protein Affinity Purification by Peptides’’ 
(Ago-APP) (Hauptmann et al., 2015). This strategy allows the simultaneous purification 
of all Ago proteins. Thereby, a GST-tagged peptide, encompassing the region of 
TNRC6B interacting with the binding pockets on the surface of all Ago-proteins (Pfaff et 
al., 2013) is used as bait to precipitate these proteins from cell lysates. Importantly, 
sRNAs bound to Ago proteins are retained in the isolated complexes and can be further 
used for library preparation and deep-sequencing approaches. As exemplary shown for 
Ago2 in Figure 3.4, similar amounts of Ago proteins were isolated upon La and control 
knockdown treatment of HEK293 cells.  
 
 
 
 
 
 
 
 
 
We next generated sRNA libraries from the Ago-associated RNAs as well as from input 
samples and mapped the reads to miRNAs and to a custom database comprising known 
Pol III transcripts. Latter are the canonical La substrates, which are bound and protected 
immediately after transcription termination. As expected, the great majority of Ago1-4- 
associated RNAs mapped to known miRNAs. The composition of the input samples 
instead, was more variable and several sRNAs derived from Pol III transcripts were 
detected. In general, no prominent difference between La and control knockdown samples 
became evident from such data analysis (Figure 3.5).  
 
 
 
Figure 3.4: Efficient Purification of Ago Complexes and La Depletion. All four Ago proteins were co-
purified by Ago-APP following transfection of La or control siRNAs. The Western blot analysis is 
exemplarily shown for Ago2 in Ago-APP samples (lanes 1-2) and inputs (lanes 3-4). The efficiency of the 
La knockdown (lanes 5 and 6) was confirmed. Detection of actin served as loading control. The molecular 
size marker weights are indicated on the left side of the blots. 
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Figure 3.5: Composition of the sRNA Libraries in the Presence or Absence of La. For each indicated 
library, the sequenced sRNAs counts, given in reads per million, were mapped to known miRNAs and to a 
custom database of Pol III transcripts. The different categories are indicated on the right. Reads derived 
from tRNAs are grouped in reads unambiguously derived from pre-tRNA (pre-tRNA), unambiguously 
derived from mature tRNAs (mature tRNA), and reads which could originate from both (pre- and mature 
tRNA). A similar distinction was done for miRNAs and tRNAs in case reads mapped to both categories 
(‘‘miRNA’’ or ‘‘miRNA and tRNA’’). All reads, which mapped to sequences from two or more of the other 
categories, are referred as ‘‘ambiguous’’. Vault RNA (vtRNA), small NF90-associated RNA (snaR). 
However, detailed mapping of the miRNA population revealed that the expression level 
of single miRNAs was moderately affected by the depletion of La. Consistent with 
previous reports (Liang et al., 2013), the abundance of let-7 miRNA family members 
decreased upon La knockdown in the Ago-associated fraction, as well as in the inputs. 
Few other rather low abundant miRNAs had a similar effect e.g., miR-1255a in the Ago-
associated fraction, miR-98-5p and miR-3741-3p in the input samples. Also, a handful of 
miRNAs, e.g., miR-1290, was positively affected by the knockdown of La (Figure 3.6).  
Figure 3.6: La Depletion Affects MiRNA Expression Levels. Scatterplots showing reads per million 
counts of Ago1-4-associated miRNAs (left) or miRNAs from input samples (right) in La (x axis) versus 
control (y axis) knockdowns. The dashed lines indicate 3-fold up- or downregulation. The miRNAs 
exceeding these thresholds are indicated (red). The low abundant miRNAs with 20 or less reads per million 
in both libraries were not considered (gray box). 
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The mild miRNA expression changes detected by deep-sequencing could also be 
validated by Northern blot analyses performed with total RNA (Figure 3.7A). Though, the 
miRNAs tested in Northern blots appeared to be more moderately affected by the 
knockdown of La compared to the extent revealed by the deep sequencing analysis (see 
quantification of the signals in Figure 3.7B compared to Figure 3.6). We conclude from 
these data that La does not play a major role in the regulation of miRNA biogenesis, since 
La depletion resulted in small expression changes of only a small subset of miRNAs.  
We next focused on the influence of La depletion on tRNAs, 5S rRNA, U6 snRNA and 
other known Pol III transcripts. Since tRNAs are processed from longer precursors and La 
has been shown to govern the tRNA maturation at several steps, we decided to look 
separately at reads, which are derived unambiguously from pre-tRNAs or unambiguously 
from mature tRNAs. Those reads that could either be derived from pre-tRNAs or from 
mature tRNAs were grouped in a distinct category termed ‘‘pre- and mature tRNA’’. This 
analysis indicated that the greatest effect of La depletion concerned pre-tRNA-derived 
reads, which were enriched approximately 4-fold in Ago1-4 compared to the control 
condition. Reads exclusively derived from mature tRNAs were instead twice less frequent 
upon knockdown of La (Figure 3.8, left panel).   
Figure 3.7: Validation of the Effect of La Depletion on MiRNA Expression Levels. (A) HEK293 cells 
were transfected with a siRNA against La (lanes 2, 5 and 8) or a control siRNA (lanes 3, 6 and 9). Lanes 1, 
4 and 7 show a size marker. Total RNAs were analyzed by Northern blotting with probes complementary to 
let-7i, miR-98, miR-1290 and miR-17. (B) Quantification of the miRNA signal intensities normalized to 
miR-17 and to the control knockdown. 
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Importantly, we plotted the abundance of each Pol III transcript category and realized that 
among them, the most abundant Ago1-4-associated fragments were indeed derived from 
pre-tRNAs as well as from mature tRNAs. Other sRNAs were either affected by La to a 
lesser extent or they associated poorly with Ago proteins (Figure 3.8, right panel). 
Therefore, we did not consider them for further investigations. 
 
The same analysis was conducted on the libraries obtained from the input samples 
revealing that the overall abundance of tRNA- and 5S rRNA-derived sRNAs was much 
greater in the inputs than in Ago1-4. Of note, the knockdown of La led to a reduction of 
reads unambiguously derived from pre-tRNAs (Figure 3.9). This is the opposite effect 
compared to what has been observed in Figure 3.8 regarding the Ago1-4-bound pre-tRNA 
fragments. This might reflect the existence of two distinct groups of pre-tRNA-derived 
fragments, which are influenced by La in opposite ways (see section 4.2).      
  
Figure 3.8: La Depletion Affects Ago-loaded sRNAs Originating from tRNAs. Log2-fold changes of 
Ago1-4-associated reads from Pol III transcripts detected upon La knockdown or control knockdown (left). 
The corresponding abundance in reads per million of fragments derived from the indicated transcripts for 
both conditions is shown (right).  
Figure 3.9: TRNA Fragments Are Less Abundant in the Input Samples upon La Depletion. The log2-
fold changes of reads derived from the indicated Pol III transcripts detected upon La knockdown or control 
knockdown (left) and the corresponding abundances in reads per million (right) are shown for the input 
samples. 
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3.3. La Regulates the Abundance of Specific Ago-loaded tRNA Fragments 
 
Since the strongest effects observed upon depletion of La concerned sRNAs specifically 
derived from pre-tRNAs (Figure 3.8 and Figure 3.9), we examined their origin in more 
detail by determining the tRNA isotype they were processed from. Fragments derived 
from pre-tRNA-Pro, -Ile, -Ser, -Lys, -Ala and -Leu were enriched more than 3-fold in 
Ago1-4 upon La knockdown (shown in red in Figure 3.10, left panel). We also observed 
that this effect was not common to all Ago-bound pre-tRNA fragments. For example, 
reads mapping to pre-tRNA-Val were among the most abundant, but they were equally 
present in both conditions. Of note, the knockdown of La did not lead to the reduction of 
Ago-associated tRNA fragments originating from any isotype. In the input samples, 
instead, the absence of La resulted in a general decrease of the expression of pre-tRNA 
fragments, particularly of sRNAs derived from pre-tRNA-Val, -Ser, -Lys and -Asp 
(shown in red in Figure 3.10, right panel). Only the processing products of pre-tRNA-Pro 
were enriched upon La knockdown in the Ago1-4 fraction as well as in the input sample 
(Figure 3.10). In sum, La seems to regulate the abundance of sRNAs derived from a 
specific subset of pre-tRNA isotypes.    
 
 
 
Figure 3.10: Specific Pre-tRNA-Derived Fragments Accumulate in Ago1-4 upon La Depletion. 
Scatterplots showing reads per million counts in La knockdown or control knockdown samples from Ago1-
4-associated (left) or input (right) RNA which are unambiguously mapping to pre-tRNAs. Graphical 
representation as described in Figure 3.6.  
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It is well known that different fragments can be processed from the entire tRNA body 
(Telonis et al., 2015). We asked whether the sequences accumulating in Ago1-4 upon La 
knockdown originate from all over the pre-tRNA or rather from a specific region. To this 
end, we performed a coverage analysis for the reads mapping unambiguously to pre-
tRNAs or both to pre-tRNAs and mature tRNAs. The lengths of the genomic pre-tRNA 
sequences differ slightly between each other, mainly due to the different sizes of the 
variable tRNA arm or due to the presence of introns. Thus, we first mapped the Ago1-4-
associated tRNA reads and then we normalized our genomic pre-tRNA database to a 
common length for the graphical representation depicted in Figure 3.11.  
 
 
 
 
 
  
Figure 3.11: 3’ Terminal Pre-tRNA Fragments Accumulate in Ago Complexes upon La Depletion. 
Coverage on pre-tRNA loci by reads detected in Ago1-4 associated RNAs upon control knockdown (upper 
panel) or La knockdown (lower panel). The sequences mapping unambiguously to pre-tRNAs and 
sequences, which could originate either from pre-tRNAs or mature tRNAs were used. A schematic 
representation of the pre-tRNA is shown beneath the graphs. The color code indicates from which tRNA 
isotype the stacked reads are derived. Reads mapping to two or more different tRNA isotypes are referred 
as ‘‘ambiguous’’. 
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The coverage analysis indicates that the most abundant tRNA reads span the boundary 
between the 3’ end of the tRNA and the genomic region further downstream, i.e., they are 
derived from the 3’ end of pre-tRNAs. Strikingly, Ago-loaded sRNAs from exactly this 
region strongly accumulate upon knockdown of La, in particular fragments mapping to 
pre-tRNA-Pro and –Ile (compare upper and lower panel in Figure 3.11).  
The pattern emerging from the sequence coverage analysis performed with the input 
samples differed from the Ago1-4-associating sRNAs inasmuch as 5’ terminal fragments 
were detected at similar levels like those processed from the 3’ end of pre-tRNAs 
(compare upper panels in Figure 3.11 and Figure 3.12).  
  
Figure 3.12: La Depletion Causes a Reduction of 3’ Terminal Pre-tRNA Fragments in the Input. 
Coverage on pre-tRNA loci by reads detected in the total RNA of cells treated with a control siRNA (upper 
panel) or a siRNA against La (lower panel). The analysis was performed as described in Figure 3.11. Note that 
some reads were assigned to the category referred to as “undetermined” (Undet) in gtRNAdb 2.0 (Chan and 
Lowe, 2016). It consists of tRNA pseudogenes for which no clear anticodon sequence could be determined. 
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Figure 3.13: TRNA Fragments of MiRNA Size Are Loaded on Ago Proteins upon La Depletion. 
Length distribution of reads detected in Ago1-4 associated RNAs upon control knockdown (upper panel) or 
La knockdown (lower panel). The same sequences as in Figure 3.11 were used for the analysis. 
Also in this case, the depletion of La mainly affected fragments mapping to the 3’ trailer 
of pre-tRNAs, although, as already noticed, within the input such fragments became less 
abundant compared to the control (compare upper and lower panel in Figure 3.12). 
   
3.4. La-dependent Pre-tRNA Fragments Have MiRNA Characteristics  
 
TRNA fragments are a heterogeneous and highly abundant class of sRNA (Keam and 
Hutvagner, 2015; Megel et al., 2015) and their association and function in Ago complexes 
is a matter of debate. MiRNAs, the canonical interaction partners of Ago proteins, are 
characterized by a specialized biogenesis pathway, which gives rise to a very definite 
population of sRNA in the size range of 19-24 nt. This length enables the perfect fitting 
into the miRNA-binding surface of Ago proteins (Elkayam et al., 2012; Schirle et al., 
2014).  We therefore analyzed the length distribution of the tRNA-derived reads 
sequenced in our libraries (Figure 3.13 and Figure 3.14).  
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Under control conditions (Figure 3.13, upper panel), mainly shorter fragments of about 
18-19 nt were found to co-precipitate with Ago proteins. Thus, the majority of Ago1-4- 
associated tRNA processing products appear to be shorter than functional miRNAs under 
control knockdown conditions. However, upon depletion of La, a second population of 
tRNA fragments mainly derived from tRNA-Pro, -Ile and -Gln, appeared in the range of 
21-23 nt with a sharp peak at 23 nt (Figure 3.13, lower panel). Importantly, these Ago-
associated tRNA processing products have a size similar to miRNAs, suggesting that they 
might have even more characteristics in common with miRNAs.  
A much greater variability in the length distribution of tRNA reads was observed in the 
input samples although even here, the highest peak appeared at 18 nt and an additional 
peak at 32 nt (Figure 3.14). Latter consisted mainly of reads derived from the 5’ end of 
tRNAs (Figure 3.12).  
 
 
  
Figure 3.14: The Reduction of TRNA Reads in the Input Is not Restricted to a Particular Fragment Length. 
Length distribution of reads detected in the input samples upon control knockdown (upper panel) or La 
knockdown (lower panel). The same sequences as in Figure 3.12 were used for the analysis. 
 
66      RESULTS    
 
             
Upon depletion of La, the global decrease in tRNA expression levels applies to the 
fragments of all sizes and does not seem to be restricted to a specific subpopulation. 
However, the effect might be more pronounced for the 32 nt long tRNA-Gly processing 
products. 
Altogether, our analyses suggest that La prevents the formation and, by that, the loading 
of a specific class of pre-tRNA-derived fragments into Ago proteins. These fragments 
might have the potential to function as miRNAs and we next aimed to characterize them 
in more detail.   
 
3.5. The Pre-tRNA Pro-CGG-2-1 Generates an Ago-loaded sRNA in the 
Absence of La   
 
An interesting pre-tRNA that showed a considerably enhanced loading of processing 
products upon knockdown of La was pre-tRNA-Pro. Since several tRNA-Pro genes exist 
in human (see section 1.1.2), we investigated whether this effect was driven by a pre-
tRNA-Pro originating from one distinct locus. Indeed, most of the reads could be assigned 
to the Pro-CGG-2-1 pre-tRNA. A coverage analysis of this specific genomic region was 
then performed using the input libraries (Figure 3.15). For the graphical representation, 
the sequenced reads were depicted separately depending on whether they mapped 
unambiguously to the pre-tRNA (black) or to the mature tRNA (light gray) or whether 
they could be derived either from the pre-tRNA or from the mature tRNA (dark gray).  
In the control samples, ~200 reads per million contained the CCA end, which is added 
post-transcriptionally after maturation. Thus, they originated from the 3’ end of the 
mature Pro-CGG-2-1 tRNA. In comparison, only few fragments contained the 
genomically encoded 3’ trailer sequence and mapped to the 3’ end of the pre-tRNA 
(Figure 3.15, upper panel). Strikingly, the knockdown of La led to a remarkable increase 
of the pre-tRNA-derived fragments only, in particular of those mapping to the 3’ end and, 
to a lower extent, also to the 5’ end of the pre-tRNA (compare upper and lower panel in 
Figure 3.15).   
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We next intended to validate the sequencing results by Northern blot assays  performed 
on total RNA from cells treated with different siRNAs against La. In addition, to test for 
the specificity of the La-dependent effects, we included the knockdown of two La-related 
proteins (LARPs), LARP1 and LARP4B. The Northern blot probe used was 
complementary to the 3’ terminal fragment of the pre-tRNA-Pro-CGG-2-1. Indeed, a signal 
was readily detected at the expected size range of the processed sRNA (sRNA-Pro) 
(Figure 3.16A). Although we confirmed the efficiency of the La knockdowns by qPCR 
and by Western blotting (Figure 3.16B), no relevant changes between the different 
treatments were observed regarding the expression of sRNA-Pro (Figure 3.16A). Thus, 
the sRNA detected in this experiment appears to be produced independently of La. Since 
the Northern blot probe also strongly recognized the mature tRNA-Pro, we argued that 
Figure 3.15: The La-dependent Fragment of Pre-tRNA-Pro-CGG-2-1 Overlaps with a sRNA 
Processed from the Mature tRNA. Coverage of Pro-CGG-2-1 by reads detected in total RNA upon 
control knockdown (upper panel) or La knockdown (lower panel). See main text for more details. 
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the sRNA-Pro signal observed in Figure 3.16A might be mainly due to cross-
hybridization of the probe to the La-independent fragment derived from the 3’ end of the 
mature tRNA which was sequenced in the input libraries (Figure 3.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In general, we had previously observed that tRNA fragments were highly abundant in the 
input samples, while a more specific subpopulation of tRNA processing products which is 
associated with Ago proteins was responsive to the depletion of La. For this reason, we 
repeated the Northern blot experiment, but this time selectively looking at RNAs co-
immunoprecipitating with Ago2. By that, we could avoid the abundant, La-independent 
Figure 3.16: Northern Blot of Total RNA Does Not Confirm the Impact of La on sRNA-Pro. (A) 
HEK293 cells were transfected with three different siRNAs against La (lanes 2-4), LARP1 (lane 5), 
LARP4B (lane 6), or control siRNA (lane 7). Lane 1 shows a size marker. Total RNAs were analyzed by 
Northern blotting against the sRNA derived from the 3’ end of the Pro-CGG-2-1 pre-tRNA (sRNA-Pro). 
The membrane was subsequently probed for miR-17 as loading control. (B) Validation of the knockdown 
efficiencies by qPCR (left panel). Protein levels of La in cells transfected with three different siRNAs 
against La (lanes 1-3) or with a control siRNA (lane 4) were assayed by Western blotting. Equal loading of 
the samples was monitored by the detection of actin. The molecular size marker weights are depicted on the 
left side of the blots (right panel). 
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tRNA-Pro fragments which, in total RNA samples, might overshadow the effects 
occurring to the Ago2-loaded sRNA population. In fact, a specific fragment derived from 
the pre-tRNA-Pro-CGG-2-1 appeared in Ago2 complexes only upon knockdown of La 
(Figure 3.17A). The efficient immunoprecipitation of Ago2 from cells transfected with 
siRNAs against La or with control siRNAs and the successful depletion of La were 
confirmed by the Western blots shown in Figure 3.17B.        
 
  
 
The results so far indicate that La might repress the processing and loading of the pre-
tRNA-Pro-derived sRNA into Ago proteins. We next reasoned whether a strong 
overexpression of the pre-tRNA-Pro-CGG-2-1 would lead to the production and loading 
of this specific fragment into Ago proteins. Indeed, a strong signal for sRNA-Pro was 
detected by Northern blot analysis in Ago2 immunoprecipitates upon transfection of a 
plasmid containing the pre-tRNA-Pro-CGG-2-1 (Figure 3.18A). Importantly, this was 
sufficient to generate the Ago-bound sRNA-Pro, while no additional knockdown of La 
was required. Importantly, Western blot analyses confirmed that similar amounts of Ago2 
were immunoprecipitated in the experiments shown in Figure 3.17 and Figure 3.18 
(compare lanes 1 and 2 in Figure 3.17B with lane 1 in Figure 3.18B). Thus, the strong 
Figure 3.17: A Distinct sRNA-Pro Fragment is Loaded into Ago2 upon La Knockdown. (A) HEK293 
cells were transfected with a siRNA against La (lanes 2 and 5) or with a control siRNA (lanes 3 and 6). 
Ago2 (lanes 2 and 3) was immunoprecipitated and associated RNAs were analyzed by Northern blotting 
against sRNA-Pro. Lane 4 shows a beads-only control, lanes 5-7 show input samples, and lane 1 shows a 
size marker. The membrane was subsequently probed for miR-17 as a loading control. The corresponding 
Western blot controls are shown in (B). Western blot analyses were performed with anti-Ago2 (lanes 1-6), 
anti-La (lanes 7-9; upper panel) and anti-actin (lanes 7-9; lower panel) antibodies. The molecular size 
marker weights are depicted on the left side of the blots. 
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signal for sRNA-Pro detected in Ago2 complexes upon overexpression of pre-tRNA-Pro-
CGG-2-1 is not due to differences in the amount of immunoprecipitated proteins.   
 
 
 
 
 
 
 
 
 
 
Almost all sRNA loaded into Ago proteins are processed by Dicer from longer precursors 
containing hairpin structures (Kim et al., 2009). RNA secondary structure predictions 
performed in silico for the pre-tRNA-Pro-CGG-2-1 revealed that it might fold into an 
alternative hairpin structure possibly resembling a Dicer substrate (Figure 3.19A). Mature 
tRNAs, instead, adopt the stable cloverleaf secondary structure (Figure 3.19B), which is 
not likely to be processed by Dicer. For this reason it is more likely that the La-
independent sRNA-Pro fragment found in the input samples originates by a different 
processing mechanism rather than from endonucleolytic cleavage by the miRNA 
biogenesis machinery.  
 
 
 
 
Figure 3.18: The sRNA-Pro Fragment Is Processed and Loaded into Ago2 upon Overexpression of 
Pre-tRNA-Pro-CGG-2-1. (A) Northern blot experiment with RNA extracted from anti-Ago2 immuno-
precipitation (lane 2), beads-only control (lane 3) and input samples of HEK293 cell transfected with an 
overexpression construct of pre-tRNA-Pro-CGG-2-1. Lane 1 shows a size marker. The membrane was first 
incubated with a probe complementary to sRNA-Pro (upper panel) and subsequently re-probed for the 
detection of miR-17 (lower panel). (B) Western blot analysis probing for Ago2 in the corresponding protein 
samples (lanes 1-3). The molecular size marker weights are shown on the left. 
                                  RESULTS      71 
 
We next aimed to collect experimental evidences for the general ability of Dicer to bind 
pre-tRNAs and, by that, process them into Ago-bound sRNAs. Since our data indicate 
that La might interfere with the activity of Dicer, we determined the pre-tRNA population 
which interacts with Dicer in the presence as well as in the absence of La and compared 
them with each other (Figure 3.20 and Figure 3.21). For this analysis we performed 
photo-activatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-
CLIP) experiments, a method which has been applied successfully in the recent years to 
identify the RNA targets of numerous RBPs (Milek et al., 2012). As shown schematically 
in Figure 3.20A, this method utilizes the incorporation of a nucleoside analogon, usually 
4-thiouridine (4SU), into nascent RNA transcripts. The modified nucleoside is 
photoreactive and can be covalently cross-linked to nearby proteins by irradiation with 
UV light of 365 nm wavelength. The RBP of interest is then immunoprecipitated together 
with the cross-linked RNA, which is subsequently applied to a specialized cloning 
strategy for the generation of deep-sequencing libraries (Hafner et al., 2010).  
  
Figure 3.19: The Secondary Structures of Pre-tRNA-Pro-CGG-2-1 and of the Mature tRNA-Pro-
CGG-2-1 Might Strongly Differ. Schematic representations of putative secondary structures of the pre-
tRNA-Pro-CGG-2-1 (A) and of the corresponding mature tRNA-Pro (B). Predictions were computed either 
with the mfold algorithm (see section 5.2.3.8) in case of the pre-tRNA sequence or were adopted from the 
gtRNAdb 2.0 database (Chan and Lowe, 2015) for the mature tRNA. The region of the pre-tRNA whereof 
most of the reads are derived upon La knockdown is shown in red, while the fragment processed from the 
mature tRNA is indicated in blue.       
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This method has been already applied for the identification Dicer substrates in different 
species. We performed the experiment accordingly, using HEK293 cells stably expressing 
FH-tagged Dicer (Rybak-Wolf et al., 2014). Upon knockdown of La (Figure 3.20B), 
RNAs crosslinked to FH-Dicer were co-immunoprecipitated and radiolabeled. The 
complexes were resolved by SDS polyacrylamide gel electrophoresis (PAGE), blotted to 
a membrane (Figure 3.20C) and the RNA fragments were extracted and finally analyzed 
by deep-sequencing.  
 
In agreement with the data of Rybak-Wolf et al. (2014), several reads mapping to tRNA 
sequences were detected. In general, we found many tRNAs significantly less associated 
with FH-Dicer upon La depletion (shown in red in the lower part of Figure 3.21). This 
effect might be due to generally reduced expression levels of these tRNAs. At the same 
time, sequences mapping to other pre-tRNA transcripts were found significantly enriched 
Figure 3.20: PAR-CLIP Experiments with FH-Dicer in La or Control Knockdown Conditions.         
(A) Schematic representation of the experimental procedure used for PAR-CLIP of FH-Dicer upon La or 
control knockdown. (B) The efficient depletion of La (lane 1) compared to the control knockdown (lane 2) 
was assayed by Western blotting. Actin served as loading control. The molecular size marker weights are 
depicted on the left. (C) Radiolabeled RNA-protein complexes from the FH-Dicer PAR-CLIP experiments 
performed under La knockdown (lanes 1-4) or control (lanes 5-8) conditions were resolved on a SDS-gel 
and blotted to a membrane. The signals corresponding to the RNA-FH-Dicer complexes are indicated on 
the right side of the autoradiogram. This region of the membrane was excised and further processed for the 
generation of the sRNA libraries.  
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in the FH-Dicer PAR-CLIP libraries generated from La knockdown cells (shown in red in 
the upper part of the plot).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most strikingly, the greatest difference between the two conditions was observed for 
reads originating from Pro-CGG-2-1. This is in agreement with our previous hypothesis, 
that La prevents the processing of pre-tRNA-Pro-CGG-2-1 by Dicer, which can bind to 
this particular pre-tRNA either if the La levels are reduced or if the pre-tRNA is highly 
transcribed, e.g., from an exogenous source.  
 
  
Figure 3.21: The Depletion of La Affects the Pool of tRNA Transcripts Interacting with FH-Dicer. 
The MA plot shows the differential coverage analysis of reads mapping to pre-tRNA sequences in the FH-
Dicer PAR-CLIP libraries. The red dots annotate tRNAs, which associate differentially to FH-Dicer 
(Benjamini-Hochberg adjusted p value < 0.05). 
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3.6. A Bona Fide MiRNA is Generated from Pre-tRNA-Ile-TAT-2-3   
 
Another interesting fragment found in the Ago-associated sRNA libraries was derived 
specifically from the 3’ end of pre-tRNA-Ile-TAT-2-3. This sRNA has been already 
detected before in the total RNA of mouse embryonic stem cells and was annotated as 
mmu-miR-1983 (Babiarz et al., 2008). The authors of this work proved, by analyzing the 
RNA content of different knockout cell lines, that the biogenesis of mmu-miR-1983 
requires Dicer, but occurs independently of the Microprocessor complex. By that, mmu-
miR-1983 differs from the processing of canonical miRNAs. However, neither the 
association with Ago proteins, nor the functionality of this sRNA has been investigated so 
far. The occurrence of this specific sRNA in human cells has also not been reported yet 
and it is not deposited in the most recent human miRNA database (miRBase21; 
Kozomara and Griffiths-Jones, 2014). The comparison between the genomic sequence of 
the human tRNA-Ile-TAT-2-3 and the corresponding mouse sequence showed that it is 
highly conserved between these two species. In particular, the sequence of the detected 
sRNA-Ile (shown in red) is exactly the same in mouse and in human. The only difference 
between the two pre-tRNA sequences occurs at one position within the tRNA intron. 
However, it is not likely that this mismatch could determine overall changes in the 
secondary structure of the two pre-tRNAs.   
 
The tRNA genes listed in the database used for our data analysis (gtRNAdb 2.0; Chan and 
Lowe, 2015) were predicted by bioinformatic tools. It might be, therefore, that the tRNA-
Ile-TAT-2-3 locus is misannotated as a tRNA while its main function is to generate the 
sRNA-Ile fragment. In order to clarify whether a functional tRNA is indeed processed 
from Ile-TAT-2-3, we conducted an amino acylation assay. Therefore, the total RNA 
from HEK293 cells was extracted under acidic conditions which preserve the labile acyl 
bond between tRNAs and the loaded amino acids. An aliquot was then incubated at 
alkaline pH to deacylate the tRNAs. The size difference between acylated and deacylated 
tRNAs can be determined by running the samples on an acidic denaturing polyacrylamide 
Figure 3.22: Pre-tRNA-Ile-TAT-2-3 Is Conserved between Human and Mouse. Alignment of the human 
pre-tRNA-Ile-TAT-2-3 and the mouse pre-tRNA-Ile-TAT-2- sequences. The sRNA (annotated in mouse as 
miR-1983) is shown in red and the tRNA intron in blue. Conserved positions are marked by asterisks. 
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gel followed by Northern blotting. As shown in Figure 3.23, we carried out the assay with 
untreated (lanes 5 and 6) or mock treated (lanes 3 and 4) samples as well as with RNA 
from cells overexpressing pre-tRNA-Ile-TAT-2-3 from a plasmid (lanes 1 and 2). This 
permitted us to exclude misinterpretation of the results due to a possible cross-
hybridization of the Northern blot probe with other endogenous tRNA-Ile of different 
genomic origin. For all conditions, the acylated tRNAs migrated slower than in the 
deacylated samples, suggesting that endogenous as well as overexpressed tRNA-Ile- 
TAT-2-3 are processed to functional tRNAs, which are competent for protein translation. 
This finding was corroborated further by the occurrence of tRNA-Ile in polyribosomal 
fractions (data not shown). Surprisingly, we noticed in the aminoacylation assay that a 
band corresponding to the charged tRNA was still visible upon alkaline treatment, while 
this was not the case for the control tRNA-Lys.    
 
 
  
Figure 3.23: Pre-tRNA-Ile-TAT-2-3 Generates a Functional tRNA. A schematic representation of the 
mature tRNA-Ile-TAT-2-3 secondary structure is depicted on the left side. On the right, amino-acylation 
assays performed with total RNA isolated from HEK293 cells. The samples in lanes 1, 3 and 5 were kept 
under acidic conditions preserving the aminoacylation state, while the samples in lanes 2, 4 and 6 were 
alkali-treated to deacylate the tRNAs. Probes either for the mature tRNA-Ile-TAT-2-3 or for tRNA-Lys, as 
positive control, were used for Northern blotting.  
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We next aimed to characterize in more details the sRNA-Ile fragment, which is generated 
from pre-tRNA-Ile-TAT-2-3. Similar to classical miRNAs, Northern blot analysis 
revealed that sRNA-Ile is differentially expressed across several human cell lines, at low 
levels e.g., in DLD-1 cells and at high levels in SK-N-MC cells (Figure 3.24). 
Interestingly, the Northern blot probe detected also the mature tRNA-Ile, which was 
present at similar levels in all samples, and the pre-tRNA-Ile, which, instead, was 
differentially expressed across the cell lines. In addition, a fragment migrating between 
the mature tRNA and the sRNA fragment was particularly prominent in DLD-1 cells and 
might correspond to the 3’ splicing intermediate of the tRNA-Ile-TAT-2-3. 
In order to execute their biological function, miRNAs are required to be expressed at 
sufficiently high levels. To clarify whether this is the case for sRNA-Ile as well, we 
determined its absolute expression in HEK293 (Figure 3.25A) and SK-N-MC (Figure 
3.25B) cells by quantitative Northern blotting using serial dilutions of a synthetic 
oligonucleotide as a reference. The results of this experiment allowed us to calculate a 
value of ~250 copies per cell in HEK293 and ~750 copies per cell in SK-N-MC (Figure 
3.25C), which is comparable to the amount of a medium abundant miRNA (Bissels et al., 
2009).     
 
Figure 3.24: The sRNA-Ile Is Differentially Expressed across Human Cell Lines. Northern blot 
experiments were performed with total RNA extracted from the indicated cell lines (lanes 2-10). A size 
marker was loaded on lane 1. The lower panel shows the ethidium bromide (EtBr) staining of the gel before 
blotting and served as a control for RNA quality and for equal loading of the samples. 
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Figure 3.25: The sRNA-Ile Is Expressed at Similar Levels Compared to Canonical MiRNAs. 
Quantitative Northern blots were performed by loading serial dilutions of defined amounts of the synthetic 
sRNA-Ile (lanes 1-4 and 8-11) and the total RNA extracted from the indicated amount of HEK293 (A) or 
SK-N-MC (B) cells (lanes 5-7). (C) The signal intensities of the synthetic ribooligonucleotide were used to 
generate standard curves, allowing for the absolute quantification of the miR-1983 copy numbers per cell. 
The average and the standard deviation were determined for lanes 5-7 of the respective blot and are 
indicated in the table. 
The results so far indicate that sRNA-Ile shares some characteristic features with 
miRNAs and we further aimed to clarify whether it is also processed similarly. Pre-
tRNA-Ile-TAT-2-3 is unusual since its 5’ and 3’ extensions are complementary, which is 
rarely found in other pre-tRNAs. By that, pre-tRNA-Ile-TAT-2-3 can fold into an 
alternative secondary structure with an extended double-stranded stem (Figure 3.26). This 
folding differs from the typical cloverleaf structure, which is acquired already by pre-
tRNA transcripts. Of note, beside the interaction of the leader and trailer sequences with 
each other, also additional unconventional base pairings are necessary to permit this 
alternative folding. These concern the interactions between nucleotides normally forming 
the D- and T-arms of the mature tRNA, as well as interactions between the intron and 
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nucleotides located within the D- and the anticodon-arms. Importantly, within this 
alternative structure, sRNA-Ile (shown in red) is entirely embedded in the double-
stranded terminal stem and might therefore be processed by Dicer.  
 
 
 
 
 
 
 
 
 
 
To experimentally test this hypothesis, we first performed cleavage assays with in vitro 
transcribed pre-tRNA-Ile-TAT-2-3 and immunoprecipitated FH-Dicer. Indeed, a sRNA 
was produced upon incubation of the pre-tRNA with FH-Dicer but not in a control 
reaction (Figure 3.27).  
 
 
 
  
Figure 3.26: Pre-tRNA-Ile-TAT-2-3 Can Fold into a Structure 
with an Extended Terminal Stem. The schematic representation 
is based on in silico predictions computed with the mfold 
algorithm The portion corresponding to the processed sRNA-Ile is 
shown in red and the intron in blue. 
Figure 3.27: FH-Dicer Processes Pre-tRNA-Ile-TAT-2-3 to sRNA-Ile in vitro. Anti-FLAG immuno-
precipitations were performed from HEK293 cells transfected with FH-Dicer (lanes 1 and 2) or from non-
transfected cells (lanes 3 and 4). Beads were incubated with in vitro transcribed pre-tRNA-Ile-TAT-2-3 
(lanes 1 and 3) or pre-miR-27a (lanes 2 and 4). After cleavage reaction, the RNA was extracted from the 
samples and was used for Northern blotting with probes against sRNA-Ile (lanes 1 and 3) or miR-27a (lanes 
2 and 4). The processing products of miRNA size are highlighted by an arrow on the left.  
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We next investigated the Dicer-dependency of sRNA-Ile in vivo and performed Northern 
blot assays with total RNA isolated from wild type (Dcr +/+) as well as Dicer-deficient 
(Dcr -/-) mouse embryonic fibroblasts (MEFs). The sRNA-Ile was detected in Dcr +/+ 
MEFs, but not in cells lacking functional Dicer (Figure 3.28, upper panel). Thus, Dicer 
seems to be required for the biogenesis of the sRNA-Ile fragment.  
  
This finding was further strengthened by the reduction of sRNA-Ile levels upon 
knockdown of Dicer which we conducted with two different siRNAs (Figure 3.29A and 
C). To analyze the involvement of further components of the miRNA biogenesis 
machinery, we knocked down Xpo5 as well. Also in this case, the abundance of sRNA-Ile 
was severely affected (Figure 3.29B and C). Of note, we subsequently probed the 
membranes for a sRNA which is derived from a mature tRNA-Gly. This sRNA was 
suggested in a previous study to have several miRNA characteristics and was termed 
CU1276 (Maute et al., 2013). Differing from what we observed for sRNA-Ile, the 
expression of CU1276 did not change across the different samples tested (Figure 3.28 and 
Figure 3.29). 
In summary, we conclude from our results that pre-tRNA-Ile-TAT-2-3 can be either 
processed to a functional tRNA or to a sRNA, which has several characteristics in 
common with miRNAs.  
Figure 3.28: The sRNA-Ile Fragment Is Absent in Dcr -/- Cells. Northern blot analysis performed with 
total RNA extracted from Dcr +/+ MEFs (lane 2) or Dcr -/- MEFs (lane 3). A size marker was loaded on 
lane 1. The membrane was first probed for sRNA-Ile and, subsequently, for the CU1276 fragment (see main 
text). Detection of the U6 snRNA served as loading control. 
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3.7. The sRNA-Ile Is Loaded into Functional Silencing Complexes   
 
The evidences collected so far linked the occurrence of sRNA-Ile to several components 
of the miRNA biogenesis pathway. We intended to clarify whether sRNA-Ile is indeed a 
functional miRNA and consequently associates with the effectors of gene silencing. For 
this, we performed Northern blot analyses (Figure 3.30A) with RNA co-purified with 
immunoprecipitated endogenous Ago1, Ago2 and Ago3 (corresponding Western blot 
Figure 3.29: The Biogenesis of sRNA-Ile Depends on the MiRNA Processing Machinery. HEK293 
cells were transfected with two different siRNAs against Dicer (A) or against Xpo5 (B). After three days 
the total RNA was extracted and used for Northern blot assays. Samples of the corresponding knock-downs 
were loaded on lanes 2 and 3, a control knockdown on lane 4. A size marker is shown in lane 1. Probing of 
the membrane occurred as described in Figure 2.28. (C) The efficiencies of the knockdowns performed in 
(A) and (B) were validated by qPCR.  
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controls shown in Figure 3.30B). In agreement with our previous deep sequencing results 
(Figure 3.10), we found sRNA-Ile associating with Ago proteins, while neither the pre-
tRNA, nor the mature tRNA-Ile were bound (Figure 3.30A).  
 
To further corroborate the interaction of sRNA-Ile with functional gene silencing 
complexes, we immunoprecipitated TNRC6 proteins and repeated the Northern blot assay 
(Figure 3.31A). TNRC6 proteins are key proteins within the miRNA-dependent 
repression pathway and they directly interact with Ago proteins, which can be co-purified 
in anti-TNRC6 immunoprecipitates (Figure 3.31B). They act as scaffolds recruiting 
several downstream factors, which are responsible for the post-transcriptional inhibition 
of mRNAs targeted by miRNA-Ago complexes (reviewed in Jonas and Izaurralde, 2015, 
see also section 1.2.4). Importantly, we were able to enrich sRNA-Ile with anti-TNRC6 
antibodies (Figure 3.31A). This finding suggests that sRNA-Ile interacts with Ago 
proteins and that together they participate to the repression of gene expression via the 
classical miRNA pathway. In contrast, the tRNA-Gly fragment CU1276 was neither co-
precipitated with the Ago nor with the TNRC6 proteins (Figure 3.30A and Figure 3.31A), 
further confirming our hypothesis that it might rather have miRNA-independent 
functions, at least in the cell lines tested here.   
 
Figure 3.30: The sRNA-Ile Is Loaded into Ago Proteins. (A) Endogenous Ago1, Ago2 and Ago3 (lanes  
2-4) were immunoprecipitated from HEK293 cells. Co-precipitated RNAs were assayed by Northern blotting 
for the indicated RNAs. Lane 5 shows a beads-only control, lane 6 shows an input sample, and lane 1 shows a 
size marker. (B) Western blots were performed with aliquots from the indicated samples and were probed for 
human Ago1 (lanes 1 and 2), Ago2 (lanes 3-5), and Ago3 (lanes 6 and 7). The molecular size marker weights 
are depicted on the left. 
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MiRNAs inhibit gene expression by binding to complementary sequences on target 
mRNAs, mainly located within their 3’ UTR (Bartel, 2009). In order to identify the 
mRNAs regulated by sRNA-Ile, we applied a bioinformatic tool (TargetScan 5.2, 
Friedman et al., 2008) and predicted potential target transcripts. We chose to validate 
three genes out of this candidate list, namely RIMS2, which is involved in the regulation 
of synaptic membrane exocytosis, and BACH1 and BACH2, two transcription factors 
involved in the metabolism of heme and oxidative stress response pathways. We cloned 
their 3’ UTR sequences into reporter plasmids downstream of the firefly luciferase gene. 
Additionally, an artificial target construct containing two full-complementary sRNA-Ile 
binding sites was generated as a positive control. We then transfected the reporters in 
HEK293 cells either together with a mimic RNA or together with plasmids expressing 
sRNA-Ile from a short hairpin (sh)RNA or from the complete pre-tRNA-Ile-TAT-2-3 
context (Figure 3.32). As expected, the firefly activity of the artificial target construct was 
strongly reduced upon overexpression of sRNA-Ile, independently of the system used. 
The effect was completely abrogated if the assay was performed with an artificial reporter 
containing mutated sRNA-Ile target sites (Figure 3.32). Importantly, the overexpression 
of sRNA-Ile consistently led to a reduced expression of the reporter constructs containing 
the 3’ UTRs of RIMS2, BACH1 or BACH2. Also in this case, the sRNA-Ile-mediated 
repression was abolished if the putative target sites within the RIMS2, BACH1 or 
BACH2 3’ UTRs were mutated (Figure 3.32).  
Figure 3.31: The sRNA-Ile Associates with TNRC6 Complexes. (A) RNAs extracted from pan-TNRC6 
immunoprecipitation (lane 2), beads-only control (lane 3), and input samples (lane 4) were used for 
Northern blotting with the same probes as in Figure 2.30. Lane 1 shows a size marker. (B) Western blot 
control for the immunoprecipitation of pan-TNRC6 (lane 1), control (lane 2), and the input (lane 3). TNRC6 
proteins and co-precipitated Ago2 are detected in the TNRC6 immunoprecipitation (lane 1). The molecular 
size marker weights are depicted on the left. 
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It should be noted that the inhibition of gene expression achieved by the pre-tRNA-Ile-
TAT-2-3 construct was always milder compared to the mimic RNA or the shRNA and did 
not reach statistical significance in the case of the BACH2 reporter (Figure 3.32). This is 
likely due to the fact that sRNA-Ile was produced less efficiently from the pre-tRNA-Ile-
TAT-2-3 plasmid in comparison to the two other constructs (Figure 3.33).  
 
 
 
  
Figure 3.32: The sRNA-Ile Functions as a Bona Fide miRNA Repressing Translation. Two fully 
complemen-tary target sequences for sRNA-Ile (artificial miR-1983 target) or 3’-UTRs from predicted 
sRNA-Ile targets were fused to the firefly luciferase gene. Constructs with the mutated seed sequences of 
the artificial or the predicted target sites were generated as well. The reporter plasmids were tested in dual 
luciferase assays by co-transfecting the indicated RNAs (see main text). Firefly/renilla luminescence ratios 
were normalized to corresponding ratios of the empty reporter plasmid and to the corresponding control co-
transfections. These were a control siRNA, the empty shRNA expression plasmid, or a plasmid 
overexpressing a different pre-tRNA-Ile, which does not generate the sRNA-Ile fragment. The 
quantifications from three biological replicates are shown. The error bars represent ±SD and significance 
was assessed by two-sided Student’s t test (*p < 0.05, **p < 0.01, ***p < 0.001, and NS = not significant). 
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Nevertheless, the results of the luciferase reporter assay indicate that sRNA-Ile is capable 
of inhibiting target gene expression (Figure 3.32). For this reason and congruent with our 
previous findings we claim that sRNA-Ile is indeed a bona fide miRNA and we therefore 
refer to it as hsa-miR-1983.   
 
  
Figure 3.33: The Overexpression of sRNA-Ile from the Pre-tRNA Is Weaker Compared to the Other 
Constructs. Northern blot for sRNA-Ile generated from the different constructs applying the same 
conditions as in Figure 3.32 (lanes 2-4). The total RNA extracted from non-transfected cells (lane 5) was 
used for comparison. Lane 1 shows a size marker. Equal loading of the sample was assayed by detection of 
miR-17. 
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3.8. La is the Main Regulator for the Transition of Pre-tRNA-Ile-TAT-2-3 to 
miR-1983  
 
We identified miR-1983 in our initial screening for sRNAs, which are loaded into Ago 
proteins in a La-dependent manner. The experiments conducted so far indicate that two 
different and functionally active products can arise from the tRNA-Ile-TAT-2-3 
precursor, either miR-1983 or the mature tRNA-Ile. In some of the cell lines tested, both 
of them exist in parallel and we set out to identify which factors determine the fate of pre-
tRNA-Ile-TAT-2-3.  
The expression levels of miR-1983 were analyzed by Northern blotting (Figure 3.34A) 
Figure 3.34: Effect of the tRNA Processing Machinery on MiR-1983 Expression. (A) HEK293 cells 
were transfected with siRNAs against two different forms of RNase Z (lanes 2-4), the POP4 subunit of 
RNase P (lane 5), a catalytic subunit (TSEN2) of the tRNA-splicing complex (lane 6), the La protein (lane 
7), or Dicer (lane 9).Control siRNA transfection is shown in lane 8. The expression levels of miR-1983 
were analyzed by Northern blotting, detection of miR-17 served as loading control. Lane 1 shows a size 
marker. (B) Validation of knockdown efficiencies by qPCR for the samples used in (A) (left). Protein levels 
of La in cells transfected with a siRNA against La (lane 1) or with a control siRNA (lane 2) were assayed 
by Western blotting (right). Equal loading of the samples was assayed by detection of actin. The molecular 
size marker weights are shown on the left. 
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upon siRNA-mediated depletion of different proteins involved in the tRNA processing 
pathway (Figure 3.34B). The result presented in Figure 3.34A shows that neither the 
knockdown of 3’ end processing enzymes (ELAC1/2) nor of components of the 5’ end 
processing complex (POP4) or of the tRNA splicing complex (TSEN2) had a relevant 
influence on the abundance of miR-1983. Instead, depletion of La severely increased 
miR-1983 levels. This effect was proven to be specific as it was reproduced by using 
three different siRNAs against La, while the knockdown of LARP1 or LARP4B had no 
effect (Figure 3.35A). Furthermore, the increase of miR-1983 upon La knockdown were 
reproducible independently of the cell line used as it occurred in SK-N-MC cells as well 
(Figure 3.35B). 
  
 
  
Figure 3.35: La Determines the Expression Levels of miR-1983. (A) HEK293 cells were transfected 
with three different siRNAs against La (lanes 2-4), a siRNA against LARP1 (lane 5), LARP4B (lane 6), or a 
control siRNA (lane 7). The expression levels of miR-1983 were analyzed by Northern blotting and 
detection of miR-17 served as loading control. Lane 1 shows a size marker. (B) Northern blot experiment 
performed with total RNA extracted from SK-N-MC cells following La knockdown (lane 2) or control 
knockdown (lane 3). A size marker was loaded on lane 1. The membrane was assayed for the U6 snRNA 
which served as loading control.  
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In addition, we performed anti-Ago2 immunoprecipitations from La-depleted or control 
cells and confirmed by Northern blotting that the levels of miR-1983 were increased in 
the Ago-bound sRNA fraction as well (Figure 3.36A). The efficient immunoprecipitation 
of Ago2 from cells transfected with siRNAs against La or with control siRNAs and the 
successful depletion of La were confirmed by the Western blots shown in Figure 3.36B. 
Due to all this findings, we hypothesize that La is a key factor controlling the processing of 
miR-1983 from pre-tRNA-Ile-TAT-2-3.  
 
  
  
Figure 3.36: Increased MiR-1983 Levels upon La Depletion Correlate with Increased Binding to 
Ago2. (A) La knockdown (lanes 2 and 5) and control knockdown (lanes 3 and 6) were performed in 
HEK293 cells. Ago2 (lanes 2 and 3) was immunoprecipitated and miR-1983 levels were assayed by 
Northern blotting. Lane 4 shows beads-only control and lanes 5-7 show input samples. A size marker was 
loaded on lane 1. The signals for miR-17 are shown in the lower panel. (B) Western blot controls for the 
experiment shown in (A). Samples were assayed for the presence of Ago2 (lanes 1-6, left panel). The 
efficient depletion of La (lane 7) compared to the control samples (lanes 8 and 9) is shown on the right. The 
molecular size marker weights are indicated on the left side of the blots. 
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We therefore speculated whether differences in La protein levels might account for the 
varying expression of miR-1983 across several cell lines, as we noted previously (Figure 
3.24). However, Western blot analyses revealed that La was almost equally expressed 
between the different samples (Figure 3.37 upper panel), indicating that other factors are 
responsible for the different miR-1983 steady-state levels. Some studies have shown in 
the past that the differential expression of components of the miRNA biogenesis 
machinery drive changes in the miRNA profile of different cell types (Kumar et al., 2009; 
Melo et al., 2010; Ma et al., 2011; Ott et al., 2016). We thus analyzed by Western blotting 
the levels of Dicer and Xpo5 in the cell lines we previously used (Figure 3.37, central and 
lower panels). Indeed, a correlation between Xpo5 and/or Dicer and mir-1983 expression 
might hold true. Xpo5, for example, is more abundant in SK-N-MC, Ntera2 and HEK293 
cells compared to other cell lines, which is similar to the expression pattern of miR-1983 
(compare Figure 3.37 lower panels with Figure 3.24).   
 
 
 
 
 
  
Figure 3.37: La Is Expressed at Similar Levels across Different Cell Lines. Western blotting for La, 
Dicer, and Xpo5 with the same cell lines used for Northern blotting of sRNA-Ile in Figure 3.24 (lanes 1–9). 
Detection of actin and tubulin served as controls. The molecular size marker weights are depicted on the 
left. 
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3.9. Full-length La Protein is Required for the Interaction with Pre-tRNA-Ile-
TAT-2-3 
 
The hallmark of all LARPs is the so-called La module, which consists of a defined 
winged-helix fold, denoted La motif (LAM), and a RNA recognition motif (RRM). In 
addition, genuine La proteins usually contain a second RRM in their C-terminal part 
(reviewed in Maraia et al., 2017). However, the La module on its own is responsible for 
binding to the 3’ terminal U-stretch of Pol III (Alfano et al., 2004; Teplova et al., 2006). 
Additional interactions between other regions of La and pre-tRNAs have been shown to 
occur (Jacks et al., 2003; Bayfield and Maraia, 2009; Kucera et al., 2011). Some 
evidences exist, which indicate that La also binds to Pol II transcripts independently of 
terminal U-stretches (Holcik and Korneluk, 2000; Trotta et al., 2003; Martino et al., 2012; 
Liang et al., 2013). For this reason we aimed to investigate in more detail the nature of the 
interaction of La to pre-tRNA-Ile-TAT-2-3. First, we confirmed the binding of 
endogenous La to pre-tRNA-Ile by anti-La immunoprecipitations and subsequent 
Northern blotting of the co-purified RNAs. A signal corresponding to the size of full-
length pre-tRNA-Ile-TAT-2-3 was detected specifically in the anti-La and not in the 
control immunoprecipitation. Furthermore, additional signals of smaller RNA species 
were present and probably correspond to some processing intermediates, i.e., 5’ end 
processed pre-tRNA and 3’ splicing intermediate. As expected, the mature tRNA-Ile was 
detected at high levels in the input but did not associate with La (Figure 3.38).  
Figure 3.38: Pre-tRNA-Ile-TAT-2-3 Associates with Endogenous La. Immunoprecipitation of La was 
performed from SK-N-MC lysate (lane 2) and co-immunoprecipitated RNAs were analyzed by Northern 
blotting. Lane 3 shows a control immunoprecipitation with pre-immune serum, lane 4 is the input sample, 
and lanes 1 and 5 are size markers. The signals were detected with the in vitro transcribed, 5’ end-labeled, 
antisense pre-tRNA-Ile. Hybridization of the membrane with a probe for the Pol III transcribed Y5 RNA 
served as positive control. 
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We then generated several mutant versions of FH-tagged La and dissected the structural 
requirements accounting for the binding of La to pre-tRNA-Ile-TAT-2-3. To this end, we 
performed Northern blot analyses (Figure 3.39A) with RNA co-precipitated with the 
overexpressed and anti-FLAG immunoprecipitated constructs (Figure 3.39B).  
  
Similar to the experiment performed with endogenous La (Figure 3.38), the full-length 
pre-tRNA-Ile-TAT, as well as some processing intermediates, were co-precipitated with 
wild type FH-La. However, an additional distinct band was also detected, and probably 
corresponds to the mature tRNA-Ile (Figure 3.39A, lane 2). Since La does not interact 
with mature tRNAs, this finding is likely to be an overexpression artifact.  
Figure 3.39: The Binding of La to Pre-tRNA-Ile-TAT-2-3 Requires All RNA Binding Domains.        
(A) HEK293 cells were transfected with constructs expressing either wild type (WT) FH-tagged La (lanes 2 
and 7) or variants of FH-La (lanes 3-5 and lanes 8-10; see main text for details). FH-GFP was used as a 
control (lanes 6 and 11). The overexpressed proteins were immunoprecipitated with anti-FLAG beads 
(lanes 2-6) and the interacting RNAs were extracted for Northern blotting with a probe complementary to 
miR-1983. Lanes 7–11 show inputs, lane 1 shows a marker for sRNAs, and in vitro transcribed pre-tRNA-
Ile served as size marker in lane 12. (B) Aliquot samples from the experiment shown in (A) were analyzed 
by Western blotting using an anti-HA antibody. The molecular size marker weights are depicted on the left. 
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Instead, all other FH-La constructs tested did not associate with full-length pre-tRNA-Ile-
TAT-2-3. Confirming the importance of the La module for the interaction to Pol III 
transcripts, no signals were detected in case critical residues were mutated (La 
Y23A/Y24A) or in case the La motif was removed (La 104-408). Interestingly, the 
presence of the intact La module in the La 1-196 variant was not sufficient to maintain the 
binding to the full-length pre-tRNA-Ile, but only to a smaller processing intermediate. As 
expected, the mature miR-1983 was neither found within endogenous nor within 
overexpressed La complexes. Altogether, these results indicate that both, the La module 
as well as the C-terminal RRM2 of La, are required for efficient binding of full-length 
pre-tRNA-Ile-TAT-2-3.   
To further corroborate this finding, we performed rescue experiments comparing the 
effects of the different FH-La truncations on the expression levels of miR-1983 in the 
absence of the endogenous protein (Figure 3.40). For this purpose, we used a siRNA 
directed against the 3’ UTR of La which, however, did not target the overexpressed 
constructs and performed Northern blot analyses. A representative blot, out of three 
biological replicates, is shown in Figure 3.40A. We quantified the signal intensities for 
miR-1983 and normalized them, in the corresponding samples, to the expression of miR-
17, which does not react to La depletion (Figure 3.40B). In comparison to the FH-GFP 
samples, we consistently observed that the miR-1983 levels increased to a lesser extent 
when full-length FH-La was transfected, reaching statistical significance (Figure 3.40B). 
In agreement with the results of the immunoprecipitation experiment (Figure 3.39A), the 
two La truncations were unable to rescue the effect of the La knockdown (Figure 3.40A 
and B). We confirmed by Western blotting, that the observed effects were not due to 
unequal expression of the different constructs (Figure 3.40C). 
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Figure 3.40: The Increased Levels of Mir-1983 Are Partially Rescued by Full-length FH-La. (A) The 
indicated overexpression constructs were transfected into HEK293 cells. The following day, cells were 
transfected with a siRNA specific for the endogenous La mRNA (lanes 2-5). Cells were harvested three 
days post knockdown transfections and the levels of miR-1983 were assayed by Northern blotting. Cells 
transfected with a control siRNA served as reference (lane 6). Lane 1 shows a size marker.  (B) The signals 
for miR-1983 shown in (A) were quantified and normalized to the corresponding miR-17 signals. The 
experiment was performed in three biological replicates. The error bars represent ±SD and significance was 
assessed by two-sided Student’s t test (**p < 0.01, and NS = not significant). (C) Western blot analysis with 
an anti-HA antibody confirmed the correct overexpression of the proteins (lanes 1-4). No FH-tagged protein 
was overexpressed for the control in lane 5. Detection of actin served as a loading control. The molecular size 
marker weights are shown on the left. 
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3.10. The Double-stranded Stem of Pre-tRNA-Ile-TAT-2-3 Reduces its Affinity to La  
 
A peculiarity of pre-tRNA-Ile-TAT-2-3 is the complementarity of the 5’ and 3’ overhangs 
which can form a RNA double-strand and thereby contribute to the folding into a Dicer 
substrate. Owing to the fact that La primarily binds to transcripts ending on a single-
stranded U-stretch, we reasoned that this interaction might be hindered by the double-
stranded termini of pre-tRNA-Ile-TAT-2-3. We aimed to prove this hypothesis by 
performing electromobility shift assays (EMSAs) with recombinant GST-tagged La 
protein versions (Figure 3.41) and several in vitro transcribed pre-tRNAs.  
First of all, we tested our assay conditions with an optimal La-substrate consisting of a 5’ 
processed pre-tRNA intermediate which terminates on the canonical U-stretch. For this 
initial EMSA experiment we used WT GST-La protein and a mutated version wherein 
two tyrosine residues involved in RNA binding were mutated to alanine (Y23A Y24A). 
As expected, we observed a strong binding of the WT protein to the RNA substrate, while 
the interaction was severely impaired in the La mutant (Figure 3.42). 
 
 
 
 
 
Figure 3.41: Recombinant Protein Expression of GST-tagged La Constructs. Left panel: Schematic 
overview of the purification strategy. Right panel: Coomassie-stained SDS gel of recombinant GST-tagged 
La WT (lane 1) or Y23A Y24A mutant. The molecular size marker is indicated on the left. 
 
(lane 2) 
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Next, we compared the affinity of GST-La to the pre-tRNA-Ile-TAT-2-3 producing miR-
1983 and a pre-tRNA of different genomic origin. We opted for an isodecoder tRNA, Ile-
TAT-2-2, which generates a mature tRNA consisting of exactly the same sequence as Ile-
TAT-2-3. However, the two pre-tRNAs differ in the composition of their leader, trailer 
and intron sequences. Interestingly, the result of the EMSA shown in Figure 3.43 
indicates that GST-La binds to pre-tRNA-Ile-TAT-2-3 weaker than to the other substrate.  
 
 
 
 
 
 
 
 
Of note, the sequence of pre-tRNA-Ile-TAT-2-3, which we have used in our experiments 
terminates on 5’-UUUUCU-3’ which is at the same time the 3’ end of the mature mir-
1983. Although this is an uncommon terminus for a Pol III transcript, the occurrence of 
non-canonical termination sites in humans has been already reported in the past (Gunnery 
Figure 3.42: GST-La Efficiently Binds Pre-tRNA Substrates with Single-Stranded 3’ Trailer. EMSA 
performed with increasing amounts of recombinant GST-La WT (lanes 1-7) or GST-La Y23A Y24A 
mutant (lanes 8-14) which were incubated with an optimal substrate for La binding, having the 5’end of the 
mature tRNA and the 3’ trailer of the precursor terminating on –UUUU-3’. Schematic representation of the 
substrate is represented on the right. 
 
Figure 3.43: GST-La Binds Weaker to Pre-tRNA-Ile-TAT-2-3 Compared to Another Pre-tRNA-Ile. 
Two different 32P-labeled pre-tRNA-Ile-TAT transcripts were incubated with increasing amounts of 
recombinant GST-La. In lanes 1–7, the precursor for Ile-TAT-2-3 was used, wherefrom a functional tRNA 
or miR-1983 is generated, and in lanes 8–14, pre-tRNA-Ile-TAT-2-2 was used, which is a tRNA-only 
precursor. 
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et al., 1999; Orioli et al., 2011). Nevertheless, structural studies indicate that the 
occurrence of a cytidine at the penultimate position of the RNA might be incompatible 
with an efficient binding to La (Teplova et al., 2006). In order to exclude that the reduced 
affinity to pre-tRNA-Ile-TAT-2-3 is due to this particular sequence composition, we 
generated an artificial version of the control pre-tRNA-Ile-TAT-2-2 which has exactly the 
same 5’-UUUUCU-3’ terminus as pre-tRNA-Ile-TAT-2-3. Also in this case, we observed 
a weaker binding of GST-La to pre-tRNA-Ile-TAT-2-3 compared to the 3’-CU ending 
pre-tRNA-Ile-TAT-2-2 construct (Figure 3.44). We therefore speculate that the reduced 
affinity of GST-La to the transcript generating miR-1983 is not due to the sequence 
variations but is mainly influenced by its particular secondary structure which could 
reduce the accessibility of the 3’ end.  
To further corroborate this assumption, we performed an additional EMSA using either 
the full-length pre-tRNA-Ile-TAT-2-3 transcript or a substrate lacking the 5’ leader 
sequence. This transcript would correspond to a processing intermediate following the 
cleavage by the RNase P complex. Supporting our hypothesis, the affinity to GST-La 
strongly increased when the complementary 5’ extension was removed leaving a single-
stranded 3’ overhang which can be easily bound by La (Figure 3.45). 
    
Figure 3.44: The Terminal 3’ Sequence of Pre-tRNA-Ile-TAT-2-3 Does not Account for the Decreased 
Affinity to La. The EMSA shows 32P-labeled pre-tRNA-Ile-TAT-2-3 (lanes 1-7) and an artificial variant of 
pre-tRNA-Ile-TAT-2-2 terminating on -UUUUCU-3’ (lanes 8-14), exactly like pre-tRNA-Ile-TAT-2-3, 
incubated with increasing amounts of recombinant GST-La. 
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3.11. Viral Pol III Transcripts Sequester La and Influence the Cellular 
Landscape of sRNAs  
 
Our investigations suggest that La constantly supervises the channeling of pre-tRNA 
transcripts into the correct tRNA maturation pathway or, at least, determines the 
equilibrium between two different processing events as shown for the tRNA-Ile-TAT-2-
3/miR-1983 chimera. We wondered whether the functionality of La might be perturbed 
under certain physiological conditions leading to similar effects, which we observed in 
our La knockdown experiments. Our attention was caught by viral ncRNAs, which are 
transcribed from the viral genome by Pol III. Several examples of such transcripts have 
been identified (reviewed in Tycowski et al., 2015); among them, the most prominent are 
two virus-associated (VA) RNAs encoded by adenoviruses (Reich et al., 1966; Söderlund 
et al., 1976) and the Epstein-Barr virus (EBV)-encoded RNA 1 (EBER1) and EBER2 
(Rosa et al., 1981). Importantly, VA RNAs as well as EBER1/2 associate stably with La 
and are highly expressed in infected cells (Lerner et al., 1981). Their abundance has in 
fact been estimated to range between 2.5 × 105 and 108 copies per cell (reviewed by 
Mathews and Shenk, 1991; Tycowski et al., 2015). We hypothesized that the induction of 
Figure 3.45: La Binding to Pre-tRNA-Ile-TAT-2-3 Is Compromised by the High Complementarity of 
the 5’ Leader and 3’ Trailer Sequences. Increasing amounts of recombinant GST-La WT were incubated 
either with 32P-labeled full-length pre-tRNA-Ile-TAT-2-3 (lanes 1–7) or with a substrate having the 5’ end 
of the mature tRNA and the 3’ trailer of the precursor (lanes 8–14). Schematic representations of the 
substrates are shown on top. 
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such abundant Pol III transcripts would demand a great portion of the available La pool. 
Consequently, under viral infection, less pre-tRNAs might be bound by La and thus the 
production of more tRNA fragments like miR-1983 could be favored.  
To test this assumption, we generated a plasmid, which allowed the expression of both 
EBERs from their endogenous promoters. We transfected EBV negative HEK293 cells 
and achieved similar expression levels of EBER1/2 compared to EBV positive cell lines 
(Figure 3.46), ruling out unspecific effects due to strong overexpression. Of note, the 
probes used for the detection of the two EBER transcripts also revealed the occurrence of 
smaller fragments, which have been recently described (Lung et al., 2009, 2013).  
 
Next, we aimed to confirm the interaction of the viral transcripts with La. We therefore 
performed immunoprecipitations from the EBV positive Raji cells (Figure 3.47A) as well 
as from HEK293 cells transfected with the EBER1/2 plasmid or from mock transfected 
cells (Figure 3.47B). In both conditions, EBER1/2 were co-precipitated with La as 
revealed by subsequent Northern blot analyses. Interestingly, some of the smaller EBER 
fragments were also bound by La. In particular, a fragment of ca. 25 nt derived from the 
5’ end of EBER1 was strongly enriched in the anti-La immunoprecipitation samples 
(Figure 3.47A and B upper panels).  
Figure 3.46: Expression of EBER1/2 across Different Cell Lines. HEK293 cells were transfected with a 
plasmid expressing the viral RNAs from their endogenous promoters (lane 3). For comparison, total RNA 
was extracted from untransfected HEK293 cells (lane 2) or from EBV positive cell lines (lanes 4–6). The 
expression levels of EBER1/2 were detected by Northern blot analysis. A radioactive size marker was 
loaded on lane 1. The signals for the U6 snRNA were detected as loading control. 
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Figure 3.47: Endogenous La Interacts with Full-length EBER1/2 and with Short EBER (sEBER) 
Fragments. (A) Endogenous La was immunoprecipitated from Raji cell lysate (lane 2) and co-immuno-
precipitated RNAs were analyzed by Northern blotting for EBER1/2. Lane 3 shows a control 
immunoprecipitation with pre-immune serum, lane 4 is the input sample and lane 1 is a size marker. (B) 
Anti-La immunoprecipitations were performed with the lysate of HEK293 cells transfected with an 
EBER1/2 over-expression construct (lane 2) or with the lysate of mock transfected cells (lane 4). The 
immunoprecipitation from EBER1/2 transfected cells with pre-immune serum served as control (lane 3). 
Co-immunoprecipitated RNAs and total RNA extracted from input samples (lanes 5 and 6) were analyzed 
by Northern blotting. Lanes 1 and 7 are size markers. Signals were detected with a probe complementary to 
the 5’ end of the EBER1 RNA (upper panel) and with the in vitro transcribed, 5’end-labeled, antisense pre-
tRNA-Ile-2-3 (lower panel). 
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Figure 3.48: Pre-tRNA Fragments Accumulate in Ago2 upon Overexpression of EBER1/2.                
(A) HEK293 cells were transfected with am EBER1/2 overexpression construct (lanes 2 and 5) or with an 
empty plasmid (lanes 3 and 6). Ago2 (lanes 2 and 3) was immunoprecipitated and associated RNAs were 
analyzed as indicated by Northern blotting. Lane 4 shows a beads-only control, lanes 5-7 show input 
samples, and lane 1 shows a size marker. (B) A Western blot assay with protein aliquots of the same 
samples used in (A) (lanes 1-5) was performed as a control for the immunoprecipitations. The molecular 
size marker weights are depicted on the left. 
 
 
Importantly, when we assayed for pre-tRNA-Ile-TAT-2-3 co-immunoprecipitating with 
La with or without overexpression of EBERs, we observed a reduced interaction to the 
pre-tRNA in the presence of the viral Pol III transcripts (Figure 3.47B, lower panel, 
compare lanes 2 and 4). This indication is in agreement with our hypothesis that viral 
ncRNAs might sequester La, precluding its efficient binding to cellular transcripts.      
Finally, we analyzed the effect of EBER1/2 overexpression on the pre-tRNA-derived 
sRNA population and focused our investigations on the La-dependent sRNA-Pro and 
miR-1983. We have shown previously that sRNA-Pro is generated exclusively upon La 
knockdown. However, this effect was overshadowed in Northern blot assays by the 
existence of a distinct fragment of similar size and sequence which, instead, is derived 
from the mature tRNA-Pro. To overcome this cross-hybridization problem, we achieved a 
reliable detection of sRNA-Pro by assaying RNA co-precipitated by anti-Ago2 
immunoprecipitations (Figure 3.17A). We adopted the same strategy and probed anti-
Ago2 immuoprecipitated samples for the occurrence of sRNA-Pro upon EBER1/2 over-
expression or upon transfection of an empty plasmid (Figure 3.48).  
 
 
 
 
 
 
 
 
 
 
 
 
Indeed, a faint signal appeared specifically if the EBV ncRNAs were expressed (Figure 
3.48A, upper panel, compare lanes 2 and 3). The same membrane was probed afterwards 
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for miR-1983, which was apparently more abundant in Ago2 complexes isolated from 
EBER1/2 transfected cells, while the effect was less pronounced for miR-19b, which 
served as a control (Figure 3.48A, lower panels). Western blot analysis confirmed that 
euqual amounts of Ago protein complexes were immunoprecipitated in the presence or 
absence of EBER1/2 overexpression (Figure 3.48B). 
To gain a deeper insight into this phenomenon, we followed by Northern blotting the 
effects, over several days, of EBER1/2 overexpression on the total levels of the functional 
miR-1983 (Figure 3.49A). The levels of EBER1/2 increased until day two and then 
steadily decreased. Similarly, the abundance of miR-1983 increased and decreased in 
correlation with the viral RNAs. We performed the experiments in triplicates and 
quantified the range of miR-1983 expression changes by normalizing the Northern blot 
signals of miR-1983 to the levels of miR-17, which was detected at almost equal levels 
over the different time points (Figure 3.49B). The strongest effect was observed at day 
three, when miR-1983 was approximately two times more abundant than in the 
untransfected sample (Figure 3.49B). In summary, our data suggest that EBER1/2, which 
are highly expressed during EBV infection, can sequester La and, by that, they can 
influence the cellular sRNA landscape of the cell mimicking the outcome of La depletion. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.49: Time Course of the Effect of the EBV-encoded EBER1/2 RNAs on the MiR-1983 Expression 
Levels. (A) EBER1/2 were overexpressed in HEK293 cells for 5 days and total RNA was extracted every 24 hr 
(lanes 3–7) and was subjected to Northern blot analysis. Lane 2 shows total RNA from non-transfected cells and 
lane 8 from cells transfected with an empty plasmid. A size marker was loaded on lane 1. The membrane was 
probed for miR-1983, miR-17, EBER1, and EBER2 expression. (B) The signal intensities of the experiment 
shown in (A) were quantified and the values for miR-1983 were normalized to the corresponding miR-17 signals. 
The quantifications are based on three biological replicates. The error bars represent ±SD. Significance was 
assessed by two-sided Student’s t test (*p < 0.05, **p < 0.01, and NS = not significant). 
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4. Discussion 
 
4.1. Crosstalk Between La and the MiRNA Machinery  
 
Beyond any doubts, the main function of La is to immediately bind and, thereby, protect 
nascent Pol III transcripts, which terminate with the typical U stretch (Fairley et al., 
2005). Nevertheless, La has long been implicated in other cellular processes as well, e.g., 
by binding and promoting translation of cellular mRNAs, either by IRES-dependent 
(Holcik and Korneluk, 2000; Kim et al., 2001; Sommer et al., 2011; Petz et al., 2012) or 
by IRES-independent mechanisms (Trotta et al., 2003; Heise et al., 2016). More recently, 
La has also stepped into the miRNA field as it was reported to interact with Ago2 (Liu et 
al., 2011; Zheng et al., 2017). Biochemical evidences suggest that La might act as a factor 
promoting multiple-turnover reactions of RISC during RNA interference (RNAi) in flies. 
This specific mechanism only occurs if either exogenous or endogenous siRNAs are fully 
complementary to a target transcript and thereby direct catalytically active Ago proteins 
to cleave the target. In this context, La might facilitate the release of the nicked target 
RNA, liberating the Ago-containing silencing complex for another round of catalysis (Liu 
et al., 2011). Although endogenous RNAi does not occur commonly in mammalian cells, 
it is widely applied by other organisms like, e.g., D. melanogaster. Further studies are 
required to elucidate the relevance of La for RNAi processes in more detail and to clarify 
whether La is also involved in miRNA-directed gene silencing reactions.    
An additional crosstalk between La and the miRNA pathway caught our attention as it 
was shown that this protein might affect the biogenesis of miRNAs (Liang et al., 2013). 
The expression of miRNAs is tightly regulated at the transcriptional as well at the post-
transcriptional level. In particular, several examples of RBPs binding to sequence 
elements within miRNA precursors have been described so far. These RBPs are able to 
modulate the biogenesis rate of specific miRNAs (reviewed in Ha and Kim, 2014) and, by 
that, they can have a tremendous impact on the cellular homeostasis (reviewed in Lin and 
Gregory, 2015). The work by Liang et al. (2013) indicates that La is able to bind in vitro 
and in vivo to the stem-loop structure of miRNA precursors, apparently without any 
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sequence specificity. The authors further propose that La binding protects a broad number 
of different pre-miRNAs from degradation by ZC3H12A (also known as MCPIP1), an 
RNA endonuclease, which was shown to cleave within the loop of pre-miRNAs 
antagonizing Dicer processing (Suzuki et al., 2011; Roy et al., 2013). As a consequence, 
depletion of La in HeLa cells triggers the reduction of several miRNAs’ expression levels 
as determined by a TaqMan qPCR array (Liang et al., 2013).  
In our study, we performed a similar experiment in HEK293 cells and profiled the impact 
of La knockdown on the miRNA population by deep sequencing. Indeed, we confirmed 
the negative consequence of La depletion on certain miRNAs, in particular our data are in 
agreement with the observations by Liang et al. (2013) concerning let-7 miRNA family 
members, miR-98 and miR-374a (Figure 3.6). However, validation of selected candidates 
by Northern blot analyses resulted in less pronounced effects (Figure 3.7). This might be 
an inherent problem of comparing miRNA expression levels by deep sequencing, as this 
method is susceptible to different kinds of technical biases (Raabe et al., 2014). 
Furthermore, thanks to our experimental setup, we were able to distinguish between La-
dependent sRNA changes in the total RNA population and the effect of La knockdown 
specifically on Ago-loaded sRNAs. Of note, the overlap between miRNAs reaching a 3-
fold deregulation threshold in both subsets was low and only members of the let-7 
miRNA family were consistently reduced in the Ago-loaded fraction as well as in the 
input sample. This might either be due to relatively stringent threshold settings or, 
alternatively, the turnover of certain miRNAs might differ between both populations and 
might thus react with different kinetics to La depletion. In sum, although expression 
levels of some miRNAs diminished, the global impact of La knockdown on miRNA 
levels was rather moderate (see high correlation rates between La and control experiments 
in Figure 3.6). This finding argues against a general influence of La on miRNA 
biogenesis as proposed by Liang et al. (2013), who observed reduced levels of ~60% of 
the tested miRNAs. Furthermore, upon La depletion we detected increased levels of some 
miRNAs in the Ago-associated pool, as well as in the input sample. Hence, our data 
suggest that La has a positive or negative influence only on a restricted number of 
miRNAs, which is in line with another recently published study (Zheng et al., 2017). The 
fact that La is able to promote or to inhibit the processing of certain miRNAs presumably 
reflects a more sophisticated regulatory mechanism. Although it remains still an open 
question how this is exactly achieved, Zheng et al. (2017) propose a different model than 
Liang et al. (2013) to explain the role of La in miRNA biogenesis. The authors of the 
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former study noted that La specifically associates in a RNA-dependent manner to 
DGCR8, a component of the Microprocessor complex responsible for the first step of 
miRNA maturation. Interestingly, no interaction was detected between La and Drosha, 
the catalytic component of the Microprocessor complex. Zheng et al. (2017) speculate 
that La promotes DGCR8 binding to specific miRNA precursors possibly by inducing 
conformational changes of the pri-miRNA.   
 
4.2. Processing Products of tRNAs are Abundant and Affected by La Depletion 
 
It is known since many years, that different Pol III transcripts can give rise to sRNA 
fragments, originating for example from tRNAs, 5S rRNA, Y RNAs and vault RNAs 
(Speer et al., 1979; Persson et al., 2009; Meiri et al., 2010; Chen and Heard, 2013). Some 
of them have been also detected in association with Ago proteins (Cole et al., 2009; 
Burroughs et al., 2011; Maute et al., 2013; Pekarsky et al., 2016). Indeed, by our Ago-
APP approach we did not only co-precipitate miRNAs (Figure 3.5), but to a minor extent 
also several sRNAs derived from different Pol III transcripts, e.g., 5S rRNA, 7SL RNA 
and snaRs, an evolutionarily recent ncRNA class, which has not been extensively 
characterized so far (Parrott and Mathews, 2007). Of note, among Pol III transcripts, 
tRNAs were the major source of Ago-associated reads. We also determined that most of 
these tRFs were unambiguously derived from mature tRNAs, i.e., the reads either covered 
the exon-exon junction of intron-containing tRNAs (see section 1.1.6) or they terminated 
on the CCA sequence, which is post-transcriptionally added to the 3’ end of mature 
tRNAs (see section 1.1.5) (Figure 3.8). Intriguingly, these tRFs resulted to be rather short 
and, at least with the experimental and computational strategy we applied, they peaked at 
a length of 18 nt (Figure 3.13). This observation is largely consistent with previous 
reports (Kumar et al., 2014; Telonis et al., 2015) and clearly differs from the size of 
miRNAs, which usually ranges between 19 and 23 nt. Although some short tRFs are 
reliably detected in the libraries of Ago1-4-associated sRNA, they were not enriched from 
the input to a comparable level as miRNAs (Figure 3.5). Taken together, we rather 
speculate that the 18 nt tRFs might be side-products of RNA pathways unrelated to the 
miRNA metabolism. A small subset of these tRFs might transiently interact with Ago 
proteins without affecting its function and might therefore be tolerated without any side-
effects. An intriguing scenario, for example, could be that 18 nt tRFs act as a buffer 
system for Ago proteins which are not loaded with a miRNA. Such tRFs might be 
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beneficial for storing Ago proteins in a folded conformation and protecting them from 
proteolytic degradation. As soon as a miRNA becomes available, it might easily displace 
the short tRF due to its correct size, which is likely to result in a stronger affinity to Ago 
proteins. However, we do not have any experimental evidence supporting this hypothesis, 
which is so far a mere speculation.   
We next wondered whether the occurrence of Pol III-derived sRNAs is influenced by La-
depletion. Interestingly, most of these fragments, which were especially abundant in the 
total RNA sequencings, did not react dramatically to the knockdown of La, e.g., in the 
case of reads mapping to the 5S rRNA sequence (Figure 3.9). This might indicate that La 
is neither strictly required for the generation nor for the stabilization of such fragments or 
of the full-length transcripts they originate from. Other proteins with a redundant function 
might for example compensate the lack of La, or, alternative maturation pathways might 
circumvent the La-dependency (Yoo and Wolin, 1997).   
Strikingly, the greatest effect we observed upon La depletion concerned read counts 
mapping to tRNA genes (Figure 3.9). This might reflect the fact, that, among all Pol III 
transcripts, tRNAs most strongly require the interaction with La for their correct 
processing as pinpointed in a nice review by Maraia and Arimbasseri (2017). The 
decreased abundance of tRNA-reads in the input sample could therefore partially be due 
to a general reduction of pre-tRNAs and/or mature tRNAs which are the source of the 
sRNAs we detect. Nevertheless, the coverage analysis performed with tRNA reads of the 
inputs (Figure 3.12) further highlights that the most substantial drop concerned fragments 
which are apparently 3’ trailers of pre-tRNAs, also called 3’ U-tRFs (see section 1.1.10.1). 
Again, the disappearance of such sRNAs could be caused by a backup mechanism for 
tRNA maturation observed in yeast lacking the orthologous La protein. In this situation, 
the 3’ end of pre-tRNAs are immediately processed by exonucleolytic cleavage (Yoo and 
Wolin, 1997; Copela et al., 2008; see as well section 1.1.4.3). Consequently, 3’ trailer 
fragments would not be generated at all from freshly transcribed tRNAs. However, the 
depletion of La might account on a second way for the reduced 3’ U-tRF levels. This 
alternative explanation is based on the evidence that removal of the 3’ trailer by RNase Z 
might occur while La is still bound to the pre-tRNA. Although the interaction of La to the 
resected 3’ trailers was shown to be weaker than to full-length pre-tRNAs (Bayfield and 
Maraia, 2009), we noticed that some 3’ U-tRFs are highly enriched in anti-La 
immunoprecipitations (data not shown). Thus, La might in particular stick to long 3’ 
trailer fragments which, therefore, would be protected and stabilized by this interaction. 
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Vice versa, La-interacting 3’ U-tRFs would be rapidly degraded under knockdown 
conditions accounting for the phenomenon which emerged from our analyses.  
 
4.3. La is a Gatekeeper Preventing Mis-channeling of tRNA Fragments into the 
Human MiRNA Pathway 
 
In contrast to the decrease observed in the input, La depletion resulted in a 4-fold 
accumulation of Ago-associated fragments, which unambiguously originate from pre-
tRNAs (Figure 3.8 and Figure 3.10). When analyzing their position within the tRNA 
transcripts, we noticed that the enriched sRNAs covered the tRNA body at its 3’ terminal 
region and protruded into the 3’ trailer (Figure 3.11). Importantly, these Ago1-4-
associated tRNA reads clearly differed from the simple trailer fragments, which were 
more abundant in the input samples (Figure 3.12). At the same time, the length of the 
accumulating Ago-loaded tRFs ranged between 21-23 nt with a prominent peak at 23 nt. 
The accurate processing of these fragments in terms of size and location within the tRNA 
sequence, corroborate the specificity of this observations. This is further supported by the 
fact that the abundance of these fragments increases upon La knockdown within Ago1-4 
complexes while simultaneously decreasing in the input. We therefore hypothesized that 
La might prevent certain pre-tRNAs to be erroneously processed by the miRNA 
biogenesis machinery into Ago-loaded tRFs. Indeed, validation experiments performed 
with two different candidates (Figure 3.17 and Figure 3.36), confirmed that specific tRFs 
accumulate in Ago1-4 complexes upon knockdown of La. Furthermore, when performing 
Dicer PAR-CLIP experiments, we observed some tRNAs to be much stronger associated 
with Dicer in the absence of La (Figure 3.21). Among them, reads originating from 
tRNA-Pro, -Ala and –Leu were detected, which are tRNA isotypes generating Ago-
loaded and La-dependent fragments (Figure 3.10). Of note, several tRNAs were also less 
frequently found in the Dicer PAR-CLIP libraries upon La knockdown (Figure 3.21). 
Again, this might be a secondary effect, since La is required for the stabilization of pre-
tRNAs. This is along the same line with the observation that the abundance of pre-tRNA 
fragments generally decreased upon knockdown of La in the profiling of input samples 
(Figure 3.9). We finally also confirmed by independent in vitro and in vivo assays that 
Dicer and Xpo5 are required for the generation of Ago-loaded tRFs in the absence of La 
(Figure 3.27Figure 3.-Figure 3.29). Nevertheless, some interesting issues emerging from 
our analyses still require to be addressed in more detail: 
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1) Surprisingly, a clear bias for the enrichment of fragments originating from the 3’ end of 
pre-tRNAs became evident in the coverage analysis of Ago1-4-associated sRNA (Figure 
3.11). Such a strict selectivity is interesting, since the actual knowledge regarding the 
mechanism of miRNA strand-selection is probably not sufficient to explain this 
phenomenon. For canonical miRNAs, Dicer processing from hairpin structures results in 
intermediate RNA-duplex products. The decision which of the two strands is finally 
giving rise to the mature miRNA obeys the so-called asymmetry rule, i.e., the strand with 
the thermodynamic less stable interactions at its 5’ end is handed over to an Ago protein 
(Khvorova et al., 2003; Schwarz et al., 2003; see as well section 1.2.2). Our data indicate 
that Dicer is also responsible for the generation of certain tRFs in a La-dependent manner. 
Nevertheless, why do only the processing products from the 3’ end of pre-tRNAs 
accumulate in the Ago1-4 complexes, while their 5’ counterparts are selectively depleted? 
A possible explanation for this finding is the chemical composition of the 5’ end of pre-
tRNAs. As all primary Pol III transcripts, pre-tRNAs possess a triphosphate at their         
5’ termini. Although Dicer has been shown to bind the 5’ monophosphate of pre-miRNAs 
(Park et al., 2011), it has not been experimentally addressed within the indicated 
reference, whether a 5’ triphosphate would be incompatible with Dicer processing. Indeed 
substrates with even more exotic 5’ ends, i.e., 7-methylguanosine (m7G)-capped miRNA 
precursors, have been shown to be efficiently cleaved by Dicer. However, only the 
opposite strand, which does not possess the m7G cap at its 5’ end, is loaded into Ago 
proteins (Xie et al., 2013). Thus, it is likely that Ago proteins cannot accommodate 
sRNAs with 5’ ends other than monophosphates. In such cases, Ago itself acts as a filter 
for strand-selection. Consistently, the 5’ triphosphorylated ends of some viral miRNAs 
were shown to be first converted by DUSP11 into 5’ monophosphates before they get 
loaded into Ago proteins (Burke et al., 2014, 2016). In this regard, our data seem to argue 
that DUSP11 is not able to dephosphorylate pre-tRNA substrates, otherwise we would 
expect 5’ terminal pre-tRNA fragments to accumulate in Ago complexes equally well as 
their 3’ terminal counterparts.  
  
2) Another interesting aspect concerns the fact that the La-dependent accumulation of 
tRFs in Ago1-4 was restricted to only a subset of tRNA isotypes (Figure 3.10). A possible 
explanation for this selectivity is that individual tRNA transcripts might depend to a 
varying degree on the function of La. For instance, several studies have emphasized the 
particular requirement of La for the correct folding of defective pre-tRNAs, e.g., in the 
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absence of selected tRNA modifications or impaired base pairings (Calvo et al., 1999; 
Chakshusmathi et al., 2003; Copela et al., 2006; Huang et al., 2006). In addition, certain 
tRNAs might be more efficiently processed by alternative maturation pathways (Copela et 
al., 2008; Maraia and Lamichhane, 2011) and owing to that they would not be sensitive to 
La depletion. The heterogeneity of pre-tRNA 3’ ends might also contribute to this 
phenomenon since the length of the 3’ terminal U-stretch was shown to influence their 
interaction with La in yeast and human (Huang et al., 2005; Gogakos et al., 2017). 
Furthermore, our biochemical data suggest that the ability of certain pre-tRNAs to form 
alternative structures (Figure 3.19 and Figure 3.26) might reduce their affinity towards La 
(Figure 3.45). These substrates would in turn be more susceptible to mis-channeling into 
tRNA-unrelated pathways, e.g., by allowing processing by Dicer and loading of tRFs into 
Ago proteins (Figure 4.1).  
It would be interesting to see whether this gatekeeping function is shared by other 
proteins with RNA chaperone activity and whether other pathways might concur with 
each other for the same RNA substrates. 
 
 
 
 
 
 
 
  
Figure 4.1: RNA Chaperones Can Contribute to the Channeling of their Substrates into the Correct 
Pathway. General model based on our observations concerning the function of La. It ensures that 
transcripts having an intrinsic potential to fold into alternative structures are channeled into the tRNA 
maturation pathway (represented on the left) and not into the miRNA pathway (represented on the right). 
RNA chaperones other than La might assist RNAs to adopt the correct structure and ensure that the RNA 
fulfill its actual function without being hampered by the machinery of competing pathways. 
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4.4. Hidden Pitfalls in the Analysis of tRFs 
 
In general, sRNAs are classified into distinct groups due to the presence of well-defined 
sequence elements or structural characteristics that determine the biogenesis and function 
of, e.g., miRNAs, snoRNAs, snRNAs and tRNAs. Unfortunately, the common 
denominator of short tRF is merely the fact that they originate from tRNA transcripts. 
Apart from that, tRFs are generated by various enzymes and the molecular mode of action 
described for some tRFs is a potpourri of different mechanisms (see section 1.1.10). In 
addition, profiling of tRFs goes along with a series of technical issues which concerns for 
instance the sequence similarity between tRNA isodecoders, the occurrence of tRNA-
derived repetitive elements or lookalikes and the negative influence of tRNA modification 
on sequencing-based detection methods (Telonis et al., 2014, 2015; Cozen et al., 2015; 
Zheng et al., 2015). In our study we come across an additional problem, namely the co-
existence of different tRFs having a similar sequence (Figure 3.15). Our data indicate that 
one of these tRFs, sRNA-Pro, is processed by Dicer from pre-tRNA-Pro-CGG-2-1 in a 
La-dependent manner (Figure 3.15 and Figure 3.21). This fragment originates from a 
region of the pre-tRNA, which partially overlaps the sequence of a 3’ CCA-tRF. 
However, we assume that latter sRNA is processed via a Dicer-independent mechanism 
from the mature tRNA-Pro-CGG. This example depicts the caution which is required to 
entangle the many functional aspects of tRFs. In this particular case we were able to 
distinguish between the two related fragments only by isolating the Ago-associated tRFs 
from the multitude of tRFs, which otherwise overshadowed the effect we were interested 
in (Figure 3.16 and Figure 3.17). Indeed, the misinterpretation of tRNA fragments as 
potential miRNAs is another pitfall to be aware of when referring to the partially 
contradictory literature (Haussecker et al., 2010; Schopman et al., 2010; Thomson et al., 
2014). This seems to be also the case for a 3’ CCA-tRF termed CU1276 which has been 
described to excerpt a miRNA function (Maute et al., 2013). In the cell lines we tested, 
CU1276 neither appeared to be processed by the miRNA biogenesis machinery (Figure 
3.28Figure 3. and Figure 3.29) nor to associate with miRNA-repression complexes 
(Figure 3.30 and Figure 3.31). Although we cannot exclude that CU1276 might acquire 
all these characteristics in other cell types, we rather think that its relevance for 
proliferation and for the DNA damage response, as shown in B cells by Maute et al. 
(2013), might occur via miRNA-unrelated pathways.   
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4.5. Pre-tRNA-Ile-2-3 Escapes La Binding by an Alternative Folding  
 
The key point of our work is the discovery that the well-known function of La for tRNA 
biology is not only beneficial for the production of mature tRNAs but also ensures that 
pre-tRNAs are not erroneously fed into the miRNA biogenesis pathway. This mechanism 
appears to work quite well in HEK293 cells, since the amount of Ago-associated tRFs 
with miRNA-like characteristics is relatively low (Figure 3.11). Nevertheless, we noticed 
that pre-tRNA-Ile-TAT-2-3 escapes La regulation even in untreated samples and gives 
rise to an Ago-loaded sRNA. In silico predictions suggest that the high degree of 
complementarity between the 5’ leader and the 3’ trailer sequences contributes to the 
formation of an alternative secondary structure, which finally renders pre-tRNA-Ile- 
TAT-2-3 an optimal prey for miRNA biogenesis factors (Figure 3.26). In detail, we 
performed EMSAs comparing the interaction of La to pre-tRNA-Ile-TAT-2-3 and pre-
tRNA-Ile-TAT-2-2, which are very similar in their overall sequence composition but the 
latter transcript does not generate an Ago-loaded tRF. Importantly, La did not bind to pre-
tRNA-Ile-TAT-2-3 equally well as to pre-tRNA-Ile-TAT-2-2 (Figure 3.43 and Figure 
3.44). We speculate that this reduced affinity is due to the fact that the 5’ and 3’ ends of 
pre-tRNA-Ile-TAT-2-3 form a stem structure, wherein the La interaction motif, i.e., the 3’ 
terminal U-stretch, is buried into a stable double-stranded environment. However, as soon 
as the 3’ end is presented in a single-stranded context, high affinity binding is restored 
(Figure 3.45). Although the interaction of La with the full-length pre-tRNA-Ile-TAT-2-3 
appears to be weaker compared to other substrates, it is still sufficient to ensure binding 
of La to pre-tRNA-Ile-TAT-2-3 in vivo, as confirmed by endogenous immunoprecipi-
tation experiments (Figure 3.38). Since multiple regions of the La protein contribute to 
contact the RNA substrates (Alfano et al., 2004; Huang et al., 2006; Teplova et al., 2006; 
Bayfield and Maraia, 2009; Kucera et al., 2011), we tested different La truncations for 
their ability to precipitate endogenous pre-tRNA-Ile-TAT-2-3. Our data indicate that 
both, the functional La module together with the C-terminal region of La, are required for 
an efficient interaction with pre-tRNA-Ile-TAT-2-3. Interestingly, also the constructs 
containing the complete La module (1-196) did not precipitate the full-length pre-tRNA-
Ile-TAT-2-3 but a RNA, which is likely to be a 5’ end-matured, 3’ trailer containing 
processing intermediate (Figure 3.39). This was rather surprising, since the La module 
alone was shown to be sufficient for high affinity binding to substrates containing a 3’ 
terminal U-stretch (Ohndorf et al., 2001) . It would be interesting to compare the ability 
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of the La 1-196 truncation to precipitate pre-tRNAs other than pre-tRNA-Ile-TAT-2-3. 
The aforementioned structural peculiarity of pre-tRNA-Ile-TAT-2-3, i.e., the stable stem 
formed by the 5’ and 3’ ends, might be responsible for an increased requirement of La’s 
C-terminal region to support efficient binding. Of note, when we tried to rescue the effect 
of La knockdown on the increased production of miR-1983, we also observed that            
La 1-196 did not behave as the full-length construct (Figure 3.40).   
 
4.6. The Chimeric Pre-tRNA-Ile-TAT-2-3 Generates Either a Functional tRNA 
or MiR-1983  
 
In our study, we collected evidences suggesting that miR-1983 is indeed a genuine 
miRNA, which is processed from pre-tRNA-Ile-TAT-2-3 owing to its ability to escape, at 
least in part, from La binding. We showed that miR-1983 is broadly detected across 
different cell lines (Figure 3.24) at expression levels comparable to a medium-abundant 
miRNA (Figure 3.25) and is clearly co-precipitating with Ago and TNRC6 protein 
complexes (Figure 3.30 and Figure 3.31). We further corroborated the functionality of 
this particular tRF by luciferase reporter assays and, importantly, we observed repression 
of the identified targets not only via artificial miR-1983 overexpression constructs but 
also by transfecting pre-tRNA-Ile-TAT-2-3 as a source for the production of miR-1983 
(Figure 3.32). Our data, together with the profiling study of Babiarz et al. (2008), 
demonstrate that miR-1983 is conserved between mouse and human (Figure 3.22) and is a 
non-canonical miRNA inasmuch it is processed in a Drosha-independent but Xpo5- and 
Dicer-dependent manner (Figure 3.27 - Figure 3.29).  
Importantly, pre-tRNA-Ile-TAT-2-3 can also generate a functional tRNA-Ile (Figure 
3.23) and La is the main switch dictating whether this pre-tRNA undergoes processing to 
a tRNA or to a miRNA (Figure 3.34). The model presented in Figure 4.2 summarizes all 
these findings.   
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Figure 4.2: Model for the Regulatory Role of the La Protein in Safeguarding the Fate of Pre-tRNAs.  
La (blue) ensures that pre-tRNAs are processed to mature tRNAs (left). However, pre-tRNAs with 
complementary 5’ and 3’ ends can escape this control and are recognized by Xpo5 and Dicer (oliv). This 
finally results in the production pre-tRNA-derived miRNAs which are bound by Ago proteins (light brown) 
(right). 
 
Why did pre-tRNA-Ile-TAT-2-3 evolve to a chimeric transcript maintaining both 
functions? Answering this question leaves room for several speculations:  
 
1) As shown in Figure 1.5, the human genome encodes four other tRNA-Ile-TAT 
isodecoders, and the corresponding AUA codon is the less frequently used for Ile. It 
might therefore be that losing a tRNA-Ile-TAT gene in favor of a miRNA gene would be 
deleterious for the efficient translation of mRNAs enriched for AUA codons. Thus, it 
would be interesting to find out whether tRNA-Ile-TAT-2-3 crucially contributes to the 
synthesis of such Ile-containing proteins. A possible strategy could be to generate stable 
tRNA-Ile-TAT-2-3 knockout cell lines and, if viable, determine the translational 
efficiency of AUA codons in comparison to wild type cells by mRNA sequencing and 
ribosomal profiling experiments (Ingolia et al., 2011). However, these time and cost 
expensive experiments would have gone beyond the scope of this study.  
 
2) An alternative interpretation of the chimeric nature of pre-tRNA-Ile-TAT-2-3 could be 
that it represents a snapshot on live evolution for the birth of a new miRNA and catches 
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the moment inbetween the transition from a tRNA to a miRNA gene. In this view, those 
pre-tRNAs, which give rise to Ago-loaded sRNAs only by the artificial depletion of La, 
might be a step further back on this evolutionary process. In order to escape from the tight 
regulation by La also under physiological conditions, such pre-tRNAs might still be 
awaiting to gain few other mutations making their secondary structure more appetizing 
for the miRNA biogenesis machinery.  
 
3) In recent years it became more and more evident that the tRNA pool of a cell varies 
between different cell types and conditions (Dittmar et al., 2006; Gingold et al., 2014; 
Goodarzi et al., 2016). However, almost nothing is known concerning the molecular 
mechanisms accounting for the modulation of tRNA levels (see section 1.1.3.2). An 
intriguing scenario could be that the miRNA biogenesis pathway is intentionally hijacked 
to regulate the expression levels of a subset of pre-tRNAs. As we have shown, some pre-
tRNAs can adopt alternative folding, which allow for processing into a tRNA or a 
miRNA-like sRNA. In our model, we have shown that these two biogenesis pathways 
compete with each other for the same transcripts (Figure 4.1) and by perturbing the 
abundance of La the equilibrium is altered into a specific direction. Since a multitude of 
mechanisms exist, which can regulate the expression level of a protein, it might be 
convenient to fine-tune the levels of such tRNAs simply by modulating the abundance of 
La or Xpo5. Although La appeared to be expressed at similar levels among the cell lines 
we have tested (Figure 3.37), its abundance is altered in cancer (Trotta et al., 2003; 
Sommer et al., 2011). The same holds true also for Xpo5 (Melo et al., 2010; Ott et al., 
2016). Interestingly, in our experiments the expression of miR-1983 seemed to correlate 
with the protein levels of Xpo5 and Dicer (compare Figure 3.24 to Figure 3.37). In 
addition, when we performed knockdown experiments targeting Xpo5 we sometimes 
observed a correlation between the decrease of miR-1983 levels and the accumulation of 
mature tRNA-Ile (Figure 3.29). However, we did not extensively focus on this aspect. In 
particular, a more reliable experimental set up should be applied for the quantification of 
the tRNA-Ile levels. Ideally, the analysis could be expanded to the global impact of Xpo5 
depletion on tRNA levels, which is nowadays less problematic thanks to the development 
of more adequate sequencing techniques (Cozen et al., 2015; Zheng et al., 2015; Gogakos 
et al., 2017). Nevertheless, our observations confirm, at least in part, the model we 
propose regarding the potential modulation of tRNA levels via the interplay of La and the 
miRNA biogenesis machinery.  
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4.7. Making a Fool of La?  
 
We have widely emphasized that apparently just one specific pre-tRNA has acquired the 
ability to partially escape from La binding, while other pre-tRNAs are mis-channeled into 
the miRNA pathways only in the absence of La. However, this tight control over the fate 
of such pre-tRNAs can be easily perturbed. It should be mentioned that, despite its 
extraordinary abundance of approximately 2 × 107 molecules per cell (Gottlieb and Steitz, 
1989), the protein levels of La might not be sufficient to cope with the sustained Pol III 
transcriptional output (Huang et al., 2005). In this study we collected some hints 
confirming that La cannot efficiently satisfy such a great demand.  
First of all, we noticed that the generation of the Ago-loaded sRNA-Pro can be achieved 
also without La knockdown by simply forcing an increased production of pre-tRNA-Pro-
CGG-2-1 (Figure 3.18). We thus speculate that the cell is not equipped with an adequate 
amount of La to ensure the processing of all overexpressed transcripts to mature tRNAs 
and, consequently, a fraction of pre-tRNA transcripts get channeled into the miRNA 
pathway.  
Similarly, when we attempted to rescue the effect of La knockdown on the increased 
production of miR-1983, we only obtained a moderate success (Figure 3.40). Although 
additional factors might contribute to this observation, it should be noted that the 
overexpression of La did not exceed by much the endogenous levels (Figure 3.2), which 
might account for the partial rescue shown in Figure 3.40. 
The aforementioned findings are derived from rather artificial experimental setups, so we 
wondered whether more physiological conditions could impact the efficiency of the 
surveillance by La over the fate of pre-tRNAs. We realized that several viruses rely on the 
action of La to fulfill own purposes. For example, binding of La to viral mRNAs is 
required for their efficient translation. This has been reported in the case of poliovirus 
(Meerovitch et al., 1989, 1993), human immunodeficiency virus (Svitkin et al., 1994) and 
hepatitis C virus (Ali and Siddiqui, 1997; Costa-Mattioli et al., 2004). Upon infection by 
poliovirus, La was also shown to re-localize from the nucleus to the cytoplasm, which 
might have a deep impact on the processes governed by La in the nucleus (Meerovitch et 
al., 1993). An even more striking fact is the recurrent interaction between viral ncRNAs 
and La (reviewed in Tycowski et al., 2015). This is the case for the adenoviral VAI/II as 
well as the EBV-encoded EBER1/2 RNAs, which are transcribed by Pol III and 
accumulate in the host at extremely high levels (between 2.5 × 105 and 108 copies per 
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cell) (reviewed by Mathews and Shenk, 1991; Tycowski et al., 2015). Differing from all 
the other cellular transcripts, La stays stably associated to these ncRNAs. Furthermore, 
we also demonstrated that shorter EBER fragments, which also terminate on U-stretches 
(data not shown), are as well highly enriched in anti-La immunoprecipitations (Figure 
3.47A). Therefore, in EBV-infected cells, a great portion of endogenous La might be 
sequestered either by the full-length EBER1/2 or by the smaller EBER1/2 fragments. 
Owing to that, we assayed whether these interactions might consequently interfere with 
the tasks La fulfills under normal conditions. In our experiments, we overexpressed 
EBER1/2 in EBV-negative cells and monitored, as a functional readout, the production of 
Ago-loaded, pre-tRNA-derived sRNAs. Indeed, our data indicate that the interaction of 
La to pre-tRNA-Ile-TAT-2-3 is reduced in the presence of the EBERs (Figure 3.47B), 
while, at the same time, miR-1983 and sRNA-Pro accumulate in Ago2 complexes (Figure 
3.48). These effects mimic exactly the same phenotype as seen upon knockdown of La, 
suggesting that the highly transcribed viral RNAs can perturb the fragile equilibrium 
which is usually safeguarded by La. 
Since the evolution of a host and of its pathogens is always an arms race, the question 
arises whether the consequences of the EBER1/2-La interaction are beneficial for the host 
or for the virus. The former one might for instance use the interplay between the tRNA 
and the miRNA machineries as a sensor to quickly detect and react to viral infections. 
These could be achieved for example if the Ago-loaded pre-tRNA fragments would target 
some viral transcripts. However, this possibility needs to be addressed in future 
investigations. Another alternative scenario could be that the virus abuses the Ago-loaded 
pre-tRNA fragments to repress genes that are involved in the antiviral response or that 
could be otherwise harmful for the virus. In fact, the importance of EBERs for EBV 
infections is not yet fully understood. Several studies indicate that they play multiple roles 
for the viral life cycle and that EBER1/2 might also contribute to the oncogenic potential 
of EBV infections, which have been associated with different kinds of lymphomas and 
carcinomas (Kitagawa et al., 2000; Nanbo et al., 2002; Iwakiri et al., 2005; Lee et al., 
2015). At the same time, however, EBERs can be recognized by the innate immunity 
system of the host and, by that, they trigger antiviral responses (Samanta et al., 2006; 
Ablasser et al., 2009; Iwakiri et al., 2009). Interestingly, also La was shown both, to 
promote antiviral responses (Liu et al., 2011; Mahony et al., 2017), and, in other contexts, 
to protect viral transcripts from being recognized by cellular detection systems 
(Domitrovich et al., 2005; Bitko et al., 2008).  
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Another intriguing finding suggesting that the EBER-mediated production of pre-tRNA 
fragments could be beneficial for the virus is that we identified BACH1 and BACH2 
among the mRNAs, which are possibly targeted by miR-1983 (Figure 3.32). They are 
related transcription factors belonging to the basic region–leucine zipper family (Oyake et 
al., 1996) and, among other functions, both are involved in the regulation of the adaptive 
and innate immune systems, e.g. by contributing to the differentiation of B cells (Muto et 
al., 2004; Roychoudhuri et al., 2013; Swaminathan et al., 2013; Tsukumo et al., 2013; 
Itoh-Nakadai et al., 2014). Importantly, B cells are also the primary targets of EBV 
infections (reviewed in Küppers, 2003; Hatton et al., 2014). An appealing scenario could 
therefore be that sequestration of La by the EBER RNAs increases the production of  
miR-1983, which in turn leads to the repression of BACH1/2. EBV is a member of the    
-herpesvirus subfamily, which also comprises the Kaposi’s sarcoma-associated 
herpesvirus (KSHV). Intriguingly, KSHV was shown to express viral miRNAs targeting 
BACH1 (Gottwein et al., 2007). Thus, it appears that reducing the expression of this 
transcription factor is a common mechanism exploited during infection by                       
-herpesviruses. However, KSHV and EBV appear to have evolved different strategies to 
achieve the same purpose.  
Still, the implications of EBERs hindering La from its physiological functions are likely 
to be more far-reaching than the simple regulation of BACH1 by miR-1983 and should be 
addressed in future. An interesting aspect, for example, might be to determine whether 
EBV-infection leads to an alteration of the cellular tRNA pool by the La-EBERs 
interaction. This might in turn contribute to the remodeling of the cellular proteome, 
which has been observed at different stages of the EBV infection (Ersing et al., 2017). 
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5. Material and Methods 
 
5.1. Material 
5.1.1. Consumables and Chemicals 
 
Consumables and other plasticware products were ordered from Greiner Bio-One 
International GmbH (Kremsmünster, Austria), GE Healthcare (Buckinghamshire, UK), 
Sarstedt AG & Co. KG (Nümbrecht, Germany) and TPP Techno Plastic Products AG 
(Trasadingen, Switzerland). Glassware was obtained from Schott AG (Mainz, Germany), 
VWR International GmbH (Darmstadt, Germany) and Wheaton Industries Inc. (Millville, 
USA). 
If not stated otherwise, all chemicals were purchased at the highest degree of purity from 
AppliChem GmbH (Darmstadt, Germany), Carl Roth GmbH + Co. KG (Karlsruhe, 
Germany), Merck KGaA (Darmstadt, Germany), SERVA Electrophoresis GmbH 
(Heidelberg, Germany) and Sigma-Aldrich Co. (St. Louis, USA).  
The source of specific enzymes is indicated in the respective method sections. Common 
enzymes and reagents, as well as commercial DNA ladders or protein molecular weight 
markers, were purchased from Thermo Fisher Scientific Inc. (Waltham, USA) and New 
England Biolabs Inc. (Ipswich, USA). 
Custom DNA oligonucleotides were synthesized by metabion international AG (Planegg, 
Germany), while short RNA oligonucleotides were obtained from biomers.net GmbH 
(Ulm, Germany).  
 
5.1.2. Kits and Ready-made Solutions  
 
The kits and the ready-made solutions used in this study are listed in Table 5.1 together 
with their corresponding manufacturer and application. 
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Table 5.1: Kits and Ready-made Solutions.  
Name Manufacturer Application 
First Strand cDNA Synthesis Kit Thermo Fisher Scientific Inc. cDNA synthesis for qPCR 
Lipofectamine™ 2000  Thermo Fisher Scientific Inc. Transfection of plasmid DNA 
Lipofectamine™ RNAiMAX Thermo Fisher Scientific Inc. Transfection of siRNA 
NucleoBond®-Xtra-Midi MACHEREY-NAGEL 
GmbH & Co. KG (Düren, 
Germany) 
Large scale plasmid 
purification 
NucleoSpin®-Extract  
 
 
MACHEREY-NAGEL 
GmbH & Co. KG 
DNA purification from aga-
rose gel slices, PCR reactions 
or other enzymatic reactions 
NucleoSpin®-Plasmid  MACHEREY-NAGEL 
GmbH & Co. KG 
Small scale plasmid 
purification 
Passive Lysis 5X Buffer Promega Corporation 
(Fitchburg, USA) 
Cell lysis for luciferase 
assays 
pGEM®-T Easy Vector System  Promega Corporation Subcloning of DNA 
sequences 
Phusion™ High-Fidelity DNA 
Polymerase 
Thermo Fisher Scientific Inc. PCR amplification 
Roti®-Phenol/Chloroform/Isoamyl 
alcohol (25:24:1), pH 4.5-5 
Carl Roth GmbH + Co. KG Extraction of total RNA 
from immunoprecipitated 
samples 
Roti®-Quant (5X) Carl Roth GmbH + Co. KG Protein quantitation 
according to Bradford 
SequaGel® UreaGel™ System 
 
National Diagnostics Inc., 
(Atlanta, USA) 
Denaturing PAGE 
 
SsoFast™ EvaGreen® Supermix  Bio-Rad Laboratories Inc. 
(Hercules, USA) 
qPCR 
SuperScript™ III First Strand 
Synthesis Super Mix 
Thermo Fisher Scientific Inc. 
 
cDNA synthesis for  
small RNA cloning 
TRIzol Reagent Thermo Fisher Scientific Inc. Extraction of total RNA  
 
5.1.3. Materials for Small-scale Purifications and Chromatography Columns  
 
Small-scale purifications of proteins or nucleic acids were performed with the materials 
indicated in Table 5.2.  
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Table 5.2: Materials for Small-scale Purifications. 
Material Manufacturer Specification 
ANTI-FLAG® M2 Affinity 
Agarose Gel 
Sigma-Aldrich Co. Immunoprecipitation 
CNBr-activated Sepharose™ 4 
Fast Flow 
GE Healthcare Purification of antibodies  
Glutathione Sepharose™ 4  
Fast Flow 
GE Healthcare Ago-APP 
illustra™ MicroSpin™  
G-25 Columns 
GE Healthcare Purification of radiolabeled 
oligonucleotides 
Protein A Sepharose™ 4  
Fast Flow 
GE Healthcare Immunoprecipitation 
Protein G Sepharose™ 4  
Fast Flow 
GE Healthcare Immunoprecipitation 
 
The chromatography columns listed in Table 5.3 were used in combination with the 
ÄKTApurifier™ system (GE Healthcare) for large scale protein purification. 
 
Table 5.3: Chromatography Columns. 
Column Material Manufacturer Specification 
GSTrap™ FF  Glutathione Sepharose™ 4 
Fast Flow 
GE Healthcare Affinity 
chromatography 
Hiprep™  26/10 
Desalting 
Sephadex™ G-25 GE Healthcare Size exclusion 
chromatography 
RESOURCE™ Q SOURCE™ 15Q GE Healthcare Anion exchange 
chromatography 
 
5.1.4. Laboratory Equipment 
 
The instruments which were used in the course of this study are listed in Table 5.4.  
 
Table 5.4: Instruments. 
Instrument Manufacturer 
Agilent 2100 Bioanalyzer Agilent Technologies Inc. (Santa Clara, USA) 
ÄKTApurifier™ system GE Healthcare 
Biological safety cabinet HeraSafe™ KS Thermo Fisher Scientific Inc. 
Centrifuge 5417 R Eppendorf AG (Hamburg, Germany) 
Centrifuge Avanti J-20 XP  Beckman Coulter (Brea, USA) 
Centrifuge Heraeus™  Biofuge™ pico Thermo Fisher Scientific Inc. 
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Centrifuge Heraeus™  Megafuge™ 40 Thermo Fisher Scientific Inc. 
CO2 Incubator HeraCell
™ 240i Thermo Fisher Scientific Inc. 
Gel imaging system Quantum ST4  Vilber Lourmat (Collégien, France) 
Hybridization oven Shake 'n' stack™  Thermo Fisher Scientific Inc. 
Incubator shaker Innova 44 New Brunswick Scientific Co., Inc. (Enfield, USA) 
Microplate Reader Mithras LB 940  BERTHOLD TECHNOLOGIES GmbH & Co. 
KG (Bad Wildbad, Germany) 
Odyssey Infrared Imaging System LI-COR Bioscience, Lincoln, USA 
Personal Molecular Imager™ Bio-Rad Laboratories Inc. 
Power supply EV233  Consort bvba (Turnhout, Belgium) 
Power supply PowerPac HC  Bio-Rad Laboratories Inc. 
Real time PCR detection system MyiQ™ Bio-Rad Laboratories Inc. 
Screen Eraser-K Bio-Rad Laboratories Inc. 
Semi-dry transfer cell Trans-Blot® SD  Bio-Rad Laboratories Inc. 
Sequencing platform MiSeq™ Illumina Inc. (San Diego, USA) 
Spectrophotometer Nanodrop® ND-1000 Thermo Fisher Scientific Inc. 
Spectrophotometer Ultraspec 3300 pro  Amersham Biosciences AB (Uppsala, Sweden) 
Thermal cycler 2720 Applied Biosystems Inc. (Foster City, USA) 
Thermal cycler peqSTAR Peqlab Biotechnologie GmbH (Erlangen, 
Germany) 
Thermomixer® comfort Eppendorf AG (Hamburg, Germany) 
Ultrasonics sonifier 450 BRANSON Ultrasonics Corporation (Danbury, 
USA) 
 
5.1.5. Buffers and Solutions 
 
The composition of common buffers and solutions is given in Table 5.5. 
 
Table 5.5: Composition of Common Buffers and Solutions 
Buffer/Solution Composition 
Denhardt’s solution  (50X) 1% BSA; 1% Polyvinylpyrrolidon K30; 1% Ficoll® 400 
Sodium phosphate buffer (1M) Titration of NaH2PO4 (1M) and Na2HPO4 (1M) solutions 
until desired pH is reached. 
Potassium phosphate buffer (1M) 
 
Titration of KH2PO4 (1M) and K2HPO4 (1M) solutions  
until desired pH is reached. 
PBS (1X)  10 mM Na2HPO4; 1.8 mM KH2PO4; 137 mM NaCl;  
2.7 mM KCl; pH 7.5 
SDS-gel running buffer (1X) 25 mM Tris; 0.2 M glycine; 0.1% (w/v) SDS; pH 7.5 
SSC (20X) 3 M NaCl; 0.3 M trisodium citrate; pH 7.0 
TB (0.5X) 45 mM Tris; 45 mM boric acid; pH 8.0 
TBE (1X) 89 mM Tris; 89 mM boric acid; 2 mM EDTA; pH 8.3 
TBS-T (1X) 10 mM Tris; 150 mM NaCl; 0.1% (v/v) Tween® 20; pH 8.0  
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The composition of the buffers and solutions used for specific applications is indicated in 
the respective method section.  
 
5.1.6. RNA and DNA Oligonucleotides 
5.1.6.1. Oligonucleotides Used for Preparation of Deep-sequencing Libraries 
 
The RNA/DNA adapters and DNA primers shown in Table 5.6 were used for the 
preparation of deep-sequencing libraries, which were compatible with the Illumina-
sequencing sytem. 
  
Table 5.6: Oligonucleotides Used for Preparation of Small RNA and PAR-CLIP Libraries. 
Name Sequence 5’→3’ 
3’ adenylated DNA adapter App-TGGAATTCTCGGGTGCCAAGG-(C7-amino) 
5’ RNA adapter GUUCAGAGUUCUACAGUCCGACGAUC 
RT primer GCCTTGGCACCCGAGAATTCCA 
5’ PCR primer 
 
AATGATACGGCGACCACCGAGATCTACACGTTCAGA
GTTCTACAGTCCGA 
3’ PCR index primer 
 
CAAGCAGAAGACGGCATACGAGAT- 6 nt index -GTGAC 
TGGAGTTCCTTGGCACCCGAGAATTCCA 
3’ PAR-CLIP DNA adapter Phos-NNNNTGGAATTCTCGGGTGCCAAGG-Inv(dT) 
5’ PAR-CLIP RNA adapter GUUCAGAGUUCUACAGUCCGACGAUCNNNN 
 
5.1.6.2. RNA Oligonucleotides 
 
The oligoribonucleotide pairs listed in Table 5.7 were used as siRNAs for knockdown 
experiments. 
 
Table 5.7: RNA Oligonucleotides Used as siRNAs. The corresponding target transcript is indicated with 
the NCBI official gene symbol. The position targeted by each siRNA within the respective transcripts is 
indicated in the last column. CDS = coding sequence.   
Name 
 
Sequence 5’→3’ 
 
Target Transcript  
(official symbol) 
Target 
Position 
control-S r(UUGUCUUGCAUUCGACUAAU)dT 
Control sequence - 
control-AS r(UUAGUCGAAUGCAAGACAAU)dT 
Dicer-S siRNA#1 r(GGUAAGAGAACUACAGAAAUU) 
DICER1 CDS 
Dicer-AS siRNA#1 r(UUUCUGUAGUUCUCUUACCAU) 
Dicer-S siRNA#2 r(GGUUGAUACUGGUGAGACUGU) 
DICER1 CDS 
Dicer-AS siRNA#2 r(AGUCUCACCAGUAUCAACCGU) 
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ELAC1-S r(UGGACAAAGCAAAGGAGCAU)dT 
DICER1 CDS 
ELAC1-AS r(UGCUCCUUUGCUUUGUCCAU)dT 
ELAC2-S r(GUGAAUGCCUCCUCAAGUAC)dT 
ELAC2 CDS 
ELAC2-AS r(UACUUGAGGAGGCAUUCACC)dT 
La-S siRNA #1 r(AGAUUGGAUGCUUGCUGAA)dTdT 
SSB CDS 
La-AS  siRNA#1 r(UUCAGCAAGCAUCCAAUCU)dTdT 
La-S siRNA#2 r(CCAUUAAAUUGCCUUUGUA)dTdT 
SSB 3’ UTR 
La-AS siRNA#2 r(UACAAAGGCAAUUUAAUGG)dTdT 
La-S siRNA#3 r(GGACAAGUUUCUAAAGGAA)dTdT 
SSB CDS 
La-AS siRNA#3 r(UUCCUUUAGAAACUUGUCC)dTdT 
Pop4-S r(CACAGAUGAUUCAGGCCAAG)dT 
POP4 CDS 
Pop4-AS r(UUGGCCUGAAUCAUCUGUGG)dT 
TSEN2-S r(CUGGGAUGUUUAAGUAUUU)dTdT 
TSEN2 CDS 
TSEN2-AS r(AAAUACUUAAACAUCCCAG)dTdT 
Xpo5-S siRNA#1 r(CCGUGAUCCUUUGCUAUUAU)dT 
XPO5 CDS 
Xpo5-AS siRNA#1 r(UAAUAGCAAAGGAUCACGGU)dT 
Xpo5-S siRNA#2 r(GCGUCAGAAGGUGUUCCUAU)dT 
XPO5 CDS 
Xpo5-AS siRNA#2 r(UAGGAACACCUUCUGACGCU)dT 
 
The oligoribonucleotide pairs listed in Table 5.8 were used as a control or as miRNA 
mimic in dual luciferase assays. MiR-1983-mimic-S corresponds to the mature sequence 
of miR-1983. Note that miR-1983-mimic-AS is not fully complementary to miR-1983-
mimic-S. The annealing of the two oligoribonucleotides results in thermodynamically less 
stable interactions at the 5’ end of miR-1983-mimic-S. This artificial design was created 
to ensure loading of the correct strand of the miR-1983-mimic into Ago proteins (see 
section 1.2.2). 
 
Table 5.8: RNA Oligonucleotides Used as miRNA Mimic or Control in Luciferase Assays. 
Name Sequence 5’→3’ 
control-S r(UUGUCUUGCAUUCGACUAAU)dT 
control-AS r(UUAGUCGAAUGCAAGACAAU)dT 
miR-1983-mimic-S r(CUCACCUGGAGCAUGUUUUCU) 
miR-1983-mimic-AS r(AAAACAUGCUCCAGGUAAACC) 
 
The following synthetic, 5’ phosphorylated, ribooligonucleotide was used for the 
determination of miR-1983 copy numbers per cell:  
 
5’-Phos-CUCACCUGGAGCAUGUUUUCU-3’  
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5.1.6.3. DNA Oligonucleotides 
 
The oligonucleotides listed in Table 5.9 were used as probes for Northern blot assays.  
 
Table 5.9: DNA Oligonucleotides Used for Northern Blot Assays. 
Name Sequence 5’→3’ 
CU1276 TGGTGCATTGGCCGGGAATCGA 
EBER1 TCTAGGGCAGCGTAGGTCCT 
EBER2 AACAGCGGACAAGCCGAATAC 
let-7i AACAGCACAAACTACTACCTCA 
miR-17 CTACCTGCACTGTAAGCACTTTG 
miR-19b TCAGTTTTGCATGGATTTGCACA 
miR-27a GCGGAACTTAGCCACTGTGAA 
miR-98 AACAATACAACTTACTACCTCA 
miR-1290 TCCCTGATCCAAAAATCCA 
miR-1983/sRNA-Ile AGAAAACATGCTCCAGGTGAG 
sRNA-Pro GAAGTGGGCTCGTCCGGGATTT 
tRNA-Ile GCTCGAACTCACAACCTCGGCAT 
tRNA-Lys CTGATGCTCTACCGACTGAGCTATCCGGGC 
U6 GAATTTGCGTGTCATCCTTGCGCAGGGGCCATGCTAA 
Y5 AATAACCCACAACACTCGGACCAACT 
 
Expression levels of mRNAs were determined by qPCR analyses using the primer pairs 
indicated in Table 5.10. 
 
Table 5.10: Primers Used for qPCR Analyses.  
Name 
 
Sequence 5’→3’ 
 
Target Transcript  
(official symbol) 
Dicer-F GAAGACCAGGTTCCACGAAA 
DICER1 
Dicer-R GGCTGATCAGGTCTGGGATA 
ELAC1-F GGCTCTTTGACTGTGGGGAGGG 
ELAC1 
ELAC1-R AGAGGAGCCCAGGAAGGCCAA 
ELAC2-F GAGGGGTCAGGGACTCTTCCCT 
ELAC2 
ELAC2-R CGATGGCAGCTGTCCCAACTGG 
GAPDH-F AATGGAAATCCCATCACCATCT 
GAPDH 
GAPDH-R CGCCCCACTTGATTTTGG 
La-F CGGAACCTTAAAGATAGCCGCA 
SSB 
La-R CCCGTGGCAAATTGAAGTCG 
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LARP1-F GTGATGGATTCCCGTGAGCA 
LARP1 
LARP1-R ACTTGGGCAATGACTGAGGG 
LARP4B-F CGAGACAGGAGGAAATGAGTCT 
LARP4B 
LARP4B-R CATGTCACTAGCAAGGTTCTCC 
POP4-F CAGGCAAAGGAGGGAGCTGCG 
POP4 
POP4-R TGGCTTGAGCCCACTGCACAG 
TSEN2-F GGAGGCTGCCCCAAATGAG 
TSEN2 
TSEN2-R AAAAAGGCCTCTTCTAGGCTGA 
Xpo5-F TTCTTGACAATTTGCTTGCG 
XPO5 
Xpo5-R GCATATCCAGAGCCTTGGTG 
 
PCR amplification of DNA fragments as templates for in vitro transcription reactions was 
performed with the oligonucleotides indicated in Table 5.11. 
 
Table 5.11: Primers for PCR amplification of Templates for In Vitro Transcriptions. The T7 promoter 
sequence is highlighted in blue. 
Name Sequence 5’→3’ 
tRNA-AS-F AAAGCATGCTCCAGTGGCG 
tRNA-Ile29-ivt-R AAAACAATGCTCCAGGTGAGGC 
tRNA-Ile29-ivt-CT-R AGAAAACAATGCTCCAGGTGAGGC 
tRNA-Ile29-T7-F TAATACGACTCACTATAGGGAAACTGGGTGCTCCAGTGGC 
tRNA-mat-T7-F TAATACGACTCACTATAGGGGCTCCAGTGGCGCAATCG 
tRNA-short-AS-T7-R TAATACGACTCACTATAGGGGAAGAAAACATGCTCCAGGTGAGG 
tRNA-short-end-R AGAAAACATGCTCCAGGTGAG 
tRNA-short-R-TTTT AAAACATGCTCCAGGTGAGGC 
tRNA-T7-F TAATACGACTCACTATAGGGAAAGCATGCTCCAGTGGCG 
 
The following complementary oligonucleotides were annealed and directly used for 
ligations or in vitro transcriptions (Table 5.12). 
 
Table 5.12: Complementary DNA Oligonucleotides Used for Different Applications upon Annealing. 
Overhangs resulting upon annealing which were used for ligation purposes are shown in red. The T7 
promoter sequence is highlighted in blue. 
Name Sequence 5’→3’ 
miR-1983-sense 
 
GATCTCCAGAAAACATGCTCCAGGTGAGTTCAAGAGACTCA
CCTGGAGCATGTTTTCTA 
miR-1983-antisense 
 
AGCTTAGAAAACATGCTCCAGGTGAGTCTCTTGAACTCACCT
GGAGCATGTTTTCTGGA 
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miR1983-multiple-1S CTAGTATCGCCACCTTGTTTAAGCCAGA 
miR1983-multiple-1AS ATGTTTTCTGGCTTAAACAAGGTGGCGATA 
miR1983-multiple-2S AAACATGCTCCAGGTGAGATCGCCAGA 
miR1983-multiple-2AS ATGTTTTCTGGCGATCTCACCTGGAGC 
miR1983-multiple-3S AAACATGCTCCAGGTGAGATTAGACCTACGCACTCCAGGAGCT 
miR1983-multiple-3AS CCTGGAGTGCGTAGGTCTAATCTCACCTGGAGC 
miR1983-mul-mut-2S AAACATGCTCCGGATCCGATCGCCAGA 
miR1983-mul-mut-2AS ATGTTTTCTGGCGATCGGATCCGGAGC 
miR1983-mul-mut-3S AAACATGCTCCGGATCCGATTAGACCTACGCACTCCAGGAGCT 
miR1983-mul-mut-3AS CCTGGAGTGCGTAGGTCTAATCGGATCCGGAGC 
pre-miR-27a-T7-S 
 
TAATACGACTCACTATAGGGAGGGCTTAGCTGCTTGTGAGCA
GGGTCCACACCAAGTCGTGTTCACAGTGGCTAAGTTCCGC 
pre-miR-27a-T7-AS 
 
GCGGAACTTAGCCACTGTGAACACGACTTGGTGTGGACCCT
GCTCACAAGCAGCTAAGCCCTCCCTATAGTGAGTCGTATTA 
 
PCR amplification of DNA fragments for cloning purposes was performed with the 
oligonucleotides indicated in Table 5.13. 
 
Table 5.13: PCR Primers Used for Cloning Purposes. Restriction sequences used for cloning are shown 
in red. The sequence corresponding to the Tobacco Etch Virus (TEV) cleavage site is highlighted in blue. 
Name Sequence 5’→3’ 
30-ProGCC-BglII-F CAGAGATCTCTAAGTGGCTCGTTGGTCTAGGGG 
30-ProGCC-HindIII-R CTGAAGCTTAAATGAAGTGGGCTCGTCCGGG 
BACH1-UTR-SacI-R CATGAGCTCGTATGCCATCTTCTACCATTATGGC 
BACH1-UTR-SpeI-F CATACTAGTACTTGCATTCACTTCCTTCAAACC 
BACH2-UTR-F3 GGTCAACTTTGCCACTTGCACTG 
BACH2-UTR-R4 GGGACTTGAGAAAGCTTTGCAGGCAG 
EBER1-100-EcoRI-F CAGGAATTCGGCAACCCCCGCCTACAC 
EBER2-HindIII-R CTGAAGCTTAAAAAAACAGCGGACAAGCCG 
Fw-La-NotI CGCTGCGGCCGCATGGCTGAAAATGGTGAT 
hLa-104-408-NotI-F CGCTGCGGCCGCTATAAAAATGATGTAAAAAACAGATCT 
hLa-tr-196-EcoRI-R CGCTGAATTCCTATCTTTCTTCATTTTTTTTGGCAAAG 
Ile29-BglII-F CAGAGATCTAAACTGGGTGCTCCAGTGG 
Ile29-HindIII-R CTGAAGCTTAAAACAATGCTCCAGGTGAGGC 
La-BamHI-F ATAGGATCCATGGCTGAAAATGGTGATAATG 
La-NotI-R TACGCGGCCGCCTACTGGTCTCCAGCAC 
La-TEV-BamHI-F 
 
ATAGGATCCGAAAACCTGTATTTTCAGGGAATGGCTGAAAA
TGGTGAT 
Rev-La-EcoRI CGCTGAATTCCTACTGGTCTCCAGCACCAT 
RIMS2-UTR-F2 CAGCTGTAAAAAAATTGTTGTCACAGC 
RIMS2-UTR-R2 GATTATGTGACTGCATCTTAGTATCAGG 
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tRNA-BglII-F CAGAGATCTAAAGCATGCTCCAGTGGCG 
tRNA-short-HindIII-R CTGAAGCTTGGAAGAAAACATGCTCC 
 
Mutagenesis PCRs were performed with the oligonucleotides indicated in Table 5.14. 
 
Table 5.14: Primers Used for Mutagenesis PCRs. The mutations introduced in comparison to the 
templates used are highlighted in green. 
Name Sequence 5’→3’ 
BACH1-UTR-mut-F CGGTGAATTCTCGGATCCACTTTTTTCAGTTATAAAAC 
BACH1-UTR-mut-R GTTTTATAACTGAAAAAAGTGGATCCGAGAATTCACCG 
BACH2-mut-F CTAATTAAAAAGCACTCGGATCCTAATTATGTAGGAAAAAC 
BACH2-mut-F2 CAGGCTTTGGACGGATCCGTGATTTGCTGTATGTG 
BACH2-mut-R GTTTTTCCTACATAATTAGGATCCGAGTGCTTTTTAATTAG 
BACH2-mut-R2 CACATACAGCAAATCACGGATCCGTCCAAAGCCTG 
hLa-Y23A-Y24A-F CTGTCATCAAATTGAGGCCGCCTTTGGCGACTTCAATTTG 
hLa-Y23A-Y24A-R CAAATTGAAGTCGCCAAAGGCGGCCTCAATTTGATGACAG 
RIMS2-mut-F CTAAAGAAGGCCCTCGGATCCAAGAGCAGAGCTGTG 
RIMS2-mut-F2 GAAGCGGTGTTACGGATCCGGAGTGTAATCC 
RIMS2-mut-F3 CTAGGAAGCATCGGATCCAAAGCAGGAGAC 
RIMS2-mut-R CACAGCTCTGCTCTTGGATCCGAGGGCCTTCTTTAG 
RIMS2-mut-R2 GGATTACACTCCGGATCCGTAACACCGCTTC 
RIMS2-mut-R3 GTCTCCTGCTTTGGATCCGATGCTTCCTAG 
tRNA-IleTAT-human-F GCGGTACTTATACAACAGTATATGTGCGGGTG 
tRNA-IleTAT-human-R CACCCGCACATATACTGTTGTATAAGTACCGC 
 
Sequencing reactions were performed with the primers listed in Table 5.15. The last 
column indicates for which plasmid backbones the primers were used. 
 
Table 5.15: Sequencing Primers. 
Name Sequence 5’→3’ Sequenced Plasmids  
M13-F 
 
TGTAAAACGACGGCCAGT 
 
pSUPER, pMIR-RNL-TK, 
pGEM®-T Easy, pMA-T 
M13-R CAGGAAACAGCTATGACCATG pSUPER, pGEM®-T Easy 
pGEX-F GGGCTGGCAAGCCACGTTTGGTG pGEX-4T-1, pGEX-6P-1 
pGEX-R GGAGCTGCATGTGTCAGAG pGEX-4T-1, pGEX-6P-1 
pMIR-Seq-F TCATAAAGGCCAAGAAGGG pMIR-RNL-TK 
VP5-F CGAAATTAATACGACTCACTATAG VP5 
VP5-R CCCAACAGCTGGCCCTCGCAGA VP5 
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5.1.7. Plasmids 
 
An overview of the empty vectors and of the available plasmids which were used during 
the course of this study is given in Table 5.16.  
 
Table 5.16: Empty Vectors and Available Plasmids.   
Name Source and Comments 
pGEX-4T-1 GE Healthcare, contains GST-tag. 
pGEX-6P-1 
 
GE Healthcare; contains GST-tag and cleavage site for PreScission 
protease between the GST and the multiple cloning site. 
pMIR-RNL-TK 
 
pMIR-REPORT™ from Ambion Inc. (Austin, USA), modified 
according to Höck et al. (2007). 
pSUPER OligoEngine Inc. (Seattle, USA), modified according to Zhu et al. (2009). 
VP5 
 
pIRESneo from Clontech Laboratories Inc. (Mountain View, 
USA), modified according to Meister et al. (2004).  
VP5 + Dicer Meister et al. (2005) 
VP5 + GFP Meister et al. (2004) 
VP5 + La WT 
 
 
 
Contains the open reading frame (ORF) of La, which was PCR-
amplified from human cDNA using the Fw-La-NotI and Rev-La-
EcoRI primers; cloned by Dr. Julia Stöhr, Meister group (University 
of Regensburg, Germany). 
 
The plasmid pMA-T containg the mouse pre-tRNA-Ile-TAT-2-1 sequence was 
synthetized by Geneart AG (Regensburg, Germany). 
 
All other plasmids generated during the course of this work are listed in Table 5.17 with a 
brief description of the respective cloning strategy. 
 
Table 5.17: Generated Plasmids. 
Name Cloning Strategy 
pGEX-4T-1 + La WT PCR amplification from VP5 + La WT with the primers  
La-TEV-BamHI-F and La-NotI-R; cloning via BamHI and NotI. 
pGEX-4T-1 + La F44A 
 
PCR amplification from VP5 + La Y23A Y24A with the primers  
La-TEV-BamHI-F and La-NotI-R; cloning via BamHI and NotI. 
pGEX-6P-1 + La WT 
 
PCR amplification from VP5 + La WT with the primers La-BamHI-F 
and La-NotI-R 
pMIR-RNL-TK + 
artificial miR-1983 target 
 
 
Constructed using miR1983-multiple-1S/AS, -2S/AS and -3S/AS oligo-
nucleotides according to the manufacturer’s protocol using the 
restriction enzymes BglII and HindIII. 
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pMIR-RNL-TK +  
artificial miR-1983 target 
mutated 
Constructed using miR1983-multiple-1S/AS, miR1983-mul-mut-2S/AS 
and -3S/AS oligonucleotides according to the manufacturer’s protocol 
using the restriction enzymes BglII and HindIII. 
pMIR-RNL-TK +  
BACH1 mutated 
 
Subcloning into pGEM®-T Easy and mutagenesis PCR with the 
primers BACH1-UTR-mut-F/R; cloning into pMIR-RNL-TK similar to 
the corresponding WT construct. 
pMIR-RNL-TK +  
BACH1 WT 
PCR amplification from HEK293 genomic DNA with BACH1-UTR-
SpeI-F and BACH1-UTR-SacI-R; cloning via SpeI and SacI. 
pMIR-RNL-TK +  
BACH2 mutated 
 
Subcloning into pGEM®-T Easy and mutagenesis PCR with the 
primers BACH2-mut-F/R, and -F2/R2; cloning into pMIR-RNL-TK 
similar to the corresponding WT construct. 
pMIR-RNL-TK +  
BACH2 WT 
 
PCR amplification from HEK293 genomic DNA with the primers 
BACH2-UTR-F3/R4; blunt ligation into pMIR-RNL-TK linearized by 
PmeI restriction digest. 
pMIR-RNL-TK +  
RIMS2 mutated 
 
Subcloning into pGEM®-T Easy and mutagenesis PCR with the 
primers RIMS2-mut-F/R, -F2/R2, and F3/R3; cloning into pMIR-RNL-
TK similar to the corresponding WT construct. 
pMIR-RNL-TK + 
RIMS2 WT 
 
PCR amplification from HEK293 genomic DNA with the primers 
RIMS2-UTR-F2/R2; blunt ligation into pMIR-RNL-TK linearized by 
PmeI restriction digest. 
pSUPER + EBER1/2 
 
 
 
 
 
PCR amplification from DNA extracted from EBV-positive Raji cells 
with the EBER1-100-EcoRI-F and EBER2-HindIII-R primers; PCR 
product contained both EBER RNAs, as well as additional 100 nts at the 
5’ end. Cloning via EcoRI and HindIII resulted in the removal of the H1 
promoter of the vector. Therefore, expression is achieved from the 
endogenous EBER RNAs’ promoter. 
pSUPER + 
pre-tRNA-Ile-TAT-2-2 
PCR amplification from human genomic DNA with the primers Ile29-
BglII-F and Ile29-HindIII-R; cloning via BglII and HindIII. 
pSUPER +  
pre-tRNA-Ile-TAT-2-3 
 
Mutagenesis PCR of pMA-T + pre-tRNA-Ile-TAT-2-1 with the primers 
tRNA-IleTAT-human-F/R; PCR-amplification from a positive clone with 
tRNA-BglII-F and tRNA-short-HindIII-R; cloning via BglII and HindIII. 
pSUPER +  
sRNA Ile shRNA 
 
Constructed using miR-1983-sense/antisense oligonucleotides according 
to the manufacturer’s protocol using the restriction enzymes BglII and 
HindIII. 
VP5 + La 104-408 
 
PCR amplification from VP5 + La WT with the primers hLa-104-408-
NotI-F and Rev-La-EcoRI primers; cloning via EcoRI and NotI. 
VP5 + La 1-196 
 
PCR amplification from VP5 + La WT with the primers Fw-La-NotI 
and hLa-tr-196-EcoRI-R; cloning via EcoRI and NotI.  
VP5 + La Y23A Y24A 
 
 
Subcloning of the La ORF from VP5 + La WT into pGEM®-T Easy 
and mutagenesis PCR with the primers hLa-Y23A-Y24A-F/R; cloning 
into VP5 via EcoRI and NotI. 
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5.1.8. Antibodies 
 
On overview of the antibodies used and of their respective applications is given in     
Table 5.18.  
 
Table 5.18: Antibodies Used and Their Application. ID = identification, mAB = monoclonal antibody, 
pAB = polyclonal antibody, WB = Western blot, IP = immunoprecipitation. 
Antigen Origin Clonality (ID) Purity Application Source 
HA.11 mouse mAB (16B12) purified WB (1:1,000) Covance Inc. 
(Princeton, USA) 
α-Tubulin mouse mAB (DM1A)  purified WB (1:10,000) Sigma-Aldrich Co. 
β-Actin mouse mAB (AC15)  purified WB (1:10,000) Abcam plc 
(Cambridge, UK) 
Ago1 rat mAB (4B8) hybridoma 
supernatant 
IP (undiluted) 
WB (1:5) 
Beitzinger et al. 
(2007) 
Ago2 rat mAB (11A9) hybridoma 
supernatant 
IP (undiluted) 
WB (1:5) 
Rüdel et al. (2008) 
Ago3 rat mAB (5A3) hybridoma 
supernatant 
IP (undiluted) 
WB (1:5) 
Dueck et al. (2012) 
pan-TNRC6 rat mAB (7A9) hybridoma 
supernatant 
IP (undiluted) 
WB (1:5) 
Schraivogel et al. 
(2015) 
Dicer rabbit pAB  
(A301-936A) 
purified WB (1:1,000) Bethyl Laboratories 
Inc. (Montgomery, 
USA) 
La rabbit pAB  
(SY6175) 
serum 
purified 
IP (1:50) 
WB (1:1,000) 
This study 
 
Western blot signals were detected, according to the manufacturer’s instructions, with the 
secondary antibodies IRDye 800CW and IRDye 680RD (LI-COR Bioscience). 
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5.1.9. Bacterial Strains and Cell Lines 
5.1.9.1. Bacterial Strains 
 
Following E. coli strain was used for molecular cloning:  
XL1-Blue   endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44  
 F'[ ::Tn10 proAB+ lacIq Δ(lacZ)M15] hsdR17(rK- mK+)   
 
Following E. coli strain was used for protein expression:  
BL21 [DE3] F- ompT hsdSB (rB-, mB-) gal dcm (DE3) 
 
5.1.9.2. Mammalian Cell Lines and Growth Media   
 
Dulbecco’s modified Eagle’s medium (DMEM) and RPMI-1640 medium were obtained 
from Sigma-Aldrich Co.. An overview of the mammalian cell lines used is given in Table 
5.19. 
 
Table 5.19: Mammalian Cell Lines.  
Cell line 
 
Origin / Description 
 
Growth 
Medium 
A549 Human lung carcinoma DMEM 
DLD-1 Human colorectal adenocarcinoma RPMI-1640 
Flp-In 293 T-REx  
+ FH-Dicer 
Human embryonic kidney; stable, inducible  
expression of FH-Dicer (Rybak-Wolf et al., 2014) 
DMEM 
 
HEK293 Human embryonic kidney DMEM 
HeLa Human cervix adenocarcinoma DMEM 
HepG2 Human hepatocellular carcinoma DMEM 
MCF-7 Human breast adenocarcinoma DMEM 
MEF Dcr -/- 
 
Mouse embryonic fibroblast with Dicer deletion 
(Glasmacher et al., 2010) 
DMEM 
 
MEF Dcr +/+ 
 
Mouse embryonic fibroblast; wildtype but Dicer  
alleles floxed (Glasmacher et al., 2010) 
DMEM 
 
Ntera2 Human testicular embryonic carcinoma  DMEM 
Raji 
 
Human B lymphocyte, derived from Burkitt’s 
lymphoma, EBV positive 
RPMI-1640 
 
SK-N-MC Human brain neuroepithelioma DMEM 
Lysates of the B lymphocyte cell lines Jiyoye and U2932 EBV+ were kindly provided by 
the group of Prof. Dr. Friedrich A. Grässer (Saarland University Medical School, 
Homburg/Saar, Germany). The generation of the latter cell line has been described in 
Imig et al. (2011). 
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5.2. Methods 
5.2.1. Molecular Biological Methods 
5.2.1.1. Determination of Nucleic Acid Concentration 
 
The concentration and purity of DNAs and RNAs were determined by measuring the 
absorbance of 1-2 µl of the samples with the Nanodrop® ND-1000 spectrophotometer 
(Thermo Fisher Scientific Inc.).  
 
5.2.1.2. Polymerase Chain Reaction (PCR) 
 
Amplification of DNA fragments was performed with the Phusion™ High-Fidelity (HF) 
DNA Polymerase (Thermo Fisher Scientific Inc.) according to the manufacturer’s 
instruction and with the primers listed in Table 5.11 and Table 5.13. The standard PCR 
reaction mixture consisted of the following components: 
 
Template  250 ng genomic DNA or 
 10 ng plasmid DNA or 
   1µl cDNA 
Phusion™ HF Buffer (5X) 10 µl  
dNTPs (10 mM each) 1 µl   
Forward Primer (10 µM) 1.25 µl   
Reverse Primer (10 µM)  1.25 µl  
Phusion™ HF Polymerase 0.5 µl   
H2O   ad 50 µl  
 
PCRs were performed with the following cycling conditions, whereby the annealing 
temperature was determined for each primer pair with the Tm calculator tool (Thermo 
Fisher Scientific Inc.): 
 
Initial denaturation  98°C 60 s for genomic DNA or 
 98°C 30 s for plasmid DNA or cDNA 
Denaturation  98°C 30 s  
Annealing  X°C 30 s 30-35 cycles 
Extension  72°C 30 s/kb   
Final extension  72°C   5 min  
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5.2.1.3. Agarose Gel Electrophoresis 
 
DNA fragments were resolved on 0.5-2% (w/v) agarose gels by electrophoresis in 1X 
TBE buffer. The gels contained 0.1 µg/ml EtBr for the visualization of the DNA under 
UV light. If required, bands of the correct size were excised from the gel and the DNA 
was extracted with the NucleoSpin®-Extract kit (MACHEREY-NAGEL GmbH & Co. 
KG) according to the manufacturer’s instruction. 
 
5.2.2. Molecular Cloning 
5.2.2.1. Restriction Digest of DNA and Dephosphorylation of Linearized Vectors 
 
Restriction digest of purified PCR products (ca. 100 ng) or plasmid DNA (ca. 5 µg) was 
performed for >1h at 37°C with the FastDigest™ restriction enzyme system (Thermo 
Fisher Scientific Inc.) in a reaction volume of 20-30 µl. Digested PCR fragments were 
directly purified with the NucleoSpin®-Extract kit (MACHEREY-NAGEL GmbH & Co. 
KG), while digested plasmids were first purified by agarose gel electrophoresis before 
being extracted from the gel.   
 
The 5’ ends of the linearized plasmid DNA were dephosphorylated with the FastAP 
thermosensitive alkaline phosphatase (Thermo Fisher Scientific Inc.) according to the 
manufacturer’s instruction. This treatment reduces the probability of re-ligation of empty 
plasmids during the following cloning step (5.2.2.3). 
 
5.2.2.2. Annealing and Phosphorylation of DNA Fragments 
 
The generation of the plasmids pMIR-RNL-TK + artificial miR-1983 target, pMIR-RNL-
TK + artificial miR-1983 target mutated and pSUPER + sRNA Ile shRNA synthethic 
occurred without any PCR amplification procedure. Instead, complementary, synthethic 
DNA oligonucleotides (Table 5.12) were designed in such a way, that the annealed sense 
and antisense oligonucleotide pairs had overhangs compatible with the digested plasmid 
DNA. For annealing, the respective oligonucleotide pairs were diluted in water to a 
concentration of 5 µM. The mixture heated for 5 min at 95°C and was then immediately 
transferred to 37°C for 30-60 min. 
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To allow ligation into the target vectors, the annealed oligonucleotides required to be 
phosphorylated at their 5’ ends. This was achieved with the T4 polynucleotide kinase 
(PNK) (Thermo Fisher Scientific Inc.) according to the manufacturer’s instruction. 
Briefly, 20 pmol of the annealed oligonucleotides were incubated in 20 µl reaction 
volume with 1 mM ATP and 1 U/µl T4 PNK in 1X PNK buffer A (Thermo Fisher 
Scientific Inc.). The reaction was carried out for 20 min at 37°C and the enzyme was 
heat-inactivated for 10 min at 75°C.  No purification of the reaction was performed prior 
ligation. 
Purified PCR products, which were directly used for blunt-end ligations, were                  
5’ phosphorylated. In this case, the maximal possible volume of DNA was applied (ca. 
500 ng).         
 
5.2.2.3. DNA Insert Ligation into Vectors 
 
DNA fragments were ligated into linearized, dephosphorylated vectors (5.2.2.1) using the 
T4 DNA ligase (Thermo Fisher Scientific Inc.).   
The following reaction conditions were applied in case of sticky-end ligations:  
 
Linearized vector DNA  50-150 ng   
Insert DNA (molar ratio over vector)  3:1  
T4 DNA ligase buffer (10X) 2 µl   
T4 DNA ligase  5 U 
H2O  ad 20 µl  
 
The ligation mixture was incubated at least for 30 min at 16°C followed by 30 min at 
room temperature. Alternatively, the samples were incubated for several hours at 16°C. 
  
For blunt-end ligations, the reaction conditions were modified as follows:   
 
Linearized vector DNA  50-150 ng   
Insert DNA (molar ratio over vector)  5:1  
T4 DNA ligase buffer (10X) 2 µl   
50% PEG 4000 solution  2 µl 
T4 DNA ligase  5 U 
H2O  ad 20 µl  
 
The ligation mixture was incubated for several hours at 4°C. 
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5.2.2.4. Transformation and Cultivation of E. coli 
 
Chemically competent E. coli XL1-Blue cells were transformed by the heat-shock 
method. To this end, 50 μl of cell suspension was thawed on ice and mixed with 10 μl of 
the ligation reaction (5.2.2.3). After 20 min on ice, the cells were incubated for 1 min at 
42°C, followed by additional 5 min on ice. Depending on the antibiotic resistance 
encoded on the plasmid for the selection of transformed clones, a recovery phase was 
performed by adding 800 μl of LB medium (without antibiotics) to the transformation 
reaction. Cells were incubated for 30 min at 37°C and shaking. The bacteria were then 
centrifuged at 5,000 rcf for 1 min and resuspended in 50 μl of LB medium. In case of 
selection with ampicillin (Amp), the recovery phase was omitted. The bacteria were 
finally plated on LB-Agar plates containing an appropriate selection antibiotic and the 
plates were incubated overnight at 37°C.  
The following day, single clones were inoculated into 5 ml LB medium and were 
incubated shaking overnight at 37°C.   
 
LB medium:   1% (w/v) tryptone; 1% (w/v) NaCl; 0.5% (w/v) yeast extract   
 
LB-Agar plates were composed of LB-medium containing 1.5% (w/v) agar. 
The following antibiotics were added to the LB medium depending on the backbone of 
the plasmid used for transformation: 
 
100 µg/ml Amp: pGEX-4T-1, pGEX-6P-1, pMA-T pMIR-RNL-TK and VP5 
50 μg/ml Kanamycin: pSUPER  
 
5.2.2.5. Extraction of Plasmid DNA from E. coli and Test Digest 
 
A pre-screening of the inoculated clones was performed, in most of the cases, by a test 
digest of the plasmid DNA which was extracted by an alkaline treatment of the bacterial 
pellet obtained from 2 ml of an overnight culture (5.2.2.4). To this end, cells were 
resuspended in 40 µl Easy Prep buffer and heated for 1 min at 95°C. Following 1 min 
incubation on ice, the lysates were cleared by 15 min centrifugation at maximal speed. 
Test digestions were performed by incubating 5 µl of the lysate in a reaction mixture 
containing 5.8 µl H2O, 1.2 µl 10X FastDigest
™ buffer green (Thermo Fisher Scientific 
Inc.) and 0.1 µl of the desired Fast-Digest restriction enzyme(s). 
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Easy Prep buffer:   10 mM Tris (pH 8.0); 1 mM EDTA; 15% (w/v) saccharose;  
  2 mg/ml lysozyme; 0.2 mg/ml RNase A; 0.1 mg/ml BSA   
 
The plasmid DNA of positive clones was extracted from the remaining overnight cultures 
with the NucleoSpin®-Plasmid kit (MACHEREY-NAGEL GmbH & Co. KG) according 
to the manufacturer’s instructions. The plasmid DNA of all newly generated plasmids was 
submitted to sequencing (5.2.2.7).  
If required, larger amounts of plasmid DNA were recovered from 150-200 ml overnight 
cultures with the NucleoBond®-Xtra-Midi kit (MACHEREY-NAGEL GmbH & Co. KG). 
 
5.2.2.6. Mutagenesis PCR 
 
Mutations of target constructs were generated by subcloning the sequence of interest into 
the pGEM®-T Easy vector (Promega Corporation), mutagenesis PCR and re-insertion of 
the mutated constructs into the target vectors. A brief overview of the mutagenesis 
strategy is given in Table 5.17 for the respective plasmids.  
In more detail, the sequence of interest was amplified from the original plasmids with the 
Phusion™ High-Fidelity (HF) DNA Polymerase (Thermo Fisher Scientific Inc.), which 
generates blunt-ended amplification products. However, subcloning into the pGEM®-T 
Easy vector requires 3’ A-overhangs, which were added by the following tailing reaction 
with:  
 
Gel-purified PCR product  6.7 µl  
Taq Buffer with (NH4)2SO4 (10X) 1 µl  
MgCl2 (25 mM) 0.8 µl   
dATP (2 mM) 2 µl   
Taq DNA Polymerase (recombinant) (5U/µl)  0.5 µl 
(Thermo Fisher Scientific Inc.)    
 
The mixture was incubated at 72°C for 30 min and directly purified with the 
NucleoSpin®-Extract kit (MACHEREY-NAGEL GmbH & Co. KG). Subcloning was 
performed with the pGEM®-T Easy Vector Sytsem (Promega Corporation), according to 
the manufacturer’s instructions. Following transformation of E. coli (5.2.2.4), the cell 
suspension was plated on LBAmp plates supplemented with 40 μl of X-Gal solution           
(50 mg/ml dissolved in DMF) and 2 μl of IPTG (1M). This procedure allowed for the 
selection of recombinants by blue/white screening. The plasmid DNA of a positive clone 
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was used for mutagenesis PCR with the primers indicated in Table 5.14. The PCR 
amplification conditions differed from the method described in 5.2.1.2 inasmuch as 50 ng 
plasmid DNA and half of the amount of primers were used and only 25 amplification 
cycles were performed. The PCR reaction was purified with the NucleoSpin®-Extract kit 
(MACHEREY-NAGEL GmbH & Co. KG) and a restriction digest with the Dpn I enzyme 
allowed for the selective degradation of the template plasmid DNA. Following heat-
inactivation of the enzyme for 5 min at 80°C E. coli cells were transformed with the 
reaction mixture (5.2.2.4). Positive clones were then screened by sequencing. Correctly 
mutated fragments were re-inserted into the destination vector either by PCR 
amplification, or, directly via restriction digest of the pGEM plasmids with the indicated 
enzymes. 
 
5.2.2.7. Sequencing of Plasmid DNA 
 
Sequencing of plasmid DNA was performed by GATC Biotech AG (Konstanz, Germany) 
or Macrogen Inc. Europe (Amsterdam, Netherlands). The sample submission was prepared 
according to the company’s guideline. The sequencing primers used are listed Table 5.15. 
 
5.2.3. RNA-based Methods 
5.2.3.1. Isolation of RNA  
 
RNA was extracted with the TRIzol Reagent (Thermo Fisher Scientific Inc.) which was 
directly applied to cells previously washed with ice cold PBS. Total RNA from Jiyoye 
and U2932 EBV-positive cells was isolated from lysates.  
 
5.2.3.2. CDNA Synthesis and Quantitative Real-time PCR (qPCR) 
 
CDNA synthesis was carried out using 1 µg of total RNA and random hexamer primers 
with the First Strand cDNA Synthesis Kit (Thermo Fisher Scientific Inc.), according to 
the manufacturer’s instructions. The cDNA was diluted 1:10 and 2 µl per sample were 
mixed with 10 pmol each of forward and reverse primer and 10 µL of SsoFast™ 
EvaGreen® Supermix (Bio-Rad Laboratories Inc.) in a total volume of 20 µL. 
Measurements were performed on a MyiQ Analyzer (Bio-Rad Laboratories Inc.). 
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Relative gene expression levels were determined by the CT method. The values were 
normalized to the expression of the housekeeping gene GAPDH.  
 
5.2.3.3. Denaturing Polyacrylamide Gel Electrophoresis (PAGE) 
 
RNA samples were resolve by PAGE on polyacrylamide (acrylamide/bis-acrylamide 
19:1) urea gels (National Diagnostics Inc.), which were prepared according to the 
manufacturer’s instructions. Electrophoresis was performed in 1X TBE and gels were 
pre-run for approximately 20 min until they were hand-warm. Samples were mixed with 
equal amounts of 2X RNA loading dye and were heated at 95°C for 2-3 min before being 
loaded into the freshly rinsed wells. 
 
RNA loading dye (2X):   0.025% (w/v) bromophenol blue; 0.025% (w/v) xylene cyanol;  
  dissolved in deionized formamide   
 
5.2.3.4. In vitro Transcription 
 
In vitro transcriptions were performed from PCR amplified DNA templates or from 
annealed synthetic oligonucleotides containing the T7 promoter sequence. The sequences 
of the primers for the PCR amplification of the templates are listed in Table 5.11. For the 
in vitro transcription of pre-tRNA-Ile-TAT-2-3 substrates, PCR amplifications were 
performed from the pSUPER + pre-tRNA-Ile-TAT-2-3 plasmid using the following 
primer combinations: tRNA-T7-F and - tRNA-short-end-R for the full-length pre-tRNA, 
tRNA-mat-T7-F and tRNA-short-end-R for the tRNA-Ile intermediate with 5’ mature end 
and 3’ trailer, and tRNA-mat-T7-F and tRNA-short-R-TTTT for the tRNA-Ile 
intermediate with 5’ mature end  and 3’ trailer terminating on –UUUU-3’. The antisense 
pre-tRNA-Ile transcript used as Northern blot probe was generated from a PCR product 
amplified using the primers tRNA-AS-F and 5’- tRNA-short-AS-T7-R. For the in vitro 
transcription of pre-tRNA-Ile-TAT-2-2, PCR amplifications from the pSUPER + pre-
tRNA-Ile-TAT-2-2 plasmid were performed using the following primer combinations: 
tRNA-Ile29-T7-F and tRNA-Ile29-ivt-R for the wildtype pre-tRNA and tRNA-Ile29-T7-
F and tRNA-Ile29-ivt-CT for the artificial pre-tRNA terminating on –CU-3’. Pre-miR-27a 
was in vitro transcribed after annealing the oligonucleotide pair pre-miR-27a-T7-S/pre-
miR-27a- AS (Table 5.12).  
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In vitro transcription reactions were carried out using 0.1 mg/ml self-made T7 RNA 
polymerase in 30 mM Tris (pH 8.0), 25 mM MgCl2, 10 mM each NTP, 2 mM spermidine, 
1 mM dithiothreitol (DTT), 0.01% Triton™ X-100 and 2 U/ml thermostable inorganic 
pyrophosphatase (England Biolabs Inc.) for 4 h at 37°C. In vitro transcribed RNAs were 
purified by PAGE on a 6% polyacrylamide urea gel (see 5.2.3.3) and precipitated. The 
RNAs were then dissolved in water. 
 
5.2.3.5. 32P-Labeling of Nucleic Acids 
 
DNA oligonucleotides, which were used as Northern blot probes (see 5.2.3.6), were 
labeled by incubating 20 pmol of the oligonucleotides with 20 µCi of γ-32P-ATP 
(HARTMANN ANALYTIC GmbH, Braunschweig, Germany) and 0.5 U/µl T4 PNK in 
1X PNK buffer A (Thermo Fisher Scientific Inc.) in a total volume of 20 µl. Following 
30-60 min incubation at 37°C, the reaction was stopped by adding 30 µl of a 30 mM 
EDTA solution (pH 8.0). Unincorporated nucleotides were separated on a G-25 column 
(GE Healthcare) according to the manufacturer’s instructions. A custom RNA ladder, 
consisting of equimolar amounts of synthetic oligoribonucleotides with a length of 19, 21 
and 24 nt, was labeled accordingly.  
 
In vitro transcribed RNAs were dephosphorylated prior 32P-labeling by incubating          
30 pmol RNA with 0.1 U/mL FastAP thermosensitive alkaline phosphatase (Thermo 
Fisher Scientific Inc.) in 1X PNK buffer A supplemented with 2 U/µl RiboLock RNase 
Inhibitor  (Thermo Fisher Scientific Inc.). The reaction was carried out for 30 min at 37°C 
and the enzyme was heat-inactivated for 20 min at 75°C. The 32P-labeling reaction was 
performed as described above. In case the RNA was intended to be used for EMSAs, the 
T4 PNK was heat-inactivated for 10 min at 75°C without adding EDTA and subsequently 
purified with a G-25 column (GE Healthcare). 
 
5.2.3.6. Northern Blot and Determination of Copy Number per Cell  
 
Northern blots were carried out with 5–15 µg of total RNA or RNA isolated from 
immunoprecipitations. RNAs were separated by denaturing PAGE (see 5.2.3.3). Synthetic 
ribooligonucleotides with a length of 19, 21 and 24 nt or the in vitro transcribed pre-
tRNA-Ile (see 5.2.3.4) were labeled with γ-32P-ATP prior to loading and served as size 
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markers. For the determination of copy number per cell, a dilution series of a synthetic 5’ 
phosphorylated ribooligonucleotide corresponding to the mature miR-1983 sequence (see 
5.1.6.1) was loaded in the given amounts. 
Samples were mixed with equal amounts of 2X RNA loading dye and the RNA was 
resolved by PAGE on 12% polyacrylamide urea gels (see 5.2.3.3). After electrophoresis, 
the RNA was stained with EtBr to ensure equal loading of the lanes and to determine the 
RNA quality. The RNA was then blotted for 30 min at 20 V onto an Amersham™ 
Hybond™-N membrane (GE Healthcare) and crosslinked to the membrane for 1 h at 50°C 
using a crosslinking solution with 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide 
(EDC) (Pall and Hamilton, 2008). The membrane was incubated overnight at 50°C in 
hybridization solution with a 32P-labeled oligonucleotide antisense to the small RNA. The 
membrane was washed twice with wash buffer I, once with wash buffer II and wrapped in 
saran. For Northern blotting with RNA probes, hybridization and washings were 
performed at 65°C. Signals were detected by exposure to a storage phosphor screen and 
scanning with the Personal Molecular Imager™ (Bio-Rad Laboratories Inc.). Before re-
probing a membrane, the hybridized oligonucleotide was removed by incubating the 
membrane twice with a boiling 0.1% SDS solution for at least 10 min. If indicated, signal 
intensities were quantified from three biological replicates using Quantity One Software 
(version 4.6.9, Bio-Rad Laboratories Inc.). Error bars display ± standard deviations of the 
normalized signals. 
 
EDC-crosslinking solution:  188 mg EDC; 61.25 µl 1-methylimidazol; 75 µl HCl (1M); 
  ad 6 ml H2O  
Hybridization solution:   5X SSC, 7% SDS, 20 mM sodium phosphate buffer pH 7.2,  
 1X Denhardt's solution 
Wash I solution: 5X SSC; 1% SDS  
Wash II solution: 1X SSC; 1% SDS 
 
5.2.3.7. Aminoacylation Assay 
 
Aminoacylation assays were carried out according to (Zaborske et al., 2009) with some 
modifications. In short, total RNA was extracted with TRIzol (Thermo Fisher Scientific 
Inc.) performing all steps on ice. Precipitated RNA was dissolved in 10 mM sodium 
acetate (pH 5.0) for 15 min at 37°C, whereby aminoacylation of tRNAs was preserved. 
An aliquot of the RNA was then subjected to deacylation by incubation under alkaline 
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conditions, 200 mM Tris (pH 9.5), for 1 h at 37°C. Acylated and deacylated RNAs were 
mixed 1:1 with 2X acidic sample loading buffer. Samples were resolved on a 6.5% 
polyacrylamide urea gel containing 100 mM sodium acetate (pH 5.0) and no TBE. 
Electrophoresis was carried out overnight at 4°C and 100 V in 100 mM sodium acetate 
(pH 5.0). All further steps were performed similarly as described in section 5.2.3.6 for 
Northern blot assays. 
 
Acidic sample RNA loading buffer (2X): 
90% deionized formamide; 100 mM sodium acetate (pH 5.0); 0.05% (w/v) bromophenol blue; 
0.05% (w/v) xylene cyanol     
 
5.2.3.8. In silico RNA Methods 
 
RNA secondary structures were predicted with the mfold web server for nucleic acid 
folding and hybridization prediction (Zuker, 2003) and possible structures were depicted 
schematically. The secondary structures of mature tRNAs were drawn according to the 
predictions deposited in gtRNAdb 2.0 (Chan and Lowe, 2015). 
 
Potential mRNA targets of miR-1983 were predicted by TargetScan Human custom (release 
5.2) using the seed sequence of miR-1983 (nts 2-8: UCACCUG) as a query (Friedman et 
al., 2008). 
 
5.2.4. Biochemical Methods 
5.2.4.1. Determination of Protein Concentration 
 
The total protein concentration of cell lysates was determined by diluting 2 µl of the 
sample in 1 ml of Roti®-Quant solution (Carl Roth GmbH + Co. KG), which allows the 
quantitation of proteins based on the Bradford method (Bradford, 1976). 
The concentration of recombinant proteins was determined with the Nanodrop® ND-1000 
spectrophotometer (Thermo Fisher Scientific Inc.) at a wavelength of 280 nm. The values 
were corrected for a factor determined in silico for each protein sequece with the ExPASy 
ProtParam tool. This factor is based on the calculation of the respective extinction 
coefficient. 
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5.2.4.2. SDS- PAGE 
 
Proteins were resolved on 6% (for TNRC6 Western blots) or 10% polyacrylamide gels. 
Either 50-100 µg total protein from cell lysates or 1/5 aliquots of immunoprecipitaed 
samples were mixed with Laemmli buffer and incubated at 95°C for 5 min prior loading. 
Gels were run in SDS-gel running buffer in self-made chambers at a constant voltage 
(180-200 V) until the bromophenol blue running front reached the bottom of the gel. 
 
Laemmli buffer (4X):  250 mM Tris (pH 6.8); 40% (w/v) glycerol; 8% (w/v) SDS;  
 20% (v/v) -mercaptoethanol; 0.025% (w/v) bromophenol blue 
Stacking gel: 5% (w/v) acrylamide/bis-acrylamide (37.5:1); 125 mM Tris (pH 6.8) 
 0.1% (w/v) SDS; 0.15% (v/v) TEMED; 0.05% (w/v) APS  
Separating gel:  6-10% (w/v) acrylamide/bis-acrylamide (37.5:1); 380 mM Tris (pH 8.8) 
 0.1% (w/v) SDS; 0.1% (v/v) TEMED; 0.05% (w/v) APS 
SDS-gel running buffer:  25 mM Tris; 0.2 M glycine; 0.1% (w/v) SDS; pH 7.5 
  
5.2.4.3. Coomassie staining  
 
SDS-gels were transferred to a container with Coomassie staining solution, briefly heated 
in a microwave avoiding boiling, and incubated on a shaker for 30-60 min. The solution 
was replaced with Coomassie destaining solution, briefly heated and incubated on a 
shaker for 30-60 min. This procedure was repeated for a second time until the background 
staining achieved the desired intensity. 
 
Coomassie staining solution:  30% (v/v) ethanol; 10% (v/v) acetic acid;  
 0.25% (w/v) Coomassie® Brilliant Blue R-250  
Coomassie destaining solution:  30% (v/v) ethanol; 10% (v/v) acetic acid  
 
5.2.4.4. Western Blot 
 
Following SDS-PAGE, proteins were transferred by electro-blotting onto a nitrocellulose 
membrane (Amersham™ Protran™ Premium 0.45 NC, GE Healthcare). Before blotting the 
gel, the membrane and six Whatman® 3MM blotting papers (GE Healthcare) of the same 
size of the gel were soaked into transfer buffer. The gel lying on the membrane was 
enclosed between the blotting papers and assembled in the semid-dry Trans-Blot® SD 
(Bio-Rad Laboratories Inc.) cell.  The transfer was carried out at constant current of 2 mA 
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per square centimeter of the assembled transfer sandwich.The transfer duration was 
determined based on the molecular weight of the protein of interest (i.e.,  1 min per kDa).  
 
Transfer buffer:  25 mM Tris (pH 8.6); 192 mM glycine; 20% (v/v) methanol 
Antibody solution: 5% (w/v) mik; 0.02% (w/v) sodium azide; dissolved in TBS-T 
 
5.2.4.5. Immunoprecipitation, Ago-APP and Isolation of Co-precipitated RNAs 
 
Immunoprecipitations were performed as described in Dueck et al. (2012). In brief, 
antibodies against the protein of interest were incubated overnight under rotation at 4°C 
with 40 µl Protein A (for antibodies raised in rabbits) or Protein G (for antibodies raised 
in rats) Sepharose™ 4 Fast Flow (GE Healthcare) bead slurry. Purified antibodies or sera 
were diluted as indicated in Table 5.18 in 1 ml PBS. For antibodies produced from 
monoclonal hybridoma cell lines, 1 ml of the respective cell culture supernatant was used 
without dilution. Immunoprecipitations of FH-tagged proteins were performed with 30 µl 
ANTI-FLAG® M2 Affinity Agarose Gel (Sigma-Aldrich Co.). 
For each immunoprecipitation reaction, one to three cell culture dishes (150 mm 
diameter) or ~107 Raji cells were lysed on ice in 1.5 ml IP lysis buffer. Lysates were 
cleared by 30 min full-speed centrifugation at 4°C. Small aliquots were taken, which 
served as input samples for subsequent Western blot (25 µl) and Northern blot analyses 
(75 µl). The remaining 1.4 ml lysate was transferred to a fresh tube containining the 
antibody-coupled beads. In a control reaction, the lysate was incubated with beads only. 
The mixtures were incubated under constant rotation for 2-3 h at 4°C. In case of immuno-
precipitation experiments performed in parallel with samples originating from cells 
treated differently, the total protein concentration of the lysates was first determined as 
described in 5.2.4.1. The volumes taken for the input samples were adjusted accordingly, 
and the different immunoprecipitations were performed from equal amounts of starting 
material. 
Following the incubation at 4°C, the beads were transferred to a fresh reaction tube and 
they were washed four to five times with ice-cold IP wash buffer, and once with ice-cold 
PBS. The beads were resuspended in 100 µl PBS and a 20 µl aliquot was taken for 
Western blot analysis. The remaining beads were collected and they were mixed with  
200 μl proteinase K buffer containing 0.2 mg/ml proteinase K (Thermo Fisher Scientific 
Inc.). Proteins were digested for 30 min at 50°C and the co-precipitated RNA was 
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extracted with 200 µl Roti®-phenol/chloroform/isoamyl alcohol solution (Carl Roth 
GmbH + Co. KG). The samples were mixed vigourosly and centrifuged for 10 min at 4°C 
and 17,000 rcf. The aqueous phase was transferred to a fresh reaction tube and the RNA 
was precipitated overnight at -20°C by adding 600 µl 100% ethanol and 1 µl glycogen as 
carrier. The following day, the RNA was collected by full-speed centrifugation at 4°C for 
at least 30 min, and the pellet was washed once with 80% (v/v) ethanol (pre-cooled at -
20°C). The air-dried RNA pellet was finally dissolved in 15 µl H2O by incubation at 65°C 
for 5 min and was later analyzed by Northern blotting (5.2.3.6). The RNA was extracted 
from the input samples using TRIzol Reagent (Thermo Fisher Scientific Inc.) according to 
the manufacturer’s instructions. 
For Ago-APPs, 100 mg of the GST-tagged TNRC6B 599-683 peptide (Hauptmann et al., 
2015) were coupled to 40 µl Glutathione Sepharose™ 4 Fast Flow (GE Healthcare) beads. 
Lysate preparation, precipitation of RNA-protein complexes, and RNA extraction from 
the precipitated samples were carried out as described above for immunoprecipitations. 
 
IP lysis buffer: 25 mM Tris (pH 7.5); 150 mM KCl; 2 mM EDTA; 1 mM NaF;  
 0.5% (v/v) NP-40 alternative; 1 mM DTT; 0.5 mM AEBSF 
IP wash buffer: 50 mM Tris (pH 7.5); 350 mM KCl; 1 mM MgCl2;  
 0.5% (v/v) NP-40 alternative 
Proteinase K buffer: 200 mM Tris (pH 7.5); 300 mM NaCl; 25 mM EDTA; 2% (w/v) SDS 
 
5.2.4.6. Small RNA Cloning and Data Analysis 
 
Ago-associated RNA isolated either by immunoprecipitation or by Ago-APP was ligated 
to an adenylated 3’ DNA adapter using a self-made truncated T4 RNA ligase 2. The 
ligation of the 5’ RNA was performed with T4 RNA ligase 1 (New England Biolabs Inc.). 
3 μg of total RNA were used for small RNA cloning from the input samples. 
The resulting ligation products were reverse-transcribed using the RT primer the 
SuperScript™ III First Strand Synthesis Super Mix SuperScript III First Strand Synthesis 
Super Mix (Thermo Fisher Scientific Inc.), followed by PCR amplification with the 
primers 5’ PCR primer and 3’ PCR index primer, wherein index sequences and other 
Illumina-specific sequences were added. The sequences of the adapters and primers used 
are indicated in Table 5.6. 
The samples were run in 1X TBE buffer on 6% polyacrylamide urea gels (see 5.2.3.3) 
under non-denaturing conditions. The DNA was stained by incubating the gels for 10 min 
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in a 1X TBE solution containing 50 µg/ml EtBr. The bands corresponding to PCR 
amplification products containing miRNA-sized inserts were cut out and eluted overnight 
in 300 mM NaCl and 2 mM EDTA. The supernatants containing the libraries were 
collected using Costar® Spin-X® filter tubes (Corning Inc., Corning, USA), precipitated 
with ethanol overnight at -20 °C, pelleted and dissolved in water. 
The quality of the libraries was assessed on an Agilent 2100 Bioanalyzer (Agilent 
Technologies Inc.) and the libraries were quantified by qPCR measurements. After library 
pooling, the deep sequencing run was performed on a MiSeq™ platform (Illumina Inc.). 
The raw data for these experiments can be accessed at the Gene Expression Omnibus 
(GEO) data repository (Edgar, 2002) under the number GSE76676. 
 
For data analysis, 3’ adapters were trimmed using cutadapt, all reads <18 nts and >35 nts, 
as well as untrimmed reads, were discarded. Reads were collapsed, annotated using 
custom scripts to the indicated datatypes allowing one mismatch and no 
insertions/deletions. All reads which mapped to sequences from two or more datatypes 
(see below) were counted as a separate group. Data were processed similarly for 
subgroups within the given datatype (e.g. miRNA families, tRNA isotype, etc.). Within 
subgroups, annotations were counted to single records. The count of reads mapping to 
ambiguous annotations were split on affected annotations. Reads per million were 
calculated on valid reads. Plots were drawn with R (library ggplot2). The following 
databases were used: pre-tRNA: gtRNAdb 2.0 (Chan and Lowe, 2015), sequences were 
extended by 100 nt genomic sequence at the 5’ end and at the 3’ end; mature tRNA: 
sequences from gtRNAdb were processed by removing introns at the indicated splice 
positions and CCA was added at the 3’end of the sequences; miRNAs: miRBase21 
(Kozomara and Griffiths-Jones, 2014) miRNA sequences; sequences for 5S rRNA, U6 
snRNA, 7SL RNA, 7SK RNA, Y RNA and BC200 were obtained from the Repeat 
Masker USCS hg19.rmsk Table browser, status 2015-11; Sequences for snaR, vtRNA and 
RMRP were obtained from UCSC refGene (hg19). 
 
5.2.4.7. PAR-CLIP Experiments and Data Analysis 
 
PAR-CLIP experiments were performed together with Dr. Yasuhiro Murakawa in the 
group of Prof. Dr. Markus Landthaler at the Max-Delbrück Center for Molecular 
Medicine (Berlin, Germany). Stable, inducible FH-Dicer HEK293 cells (Rybak-Wolf et 
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al., 2014) were transfected with siRNAs against La or control siRNAs and were harvested 
after 4 days. Induction of protein expression with 1 μg/ml doxycycline and labeling with 
100 μM 4SU was performed 9-12 h before crosslinking. Cells were treated additionally 
with 100 μM 4SU (Sigma-Aldrich Co.) 4 h before crosslinking. All subsequent steps were 
performed as described in (Rybak-Wolf et al., 2014). For generation of small RNA 
libraries the 3’ PAR-CLIP DNA adapter and the 5’ PAR-CLIP RNA adapter (Table 5.6) 
were used. Libraries were sequenced on a HighSeq™2000 platform (Illumina Inc.) at the 
Max-Delbrück Center for Molecular Medicine (Berlin, Germany). The raw data can be 
accessed at GEO data repository (Edgar, 2002) under the number GSE77897. 
 
Data analysis of PAR-CLIP experiments was performed by Dr. Filippos Klironomos in 
the group of Prof. Dr. Nikolaus Rajewsky at the Max-Delbrück Center for Molecular 
Medicine (Berlin, Germany). The 5’ end as well as 3' end adapters were trimmed from 
sequenced reads using flexbar (v2.5) (Dodt et al., 2012). Reads were then collapsed so 
that PCR amplification biases could be eliminated. Consequently, the random 4mers at 
the 5’ and 3’ ends of the collapsed reads were trimmed and the resulting reads were 
mapped against the hg19 genome using bwa mem (v0.7.12-r1039) (Li and Durbin, 2010). 
A custom script identified aligned reads with at least one RNA T:C. The overlaps with 
annotated tRNAs of reads with at least one RNA T:C transition, were counted using the 
GenomicAlignment Bioconductor package (Lawrence et al., 2013). Differential 
expression of tRNAs based on those counts was done using the DESeq2 Bioconductor 
package (Love et al., 2014).  
 
5.2.4.8. Dicer Cleavage Assay 
 
HEK293 cells were transfected with plasmids for FH-Dicer overexpression and anti-
FLAG immunoprecipitations were performed. After washing, beads were resuspended in 
Dicer cleavage buffer and ~50 fmol in vitro transcribed RNA was added. Samples were 
incubated for 30-60 min at 37°C under constant agitation. Subsequently, proteins were 
digested with proteinase K and the RNA was extracted as described in 5.2.4.5. 
 
Dicer cleavage buffer:  PBS supplemented with 7.5 mM MgCl2, 5 mM ATP;  
 1 U/µl RiboLock RNase Inhibitor (Thermo Fisher Scientific Inc.) 
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5.2.4.9. Expression and Purification of Recombinant Proteins 
 
Expression of proteins was performed in the E. coli strain BL21 [DE3]. All purification 
steps were performed at 4°C.  
Recombinant La protein used for the generation of anti-La antibodies was expressed from 
the pGEX-6P-1 + La WT plasmid. Cells were grown at 37°C to an OD600 of 0.6 and 
protein expression was induced by the addition of 1 mM IPTG. Cells were grown 
overnight at 18 °C under constant agitation. The lysis occurred in 1X PBS supplemented 
with 1M NaCl, 1 mg/ml lysozyme, 1 mM AEBSF, 1 mM DTT and 5 U/ml Benzonase® 
nuclease (Merck KGaA). Following washing with lysis buffer, bound proteins were 
eluted with 20 mM glutathione dissolved in PBS (pH 7.5). The pGEX-6P-1 + La WT 
plasmid contains a cleavage site for the PreScission protease between the GST-tag and the 
La protein. Thus, self-made, GST-tagged PreScission protease and 1 mM DTT were 
added to the eluate, while dialyzing overnight against PBS. The following day, the 
mixture was used for a second affinity purification on a GSTrap™ FF column (GE 
Healthcare) to get rid of the cleaved tag and of the GST-tagged protease. The flowthrough 
was pooled and concentrated by ultrafiltration with Vivaspin® 20 centrifugal 
concentrators (Sartorius AG, Göttingen, Germany). Glycerol was added to 5% and the 
samples were flash-frozen in liquid nitrogen and stored at -80°C. 
Recombinant GST-tagged La protein variants used for EMSA assays were expressed 
from pGEX-4T-1 plasmids. Pelleted cells were resuspended in lysis buffer supplemented 
with 1 mg/ml lysozyme, 1 mM AEBSF, 1 mM DTT and 5 U/ml Benzonase® nuclease 
(Merck KGaA). Sonication occurred subsequently. The supernatant obtained after 
centrifugation (48,000 rcf for 40 min at 4°C) was filtered and loaded on a 5 ml GSTrap™ 
FF column (GE Healthcare) equilibrated with lysis buffer. The column was washed with 
7 column volumes (cv) of wash buffer and bound proteins were eluted with elution buffer. 
GST fusion protein containing fractions were pooled and applied to a Hiprep™ 26/10 
Desalting column (GE Healthcare), exchanging the buffer to buffer A. After desalting, 
anionic exchange chromatography was performed on a 6 ml RESOURCE™ Q column 
(GE Healthcare), eluting in a linear gradient over 20 cv from 0% to 50% buffer B. 
Fractions containing GST fusion proteins were pooled, glycerol was added to a final 
concentration of 5% and samples were flash-frozen in liquid nitrogen and stored at -80°C.  
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Lysis buffer: 50 mM Tris (pH 7.5); 1 M NaCl; 10 mM MgCl2 
Elution buffer: 50 mM Tris (pH 7.5); 1 M NaCl; 10 mM MgCl2; 20 mM gluthathione 
Wash buffer: 50 mM Tris (pH 7.5); 300 mM NaCl; 10 mM MgCl2; 1 mM DTT  
Buffer A: 20 mM Tris (pH 7.5); 50 mM NaCl; 1 mM DTT 
Buffer B: 20 mM Tris (pH 7.5); 2 M NaCl; 1 mM DTT 
 
5.2.4.10. Generation and Purification of Polyclonal Antibodies  
 
The polyclonal anti-La antibody was generated by the company Eurogentec SA (Seraing, 
Belgium) with a protocol consisting of four immunizations with 100 µg recombinant La 
protein each.  
Antibodies were affinity purified from 10 ml rabbit serum. All steps were performed at 
4°C if not stated otherwise. First of all, 20 mg recombinant La protein were dialyzed 
overnight against coupling buffer. The following day, 300 mg CNBr-activated 
Sepharose™ 4 Fast Flow (GE Healthcare) beads were swollen for 30 min in 1 M HCl and 
were then transferred to a gravity flow Poly-Prep® column (Bio-Rad Laboratories Inc.). 
The beads were washed with 15 ml 1 mM HCl before equilibration of the column with 
coupling buffer. Recombinant La protein was added in 6.5 ml coupling buffer, the column 
was sealed and incubated overnight under constant rotation. The coupled matrix was 
washed with 6.5 ml coupling buffer and the sealed column was incubated with 6.5 ml of  
1 M ethanolamine (pH 8.0) solution under constant rotation for 2 h at room temperature. 
By that, any unreacted site of the matrix was blocked. The column was then washed eigth 
times alternating wash buffer 1 and wash buffer 2 (2.5 ml each) and an additional time 
with 10 ml PBS. The serum of a rabbit immunized with recombinant La protein was 
added and the sealed column was incubated overnight under constant rotation. The 
following day, the matrix was washed with 10 ml PBS and the antibodies were eluted 
with 10 ml 100 mM glycine (pH 2.3). Approximately 1 ml fractions were collected in 
separate reactions tubes containing 100 µl Tris (pH 8.8), for neutralization, and, 65 µl 
100% glycerol to preserve the antibodies during flash-freezing in liquid nitrogen. The 
purified anti-La antibody used in this study was derived from the most concentrated, first 
fraction.      
 
Coupling buffer: 0.1 M NaHCO3 (pH 8.3); 0.5 M NaCl 
Wash buffer 1: 0.1 M sodium acetate (pH 3-4); 0.5 M NaCl  
Wash buffer 2: 0.1 M Tris (pH 8-9); 0.5 M NaCl 
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5.2.4.11. EMSA 
 
EMSAs were performed according to Bayfield and Maraia (2009) with some 
modifications. In short, 500 pmol 32P-labeled RNA were incubated in EMSA buffer with 
various amounts of recombinant GST-La proteins at 37°C for 30 min and were then 
cooled on ice for 20 min. Complexes were resolved on 8% native polyacrylamide gels. 
Electrophoresis was carried out overnight at 4°C and 50 V in 0.5X TB buffer. Gels were 
dried and signals were detected using the Personal Molecular Imager™ System (Bio-Rad 
Laboratories Inc.). 
 
EMSA buffer:   20 mM Tris (pH 8.0); 100 mM KCl; 1 mM MgCl2;  
 5 mM -mercaptoethanol; 5% (v/v) glycerol; 30 mg/ml heparin  
Native gel: 0.5X TB with 8% (w/v) acrylamide/bis-acrylamide (37.5:1);  
 5% (v/v) glycerol; 0.1% (v/v) TEMED; 0.05% (w/v) APS  
 
5.2.5. Cell Culture Methods 
 
Cells were grown in a humidified incubator at 37°C (atmosphere 95 % air, 5 % CO2). All 
media were supplemented with 10% fetal bovine serum (Thermo Fisher Scientific Inc.), 
100 U/ml penicillin (Sigma-Aldrich Co.), and 100 mg/ml streptomycin (Sigma-Aldrich 
Co.). An overview of the cell lines and of the respective media used for their cultivation is 
given in section 5.1.9.2.   
 
5.2.5.1. Transfection of Mammalian Cells 
 
The siRNA pairs indicated in Table 5.7 were annealed by heating a 20 µM stock solution 
for 5 min at 95°C and immediately transferring the mixture to 37°C for 30 min. For 
knockdown experiments, cells were reverse transfected with Lipofectamine™ RNAiMax 
(Thermo Fisher Scientific Inc.) according to the manufacturer’s instructions using 40 nM 
siRNA. Cells were expanded after 2 days and harvested at day 4 post-transfection. 
If not stated otherwise, transfections were performed in 6-well format using 3.5 μg 
plasmid DNA and Lipofectamine™ 2000 (Thermo Fisher Scientific Inc.) according to the 
manufacturer’s instructions. 
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For immunoprecipitations of overexpressed proteins, HEK293 cells were plated and 
transfected 3-4 h later with the calcium phosphate method. For each cell culture dish cell 
culture dish with a diameter of 150 mm, 10 μg of plasmid DNA were mixed with 1 ml 
250 mM CaCl2 solution which was then added dropwise to 1 ml 2X HEPES buffered 
saline. Following a short incubation time at room temperature, the mixture containing 
calcium phosphate-DNA precipitates was added dropwise to the cell culture dishes. Cells 
were harvested for experiments after 48 h or 72 h. 
 
2X HEPES buffered saline: 54.6 mM HEPES; 274 mM NaCl; 1.5 mM Na2HPO4; (pH 7.1)  
 
5.2.5.2. Dual Luciferase Assay 
 
HEK293 cells were reverse transfected in 48-well plates with pMIR-RL-TK constructs 
(50 ng/well) and pSUPER constructs (200 ng/well) or miRNA mimic (40 nM/well) using 
Lipofectamine™ 2000 (Thermo Fisher Scientific Inc.) according to the manufacturer’s 
instructions. Two days after transfection, cells were lysed in 100 µl 1X passive lysis 
buffer (Promega Corporation) and 15 µl were assayed for firefly activities on a microplate 
reader Mithras LB 940 (BERTHOLD TECHNOLOGIES GmbH & Co. KG). 
All samples were assayed in four replicates. Firefly/renilla luminescence ratios for 
individual samples were normalized to corresponding ratios of the empty pMIR-RL-TK 
plasmid and control pSUPER construct/control miRNA mimic transfected samples. 
Experiments were performed in three biological replicates and the mean values and 
standard deviations of the normalized firefly/renilla luminescence ratios were calculated 
from all biological replicates. Error bars display ± standard deviations. 
 
Firefly luciferase buffer: 20 mM tricine (pH 8.0); 5.3 mM MgSO4; 0.1 mM EDTA;  
 530 µM ATP; 470 µM D-luciferin; 270 µM coenzyme A  
Renilla luciferase buffer:  220 mM potassium phosphate buffer (pH 5.0); 1.1 M NaCl;  
 2.2 mM EDTA; 1.3 mM sodium azide; 0.44 mg/ml BSA 
 Freshly supplemented with 1.43 µM coelenterazine  
 (from 1000X stock solution dissolved in methanol)   
 
ATP, D-luciferin, coenzyme A and coelenterazine were purchased from PJK GmbH 
(Kleinblittersdorf, Germany). 
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6. Contributions  
 
PAR-CLIP experiments were performed together with Dr. Yasuhiro Murakawa in the 
group of Prof. Dr. Markus Landthaler at the Max-Delbrück Center for Molecular 
Medicine (Berlin, Germany). 
 
Data analysis of PAR-CLIP experiments was performed by Dr. Filippos Klironomos in 
the group of Prof. Dr. Nikolaus Rajewsky at the Max-Delbrück Center for Molecular 
Medicine (Berlin, Germany). 
 
Data analysis of small RNA sequencing data was performed together with Gerhard 
Lehmann who also created several custom scripts. 
 
Norbert Eichner contributed to the sequencing of small RNA libraires by performing the 
adenylation of the 3’ DNA adapter, the BioAnalyzer and qPCR analyses and by 
performing the sequencing run on the MiSeq™ platform. 
 
Protein purifications were performed with the support of Dr. Leonhard Jakob. 
 
Prof. Dr. Friedrich A. Grässer (Saarland University Medical School, Homburg/Saar, 
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and contributed to the project with discussions. 
 
The deep-sequencing data presented in this thesis have been deposited in NCBI’s GEO 
data repository (Edgar, 2002) and can be accessed as the SuperSeries GSE77898. 
 
 
 
  
 
 150   
 
 
7. Data Publication 
 
Parts of this thesis have been published in the following articles: 
 
Hasler, D., Lehmann, G., Murakawa, Y., Klironomos, F., Jakob, L., Grässer, F.A., 
Rajewsky, N., Landthaler, M., Meister, G., 2016. The Lupus Autoantigen La Prevents 
Mis-channeling of tRNA Fragments into the Human MicroRNA Pathway. Mol. Cell 63, 
110–124. doi:10.1016/j.molcel.2016.05.026 
 
Hasler, D., Meister, G., 2016. From tRNA to miRNA: RNA-folding contributes to correct 
entry into noncoding RNA pathways. FEBS Lett. 590, 2354–2363. doi:10.1002/1873-
3468.12294 
 
Alles, J., Hasler, D., Kazmi, S., Tesson, M., Hamilton, A., Schlegel, L., Marx, S., 
Eichner, N., Reinhardt, R., Meister, G., Wilson, J., Grässer, F., 2015. Epstein-Barr Virus 
EBER Transcripts Affect miRNA-Mediated Regulation of Specific Targets and Are 
Processed to Small RNA Species. Non-Coding RNA 1, 170–191. 
doi:10.3390/ncrna1030170 
 
 
 
Parts of this thesis have been presented at the following conferences: 
 
4th Biennial Meeting of the LARP Society, Stockton (England) 
Title of the presentation: The Lupus Autoantigen La Prevents Mis-channeling of tRNA 
Fragments into the Human MicroRNA Pathway 
 
RNA 2016, Annual Meeting of the RNA Society, Kyoto (Japan) 
Title of the presentation: The Lupus Autoantigen La Prevents Mis-channeling of tRNA 
Fragments into the Human MicroRNA Pathway 
 
 
 
Furthermore, I contributed to the following articles: 
 
Grassmann, F., Schoenberger, P.G.A., Brandl, C., Schick, T., Hasler, D., Meister, G., 
Fleckenstein, M., Lindner, M., Helbig, H., Fauser, S., Weber, B.H.F., 2014. A Circulating 
MicroRNA Profile Is Associated with Late-Stage Neovascular Age-Related Macular 
Degeneration. PLoS One 9, e107461. doi:10.1371/journal.pone.0107461 
 
Hasler, D., Meister, G., 2012. An Argonaute Protein Directs Nuclear Xrn2 Function. Mol. 
Cell 48, 485–486. doi:10.1016/j.molcel.2012.11.015 
                        
                  151   
 
 
8. Abbreviations 
 
A 
A   Adenine 
AARS   Alanyl-tRNA synthetase 
ADP   Adenosine diphosphate 
AEBSF  4-(2-aminoethyl)benzenesulfonyl fluoride 
Ago   Argonaute 
Ago-APP  Ago protein Affinity Purification by Peptides 
AIMP1-3  Aminoacyl tRNA synthetase complex-interacting multifunctional 
    protein 1-3 
Ala   Alanine 
amol   Attomole 
AMP   Adenosine monohosphate 
Amp   Ampicillin 
ANG   Angiogenin 
APOER2  Apolipoprotein E receptor 2 
APS   Ammonium persulfate 
Arg   Arginine 
ARS   Aminoacyl-tRNA Synthetase 
Asn   Asparagine 
Asp   Aspartic acid 
ASW   Ashwin 
ATP   Adenosine triphosphate 
A549   Human lung carcinoma cell line 
B 
BACH 1/2  BTB Domain And CNC Homolog 1/2 
BDP   TFIIIB component B'' homolog 
BLV   Bovine leukemia virus 
bp   Base pair 
BRF1/2  TFIIB-related factor 1/2 
BSA   Bovine serum albumin 
C 
C   Cysteine (in protein sequences) / Cytosine (in RNA sequences) 
Cbp1   Cytochrome b mRNA processing 1 
CCR4-NOT  Carbon catabolite repressor 4-negative on TATA 
cDNA   Complementary DNA 
CDS   Coding sequence 
ChIP   Chromatin immunoprecipitation 
CLP1   Cleavage/polyadenylation factor Ia subunit 
CPSF-73  Cleavage and polyadenylation specificity factor 73 
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C-terminus  Carboxyl-terminus 
Ctrl   Control 
Cys   Cysteine 
C7-amino  C7-amino linker (C7H16NO4P) 
D 
dATP   Deoxyadenosine triphosphate 
DCP2   Decapping protein 2 
Dcr   Dicer 
DDX1   DEAD-Box Helicase 1 
DEAD   Asp-Glu-Ala-Asp 
DEDX   Asp-Glu-Asp-Asp/His 
Dgcr8   DiGeorge syndrome critical region 8 
DLD-1  Human colorectal adenocarcinoma cell line 
D. melanogaster Drosophila melanogaster 
DMEM  Dulbecco’s modified Eagle’s medium 
DMF   Dimethylformamide 
DNA   Desoxyribonucleic acid 
DNMT2  DNA methyltransferase 2 
dNTP   Deoxynucleoside triphosphate 
DSE   Distal sequence element 
dT   Deoxythymidine 
DTT   Dithiothreitol 
DUSP11  Dual specificity phosphatase 11 
E 
EBER1/2  Epstein-Barr virus encoded RNA 1/2 
EBV   Epstein-Barr virus 
E. coli   Escherichia coli 
EDTA   Ethylenediaminetetraacetic acid 
eEF1A   Eukaryotic translation elongation factor 1 
EF-Tu   Elongation factor thermo unstable 
eIF4F   Eukaryotic translation initiation factor 4F 
eIF4G   Eukaryotic translation initiation factor 4G 
ELAC1/2  ElaC Ribonuclease Z 1/2 
EM   Electron microscopy 
EMSA   Electromobility shift assay 
Endo-siRNA  Endogenous small interfering RNA  
EPRS   Glutamyl-prolyl-tRNA synthetase 
EtBr   Ethidium bromide 
F 
FAM98B  Family with sequence similarity 98 member B 
fmol   Femtomole 
FH   FLAG/HA 
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G 
g   Gram 
G   Guanine  
GAPDH  Glycerinaldehyd-3-phosphat-dehydrogenase 
GEO   Gene Expression Omnibus 
Gln   Glutamine 
Glu   Glutamic acid 
Gly   Glycine 
GMP   Guanosine monophosphate 
GST   Glutathione-S-transferase 
GTP   Guanosine triphosphate 
GtRNAdb  Genomic tRNA Database 
H 
h   hour 
HA   Human influenza hemagglutinin 
HAC1   Homologous to Atf/Creb1 
HEK293  Human embryonic kidney 293 
HeLa   Henrietta Lacks  
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HepG2  Human hepatocellular carcinoma cell line 
His   Histidine 
Hsp   Heat shock protein 
HVS   Herpesvirus saimiri 
I 
ID   Identification 
IE   Intermediate element 
Ile   Isoleucine 
Inv(dT)  5’-3’ reverse deoxythymidine 
IP    Immunoprecipitation 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
IRES   Internal ribosomal entry site 
i-tRF   Internal tRNA-derived fragment 
K 
kb   Kilo base pair 
kd   Knockdown 
kDa   Kilodalton 
KSHV   Kaposi’s sarcoma-associated herpesvirus 
L 
LAM   La motif 
LARP   La-related protein 
LB   Luria Broth 
Let-7   Lethal-7 
Leu   Leucine 
Lhp1   La homologous protein 1 
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Los1   Loss of suppression 1 
LTR   Long terminal repreat 
Lys   Lysine 
M 
M   Molar 
mA   Milliampere 
mAB   Monoclonal antibody 
MCF-7  Michigan Cancer Foundation - 7 cell line 
MEF   Mouse embryonic fibroblast 
Met   Methionine 
Mex67   Messenger RNA export factor of 67 kDa 
mg   Milligramm 
µg   Microgramm 
MHV68  Murine gammaherpesvirus 68 
MID domain  Middle domain 
min   Minute 
miRBase  MiRNA database  
MiRISC  MiRNA-induced silencing complex 
MiR-X  MicroRNA-X 
MiRNA  MicroRNA 
MiRNA*  MicroRNA star 
ml   Milliliter 
µl   Microliter 
mM   Millimolar 
µM   Micromolar 
Mtr2   Mrna transport 2 
mt-tRNA  Mitochondrial tRNA 
MuERV-L  Murine endogenous retrovirus-like 
Mut   Mutant 
m7G    7-methylguanosine  
N 
N   Any nucleotide (in Figures and Tables) 
ncRNA  Non-coding RNA 
nm   Nanometer  
N-terminus  Amino-terminus 
NS   Not significant 
NSun2   NOP2/Sun RNA Methyltransferase Family Member 2 
nt   Nucleotide 
Ntera2   Human testicular embryonic carcinoma cell line 
NXF1    Nuclear export factor 1  
NXT1    Nuclear transport factor 2 like export factor 1 
O 
OCT1   Octapeptidyl aminopeptidase 
OD600   Optical density at 600 nm wavelength 
OH   Hydroxyl 
ORF   Open reading frame 
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P 
pAB   Polyclonal antibody   
PACT   Protein activator of interferon induced protein kinase EIF2AK 
PAGE   Polyacrylamide gel electrophoresis 
PAN2-PAN3  Poly(A)-binding protein-dependent poly(A) ribonuclease 2-3 
PAR-CLIP  Photo-activatable ribonucleoside-enhanced crosslinking and  
   Immunoprecipitation 
PAZ   PIWI–ARGONAUTE–ZWILLE 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PHAX   Phosphorylated adaptor for RNA export 
Phe   Phenylalanine 
Phos   Phosphate 
piRNAs  PIWI-interacting RNAs 
PIWI   P-element induced wimpy testis 
pmol   picomole 
Pol III   RNA Polymerase III 
POP4   POP4 homolog, ribonuclease P/MRP  
Pre-miRNA  Precursor miRNA 
Pre-tRNA  Precursor tRNA 
Pri-miRNA  Primary miRNA 
Pro   Proline 
PSE   Proximal sequence element 
Q 
qPCR   Quantitative polymerase chain reaction 
R 
Raji   Human B lymphocyte cell line 
RBP   RNA-binding protein 
rcf   Relative centrifugal force 
Rep   Replicate 
RIMS2  Regulating synaptic membrane exocytosis protein 2 
RNA   Ribonucleic acid 
RNAi   RNA interference 
RNase   Ribonuclease 
RNP   Ribonucleoprotein 
Rny1   Ribonuclease T2 
RPPH1  Ribonuclease P RNA component H1 
RPS   Ribosomal protein S 
RRM   RNA recognition motif 
rRNA   Ribosomal RNA 
RSV   Respiratory syncytial virus 
RTCB   RNA 2’,3’-cyclic phosphate and 5’-OH Ligase 
RTD   Rapid tRNA decay 
RTRAF  RNA transcription, translation and transport factor (also known as CGI-99)  
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S 
s   second 
S. cerevisiae  Saccharomyces cerevisiae 
SD   Standard deviation 
SDS   Sodium dodecyl sulfate 
sEBER  Short Epstein-Barr virus encoded RNA 
SeC    Selenocysteine 
Sen   Splicing endonuclease  
Ser   Serine 
SHOTRNA  Sex hormone-dependent tRNA-derived RNA 
shRNA  Short hairpin RNA 
siRNA   Small interfering RNA 
SK-N-MC  Human brain neuroepithelioma cell line 
SNAPc   Small nuclear RNA-activating protein complex 
snaR   Small NF90-associated RNA 
snoRNA  Small nucleolar RNA   
snRNA  Small nuclear RNA 
S. pombe  Schizosaccharomyces pombe 
sRNA   Small RNA 
sRNA-Ile  tRNA-Ile derived small RNA 
sRNA-Pro  tRNA-Pro derived small RNA 
SSB   Sjögren’s syndrome antigen B 
SSC   Saline sodium citrate 
STAF   Selenocysteine tRNA gene transcription-activating factor   
Sup   Suppressor 
4SU   4-thiouridine 
T  
T   Thymine 
Taq   Thermus aquaticus 
TB   Tris-borate 
TBE   Tris-borate-EDTA 
TBP   TATA box-binding protein 
TBS-T   Tris-buffered saline with Tween® 20 
TEMED  Tetramethylethylenediamine 
TEV   Tobacco etch virus 
TFIIB   Transcription factor IIB 
TFIIIA  Transcription factor IIIA 
TFIIIB   Transcription factor IIIB 
TFIIIC   Transcription factor IIIC 
Thr   Threonine 
tiRNA   TRNA-derived stress-induced small RNA 
TNRC6  Trinucleotide repeat-containing 6 
Tpt1   TRNA 2’-phosphotransferase 1 
TRAMP  Trf4/Air2/Mtr4 polyadenylation 
TRBP   Trans-activation responsive RNA-binding protein (also known as TARBP2) 
TRDMT1  TRNA aspartic acid methyltransferase 1 
tRF   TRNA-derived fragment 
Tris   Tris(hydroxymethyl)aminomethane 
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Trf4   Also known as poly(A) RNA polymerase D7 (PAPD7) 
Trl1   TRNA ligase 1 
Trp   Tryptophan 
tRNA   Transfer RNA 
TSEN   TRNA splicing endonuclease 
TUTase  Terminal RNA uridylyltransferases 
Tyr   Tyrosine 
U 
U   Unit 
U   Uracil 
Undet   undetermined 
UTR   Untranslated region 
UV   Ultraviolet 
V 
V   Volt 
Val   Valine 
VA RNA  Virus-associated RNA 
W 
WB   Western blot 
Wt   Wildtype 
X 
XBP1    X-box binding protein 1 
X-Gal   5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
Xpo1/5  Exportin-1/-5 
Xpo-t   Exportin for tRNA 
Xrn1/2   5’-3’ exoribonuclease 1/2  
Y   
YBX1   Y-box binding protein 1 
YBX1-tRF  Y-box binding protein 1 interacting tRNA fragment 
   Pseudouridine 
Z 
ZBTB8O  Zinc finger and BTB domain containing 8 opposite strand 
 
%   Per cent 
% v/v   Per cent volume/volume (ml/100 ml) 
% w/v   Per cent weight/volume (g/100 ml) 
°C   Degree Celsius  
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